STOCK TITAN

ASP Isotopes Q3 2026 shareholder loss widens to $30.4M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

ASP Isotopes Inc. (ASPI) reported third-quarter 2026 revenue of $5.124 million, versus $1.271 million a year earlier, while net loss attributable to shareholders widened to $30.371 million from $12.617 million. For the first nine months, revenue was $14.427 million versus $3.571 million; net loss from continuing operations was $91.567 million versus $96.802 million.

Net cash used in operating activities for the nine months was $66.449 million, compared with $19.935 million a year earlier. Cash and cash equivalents were $201.663 million at September 30, 2026; the company expects this cash to fund operating expenses and capital requirements for more than 12 months from issuance of the financial statements. Convertible notes payable at fair value were $85.860 million, compared with $199.323 million at December 31, 2025.

ASP Isotopes acquired Renergen in January 2026 and issued 14,270,000 shares in the acquisition. It deconsolidated Skyline on March 29, 2026, retaining approximately 8.6% of its outstanding Class A ordinary and preferred shares. Continuing operations include nuclear fuels, specialist isotopes and related services, and helium and LNG.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose to $5.124 million from $1.271 million.
  • Moderate pointNine-month continuing-operations loss narrowed to $91.567 million from $96.802 million.

Negative

  • Moderate pointQuarterly shareholder-attributable loss widened to $30.371 million from $12.617 million.
  • Moderate pointNine-month operating cash used rose to $66.449 million from $19.935 million.

Filing Explained

In the quarter, ASP Isotopes issued 23,160,682 common shares for convertible notes; the new shares increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.

Revenue, three months $5.124 million in 2026; $1.271 million in 2025 Three months ended September 30; total revenue
Net loss attributable to ASP Isotopes shareholders, three months $30.371 million in 2026; $12.617 million in 2025 Three months ended September 30
Revenue, nine months $14.427 million in 2026; $3.571 million in 2025 Nine months ended September 30; total revenue
Net loss from continuing operations, nine months $91.567 million loss in 2026; $96.802 million loss in 2025 Nine months ended September 30
Net cash used in operating activities, nine months $66.449 million in 2026; $19.935 million in 2025 Nine months ended September 30
Cash and cash equivalents $201.663 million As of September 30, 2026
Convertible notes payable at fair value $85.860 million As of September 30, 2026
Common shares outstanding 155,834,430 shares As of September 30, 2026
HALEU technical
"high-assay low-enriched uranium (“HALEU”)-fueled small modular reactors"
HALEU (high-assay low-enriched uranium) is uranium fuel enriched to a higher level than traditional reactor fuel but below weapons-grade, roughly like a higher-octane gasoline for nuclear reactors. It matters to investors because this fuel enables newer, smaller and more efficient reactors to run longer or produce more power from less material, so availability, regulation and production costs can affect utilities, reactor developers and mining companies’ prospects.
deconsolidation financial
"deconsolidation of Skyline was completed on March 29, 2026"
Deconsolidation occurs when a company stops combining another business’s financial results and balances with its own—usually because it no longer controls that business. For investors this matters because it can suddenly shrink reported revenue, assets, debt and profit, or create a one‑time gain or loss, changing how risky or profitable the remaining company appears; think of it like removing a roommate from a shared household budget and seeing your monthly totals change.
Level 3 fair value financial
"measured as a Level 3 fair value on a recurring basis"
units-of-production method financial
"recorded using the units of production method"
asset retirement obligation financial
"legal obligations associated with the retirement of its natural gas properties"
A liability recorded for the future cost to retire, dismantle or clean up a long-lived asset — for example removing an oil rig, closing a mine, or decommissioning a plant. Investors care because it reduces reported profit and ties up capital: companies must estimate and set aside money now for a known future expense, and changes to that estimate can swing earnings, debt ratios and the company’s cash needs much like setting aside savings to repair or return a rented property later.
measurement alternative financial
"accounted for under the measurement alternative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did ASPI report in Q3 2026?

ASP Isotopes reported $5.124 million in revenue for the three months ended September 30, 2026, compared with $1.271 million in the same 2025 period. Product revenue was $5.124 million in the 2026 quarter.

How much did ASPI lose in Q3 2026?

Net loss attributable to ASP Isotopes Inc. shareholders was $30.371 million for the three months ended September 30, 2026, compared with $12.617 million in the 2025 period. Net loss from continuing operations was $30.868 million.

How much operating cash did ASPI use in the first nine months of 2026?

Net cash used in operating activities was $66.449 million for the nine months ended September 30, 2026, compared with $19.935 million in the same 2025 period. Continuing operations used $65.328 million.

How long does ASPI expect its cash to last?

ASP Isotopes expects its $201.663 million in cash and cash equivalents at September 30, 2026, to fund operating expenses and capital requirements for more than 12 months from the date the financial statements are issued.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001921865Q3false--12-31http://fasb.org/srt/2026#ChiefExecutiveOfficerMemberSeptember 30, 20280.030.010.0130.013October 31 2025October 31 2025January 31 2026March 31 20560001921865aspi:ProvedReservesMember2026-09-300001921865aspi:PrefundedWarrantMemberaspi:ENDRALifeSciencesIncMember2026-05-270001921865us-gaap:NoncontrollingInterestMember2025-12-310001921865us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2025-12-310001921865aspi:RenergenLimitedMember2026-04-012026-06-300001921865us-gaap:StockOptionMember2026-09-300001921865aspi:NobleMemberaspi:MergerAgreementMember2026-06-252026-06-250001921865us-gaap:RetainedEarningsMemberus-gaap:IPOMember2025-07-012025-09-3000019218652025-08-012025-08-310001921865us-gaap:SegmentDiscontinuedOperationsMember2026-01-012026-09-300001921865us-gaap:IPOMemberus-gaap:TreasuryStockCommonMember2025-04-012025-06-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2026-01-012026-09-300001921865us-gaap:StockOptionMember2025-01-012025-09-300001921865us-gaap:NoncontrollingInterestMember2026-01-012026-03-310001921865aspi:JuneTwoThousandAndTwentyFiveMember2025-06-300001921865aspi:AIRSOLMember2026-08-040001921865aspi:IsoBioIncMember2026-09-300001921865aspi:HeliumAndLNGMember2025-07-012025-09-3000019218652026-09-300001921865us-gaap:PropertyPlantAndEquipmentMembersrt:MaximumMember2026-01-012026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2025-07-012025-09-300001921865aspi:ProvedReservesMember2025-12-310001921865aspi:SpecialistIsotopesAndRelatedServicesMember2025-07-012025-09-300001921865aspi:QLE2024EquityIncentivePlanMember2024-03-012024-03-310001921865aspi:SpecialistIsotopesAndRelatedServicesMemberus-gaap:ProductMember2026-01-012026-09-300001921865aspi:TotalSegmentMember2025-01-012025-09-3000019218652025-10-010001921865aspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:TreasuryStockCommonMember2025-07-012025-09-300001921865aspi:FinanceLeasesMember2026-09-300001921865aspi:FacilityAgreementMember2019-08-200001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember2026-09-300001921865aspi:TotalSegmentMember2026-01-012026-09-300001921865aspi:ConvertibleNotesMember2026-07-160001921865aspi:EastCoastNuclearPharmacyLLCMember2025-12-3100019218652026-11-160001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001921865us-gaap:CommonStockMember2025-12-310001921865aspi:PromissoryNotesOneMember2026-09-300001921865aspi:RenergenLimitedMemberus-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001921865aspi:NuclearFuelsMember2025-07-012025-09-300001921865aspi:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001921865aspi:HeliumAndLNGMember2026-07-012026-09-3000019218652024-12-310001921865aspi:TerraPowerLoanAgreementMember2025-05-312025-05-310001921865aspi:ENDRALifeSciencesIncMember2026-07-012026-09-300001921865us-gaap:RetainedEarningsMember2024-12-310001921865us-gaap:UnsecuredDebtMember2026-09-300001921865aspi:RenergenFirmIntentionLetterAndLoanAgreementMember2025-05-192025-05-190001921865aspi:RenergenLimitedMemberus-gaap:NoncontrollingInterestMember2026-04-012026-06-300001921865aspi:OpeongoMember2026-07-012026-09-300001921865us-gaap:UnsecuredDebtMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberaspi:AIRSOLMember2023-08-302023-08-300001921865aspi:CollaborationRevenueMember2025-07-012025-09-300001921865aspi:SharePurchaseAgreementRelatingToPetLabsMember2026-09-300001921865aspi:OpeongoMember2026-09-300001921865us-gaap:GeneralAndAdministrativeExpense2025-07-012025-09-300001921865aspi:SpecialistIsotopesAndRelatedServicesMemberus-gaap:ProductMember2026-07-012026-09-300001921865aspi:IDCLoanMember2026-01-012026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2025-03-310001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMember2025-12-310001921865us-gaap:UnsecuredDebtMember2014-04-112014-04-110001921865us-gaap:CommonStockMemberus-gaap:IPOMember2025-07-012025-09-300001921865srt:MaximumMemberaspi:SoftwareMember2026-01-012026-09-300001921865us-gaap:IPOMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-3000019218652025-12-310001921865aspi:RenergenLimitedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001921865aspi:CollaborationRevenueMemberaspi:NuclearFuelsMember2026-01-012026-09-300001921865us-gaap:TreasuryStockCommonMember2025-03-310001921865us-gaap:CommonStockMemberus-gaap:IPOMember2025-04-012025-06-300001921865aspi:HeliumAndLNGMember2026-09-300001921865us-gaap:SubsequentEventMemberaspi:CertainFirstAmendmentToMergerAgreementMember2026-10-010001921865aspi:RenergenMember2026-09-300001921865country:US2025-01-012025-09-300001921865us-gaap:CommonStockMemberaspi:RenergenLimitedMember2026-07-012026-09-300001921865us-gaap:ResearchAndDevelopmentExpense2025-07-012025-09-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2026-09-300001921865aspi:EnlightenedIsotopesMember2026-09-300001921865us-gaap:TreasuryStockCommonMember2025-09-300001921865us-gaap:SecuredDebtMemberaspi:SBSALoanMember2024-08-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2026-09-300001921865us-gaap:TreasuryStockCommonMember2025-07-012025-09-300001921865us-gaap:CommonStockMember2025-03-310001921865aspi:TwoThousandAndTwentyOneStockIncentivePlanMember2021-10-310001921865aspi:MergerAgreementMemberaspi:ENDRALifeSciencesIncMember2026-06-250001921865us-gaap:ProductMemberaspi:HeliumAndLNGMember2026-07-012026-09-300001921865us-gaap:CommonStockMember2026-09-300001921865us-gaap:SalesRevenueNetMember2025-01-012025-09-300001921865srt:MinimumMemberaspi:IsoBioAndSkylinesJointVenturesWithKC-GloryJVKC-GeotechJVAndKC-CRFGJVMember2026-09-3000019218652024-06-012024-06-300001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:NoncontrollingInterestMember2026-01-012026-03-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2026-03-290001921865aspi:ENDRALifeSciencesIncMember2026-05-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001921865aspi:USTreasurySecuritiesMatureApril2026Member2025-12-310001921865us-gaap:CommonStockMember2026-07-012026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2025-06-300001921865aspi:IsoBioIncMember2025-12-310001921865us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001921865aspi:CommonStockWarrantsMember2025-05-012025-05-310001921865us-gaap:TreasuryStockCommonMember2025-06-3000019218652025-04-012025-06-300001921865aspi:NuclearFuelsMember2026-01-012026-09-300001921865aspi:CommonStockWarrantsMember2025-07-012025-07-310001921865aspi:ClassAUnitsMemberaspi:NobleMemberaspi:MergerAgreementMember2026-06-252026-06-250001921865us-gaap:ProductMemberaspi:HeliumAndLNGMember2026-01-012026-09-300001921865aspi:MergerAgreementMemberaspi:ENDRALifeSciencesIncMember2026-06-252026-06-250001921865us-gaap:CommonClassAMemberaspi:SkylineBuildersGroupHoldingLtdMemberaspi:SecuritiesPurchaseAgreementMemberaspi:WarrantBMembersrt:MaximumMember2025-08-290001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleNotesPayableMember2026-09-300001921865aspi:OpeongoMember2026-01-012026-09-300001921865us-gaap:UnsecuredDebtMember2024-11-140001921865aspi:NuMedDiagnosticsLLCMember2026-01-012026-03-310001921865aspi:WellsInProcessMember2025-12-310001921865srt:MinimumMemberaspi:OfficeFurnitureMember2026-01-012026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001921865us-gaap:CommonStockMember2026-03-310001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2025-12-310001921865aspi:SecuredLetterOfCreditInLieuOfLeaseDepositForQLEMember2026-09-300001921865aspi:RenergenLimitedMember2025-04-012025-04-300001921865aspi:CreditFacilityMember2026-09-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2026-03-290001921865us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2026-09-300001921865aspi:OtherAssetMember2026-07-012026-09-300001921865aspi:OfficeFurnitureMember2025-12-310001921865us-gaap:SecuredDebtMember2025-12-310001921865us-gaap:TreasuryStockCommonMember2024-12-310001921865us-gaap:TreasuryStockCommonMember2025-04-012025-06-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2025-01-012025-12-310001921865aspi:RehabilitationAssetMember2026-09-300001921865aspi:NuclearFuelsMemberus-gaap:ProductMember2026-01-012026-09-300001921865aspi:JulyTwoThousandAndTwentySixMember2026-07-310001921865aspi:JulyTwoThousandTwentyFiveMember2025-07-310001921865aspi:ReservingSixMonthsOfPaymentsToFulfillObligationsUnderTheDFCCreditFacilityMember2026-09-300001921865aspi:ConvertibleNotesMember2026-07-012026-09-300001921865aspi:TwoThousandTwentyFiveInducementEquityIncentivePlanMember2025-07-160001921865aspi:CollaborationRevenueMember2026-07-012026-09-300001921865us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-300001921865country:ZA2025-07-012025-09-300001921865aspi:NobleMemberaspi:MergerAgreementMemberaspi:PrefundedWarrantsMember2026-06-250001921865us-gaap:RetainedEarningsMember2026-01-012026-03-310001921865aspi:ENDRALifeSciencesIncMember2026-05-270001921865aspi:TwoThousandTwentyFiveConvertibleNotesMemberaspi:QuantumLeapEnergyLLCMember2025-11-120001921865aspi:IsoBioIncMember2025-12-310001921865aspi:JuneTwoThousandAndTwentyFiveMember2025-06-012025-06-300001921865us-gaap:SalesRevenueNetMember2026-01-012026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001921865aspi:RenergenMember2026-01-012026-09-300001921865us-gaap:FairValueInputsLevel2Member2026-09-300001921865aspi:QuantumLeapEnergyLLCMemberaspi:TwoThousandTwentyFiveNotesMember2025-11-012025-11-300001921865us-gaap:FairValueInputsLevel1Member2026-09-300001921865srt:MaximumMemberaspi:OfficeFurnitureMember2026-01-012026-09-300001921865aspi:TotalSegmentMember2025-07-012025-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2026-01-012026-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2026-07-012026-09-300001921865aspi:ElectricityPaymentsAndEarlyTerminationGuarantiesMember2026-09-300001921865us-gaap:TreasuryStockCommonMember2026-07-012026-09-300001921865aspi:VieAspRentalsMember2026-09-300001921865srt:MinimumMember2026-01-012026-09-300001921865aspi:IsoBioIncMember2026-07-012026-09-300001921865us-gaap:NoncontrollingInterestMember2026-06-300001921865us-gaap:CommonStockMember2025-01-012025-03-310001921865us-gaap:EquityMethodInvestmentsMemberus-gaap:FairValueInputsLevel1Member2026-09-300001921865aspi:ToolsMachineryAndEquipmentMembersrt:MaximumMember2026-01-012026-09-300001921865aspi:SixthAddendumToASPITermLoanFacilityMemberus-gaap:SubsequentEventMemberaspi:RenergenMember2026-10-010001921865aspi:PlantAndOfficeBuildingsMember2026-09-300001921865aspi:CommonStockWarrantsMember2025-09-300001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMember2026-01-012026-09-300001921865aspi:One30SevenIncMember2025-10-012025-10-310001921865aspi:SpecialistIsotopesAndRelatedServicesMember2025-01-012025-09-300001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMember2025-01-012025-12-310001921865us-gaap:TreasuryStockCommonMember2026-03-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001921865aspi:SpecialistIsotopesAndRelatedServicesMemberus-gaap:ProductMember2025-01-012025-09-300001921865us-gaap:ResearchAndDevelopmentExpense2025-01-012025-09-300001921865country:ZA2025-01-012025-09-300001921865us-gaap:GeneralAndAdministrativeExpense2026-01-012026-09-300001921865aspi:HeliumAndLNGMember2026-01-012026-09-3000019218652024-03-012024-03-310001921865aspi:StockAwardsMember2025-07-012025-09-300001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2026-03-280001921865aspi:StockAwardsMember2026-07-012026-09-300001921865us-gaap:CommonClassAMemberaspi:SkylineBuildersGroupHoldingLtdMemberaspi:SecuritiesPurchaseAgreementMemberaspi:WarrantBMember2025-08-290001921865us-gaap:SegmentDiscontinuedOperationsMember2025-12-310001921865us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001921865aspi:ENDRALifeSciencesIncMember2026-09-300001921865us-gaap:CommonStockMember2026-01-012026-03-310001921865aspi:IsoBioIncMember2026-09-300001921865us-gaap:TreasuryStockCommonMember2026-09-300001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001921865aspi:CommonStockWarrantsMember2025-07-310001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherLongTermInvestments2026-09-300001921865us-gaap:GeneralAndAdministrativeExpense2026-07-012026-09-300001921865aspi:OtherAssetMember2025-07-012025-09-3000019218652024-01-012025-07-310001921865aspi:PETLabsMember2025-12-312025-12-310001921865us-gaap:FairValueInputsLevel3Memberus-gaap:OtherLongTermInvestments2025-12-310001921865us-gaap:AccountsReceivableMember2025-01-012025-12-310001921865us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001921865aspi:StockPurchaseAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:CommonClassBMember2025-08-290001921865aspi:EastCoastNuclearPharmacyLLCMember2026-01-012026-09-300001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:CommonStockMember2026-01-012026-03-3100019218652025-11-012025-11-300001921865aspi:OtherAssetMember2026-01-012026-09-300001921865us-gaap:SecuredDebtMemberaspi:SBSALoanMember2026-09-300001921865us-gaap:CommonStockMemberaspi:RenergenMember2026-01-062026-01-060001921865us-gaap:CommonStockMember2025-07-012025-09-300001921865us-gaap:ParentMemberaspi:QuantumLeapEnergyLLCMemberaspi:TwoThousandTwentyFiveNotesMember2025-11-012025-11-300001921865us-gaap:AdditionalPaidInCapitalMember2026-03-310001921865us-gaap:FairValueInputsLevel3Member2025-12-310001921865aspi:SeriesSeed1PreferredStockMemberaspi:OpeongoMember2026-01-260001921865aspi:RenergenLimitedMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001921865aspi:CommonStockWarrantsMember2025-09-012025-09-300001921865us-gaap:NoncontrollingInterestMember2025-03-310001921865aspi:HeliumAndLNGMember2025-01-012025-09-300001921865aspi:ClassAUnitsMemberaspi:NobleMemberaspi:MergerAgreementMember2026-06-250001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMember2021-12-202021-12-200001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2024-12-310001921865us-gaap:StockOptionMember2026-01-012026-09-300001921865aspi:SpecialistIsotopesAndRelatedServicesMemberus-gaap:ProductMember2025-07-012025-09-300001921865us-gaap:NoncontrollingInterestMember2026-03-310001921865aspi:CreberMiniUnitMemberaspi:One30SevenIncMember2025-10-012025-10-310001921865aspi:ToolsMachineryAndEquipmentMember2026-09-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300001921865aspi:ToolsMachineryAndEquipmentMembersrt:MinimumMember2026-01-012026-09-300001921865aspi:PETLabsMember2024-01-012024-01-310001921865aspi:CommonStockWarrantsMember2025-05-310001921865aspi:ReservingSixMonthsOfPaymentsToFulfillObligationsUnderTheIDCDebtMember2026-09-300001921865us-gaap:NoncontrollingInterestMember2026-07-012026-09-300001921865us-gaap:TreasuryStockCommonMember2026-04-012026-06-300001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:RetainedEarningsMember2026-01-012026-03-310001921865us-gaap:IPOMember2025-07-012025-09-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherLongTermInvestments2025-12-310001921865us-gaap:NoncontrollingInterestMember2026-04-012026-06-300001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMember2026-09-300001921865us-gaap:RetainedEarningsMemberaspi:SkylineBuildersGroupHoldingLtdMember2025-07-012025-09-300001921865aspi:CollaborationRevenueMember2026-01-012026-09-300001921865aspi:GasProcessingAndLiquefactionEquipmentMember2026-09-300001921865us-gaap:WarrantMemberaspi:ENDRALifeSciencesIncMember2026-05-270001921865us-gaap:UnsecuredDebtMember2026-07-012026-09-300001921865aspi:CreditFacilityMember2025-12-310001921865us-gaap:Revenues2023-09-012023-09-300001921865us-gaap:CommonClassAMemberaspi:WarrantAMemberaspi:SkylineBuildersGroupHoldingLtdMemberaspi:SecuritiesPurchaseAgreementMembersrt:MaximumMember2025-08-290001921865aspi:GasProcessingAndLiquefactionEquipmentMember2025-12-310001921865aspi:NuclearFuelsMember2026-09-300001921865us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001921865aspi:VirginiaGasProjectMember2026-09-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleNotesPayableMember2025-12-310001921865us-gaap:ConstructionInProgressMember2025-12-310001921865aspi:RenergensObligationMember2026-09-300001921865aspi:PETLabsMember2023-10-012023-10-3100019218652026-07-012026-09-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:EquityMethodInvestmentsMember2026-09-300001921865aspi:CollaborationRevenueMemberaspi:HeliumAndLNGMember2026-01-012026-09-300001921865us-gaap:ProductMember2025-07-012025-09-300001921865aspi:TwoThousandTwentyFiveInducementEquityIncentivePlanMember2026-09-300001921865aspi:EquityIncentivePlanTwentyTwentyFourMember2024-06-300001921865aspi:AIRSOLMember2026-09-300001921865us-gaap:IPOMember2025-04-012025-06-300001921865aspi:EastCoastNuclearPharmacyLLCMember2026-09-3000019218652025-01-012025-09-300001921865aspi:RenergenLimitedMemberus-gaap:NoncontrollingInterestMember2026-01-012026-03-310001921865us-gaap:UnsecuredDebtMember2025-12-3100019218652026-01-012026-09-300001921865aspi:ClassBUnitsMemberaspi:NobleMemberaspi:MergerAgreementMember2026-06-250001921865aspi:RenergenMember2026-09-300001921865aspi:SharePurchaseAgreementRelatingToPetLabsMember2025-01-012025-12-310001921865aspi:EquityIncentivePlanTwentyTwentyFourMember2026-09-300001921865us-gaap:UnsecuredDebtMemberaspi:AIRSOLMember2023-08-300001921865aspi:ENDRALifeSciencesIncMember2026-09-300001921865country:ZA2026-07-012026-09-300001921865aspi:HDPAndWorkerTrustMember2026-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2026-09-300001921865aspi:InterestRateThroughMarchSevenTwoThousandTwentyFiveMember2026-01-012026-09-300001921865aspi:OpeongoMember2026-09-300001921865us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2026-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2025-07-012025-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2025-12-310001921865aspi:SharePurchaseAgreementRelatingToPetLabsMember2026-01-012026-09-300001921865aspi:ReservingAllPaymentsToFulfillObligationsUnderTheSBSALoanMember2026-09-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2026-09-300001921865aspi:FacilityAgreementMembersrt:MaximumMember2026-01-012026-09-300001921865us-gaap:RetainedEarningsMember2026-07-012026-09-300001921865us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001921865us-gaap:RetainedEarningsMember2025-12-3100019218652025-06-3000019218652026-01-062026-09-300001921865aspi:Tetra4Member2026-09-300001921865us-gaap:RetainedEarningsMemberus-gaap:IPOMember2025-04-012025-06-3000019218652021-10-310001921865aspi:EquityIncentivePlanTwentyTwentyFourMember2024-06-012024-06-300001921865aspi:IsoBioIncMemberaspi:SeriesSeed1PreferredStockMember2025-07-280001921865us-gaap:RestrictedStockUnitsRSUMember2026-09-300001921865us-gaap:PropertyPlantAndEquipmentMembersrt:MinimumMember2026-01-012026-09-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001921865us-gaap:NoncontrollingInterestMember2024-12-310001921865us-gaap:AdditionalPaidInCapitalMember2026-09-300001921865aspi:QuantumLeapEnergyLLCMemberaspi:TwoThousandTwentyFiveNotesMember2025-11-300001921865aspi:DevelopedAssetsMember2026-09-300001921865aspi:RenergenLimitedMemberus-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-300001921865aspi:OfficeFurnitureMember2026-09-300001921865us-gaap:StockOptionMember2026-07-012026-09-300001921865aspi:FacilityAgreementMembersrt:MinimumMember2026-01-012026-09-300001921865aspi:UnprovedReservesMember2025-12-310001921865aspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001921865aspi:WellsInProcessMember2026-09-300001921865aspi:MergerAgreementMemberaspi:RenergenMemberaspi:ASPITermLoanFacilityMember2026-06-250001921865aspi:CommonStockWarrantsMember2026-09-300001921865us-gaap:SecuredDebtMember2026-09-300001921865us-gaap:RestrictedStockUnitsRSUMemberaspi:AmericanVenturesAdvisoryAgreementMemberaspi:QuantumLeapEnergyLLCMember2026-01-012026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2026-01-012026-09-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2026-01-012026-09-300001921865aspi:OtherAssetMember2025-01-012025-09-300001921865us-gaap:VehiclesMember2026-01-012026-09-300001921865aspi:SkylineBuildersGroupHoldingLtdMember2026-07-012026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMember2026-09-300001921865us-gaap:RetainedEarningsMember2025-07-012025-09-300001921865us-gaap:CommonStockMember2024-12-310001921865aspi:PETLabsMember2025-12-012025-12-310001921865aspi:HeatherKiesslingMember2026-07-012026-09-300001921865aspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001921865us-gaap:RestrictedStockUnitsRSUMemberaspi:AmericanVenturesAdvisoryAgreementMemberaspi:QuantumLeapEnergyLLCMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-10-312025-10-310001921865us-gaap:ConvertibleNotesPayableMember2026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2025-01-012025-09-300001921865aspi:RenergenLimitedMemberus-gaap:TreasuryStockCommonMember2026-04-012026-06-300001921865country:US2025-07-012025-09-300001921865country:US2026-07-012026-09-300001921865us-gaap:CommonClassAMemberaspi:PrefundedWarrantMemberaspi:SecuritiesPurchaseAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2025-08-290001921865aspi:TwoThousandTwentyFiveNotesMember2025-11-012025-11-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-300001921865us-gaap:CommonStockMember2025-06-300001921865aspi:RenergenLimitedMember2026-09-300001921865aspi:TerraPowerLoanAgreementMember2026-01-012026-09-3000019218652026-01-060001921865aspi:RenergenMember2023-09-012023-09-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMember2025-12-310001921865aspi:One30SevenIncMemberaspi:MidiAndMaxiMember2025-10-012025-10-310001921865srt:MinimumMemberaspi:One30SevenIncMemberaspi:MidiAndMaxiMember2025-10-012025-10-310001921865aspi:ToolsMachineryAndEquipmentMember2025-12-310001921865aspi:JulyTwoThousandAndTwentySixMember2026-07-012026-07-310001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMembersrt:MinimumMember2021-12-200001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:TreasuryStockCommonMember2026-01-012026-03-310001921865aspi:SpecialistIsotopesAndRelatedServicesMember2026-01-012026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMemberaspi:SkylineMember2025-12-310001921865aspi:PromissoryNotesOneMember2025-12-310001921865us-gaap:FairValueInputsLevel3Memberus-gaap:OtherLongTermInvestments2026-09-300001921865us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2025-12-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001921865us-gaap:IPOMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-300001921865country:US2026-01-012026-09-300001921865country:ZA2026-01-012026-09-300001921865us-gaap:TreasuryStockCommonMember2025-12-310001921865aspi:OctoberTwoThousandTwentyFiveMember2025-10-012025-10-310001921865aspi:PromissoryNotesMember2026-09-300001921865us-gaap:CommonStockMemberaspi:RenergenLimitedMember2026-01-012026-03-310001921865aspi:SkylineExchangeAgreementMemberus-gaap:CommonClassAMemberaspi:SkylineBuildersGroupHoldingLtdMember2026-03-290001921865us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberaspi:AmericanVenturesAdvisoryAgreementMemberaspi:QuantumLeapEnergyLLCMember2025-10-312025-10-310001921865us-gaap:NoncontrollingInterestMember2026-09-3000019218652026-08-012026-08-310001921865aspi:ENDRALifeSciencesIncMember2026-01-012026-09-300001921865us-gaap:SecuredDebtMemberaspi:SBSALoanMember2026-07-012026-09-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:USTreasurySecuritiesMember2025-12-310001921865us-gaap:FairValueInputsLevel1Member2025-12-310001921865us-gaap:CommonStockMember2025-09-300001921865aspi:TwoThousandAndTwentyTwoEquityIncentivePlanMember2022-11-012022-11-300001921865aspi:EquityIncentivePlanMember2025-01-310001921865us-gaap:AccountsReceivableMember2026-01-012026-09-300001921865aspi:RenergenLimitedMember2026-01-012026-01-3100019218652025-03-310001921865aspi:RenergenFirmIntentionLetterAndLoanAgreementMember2025-05-190001921865aspi:RenergenFirmIntentionLetterAndLoanAgreementMember2026-01-012026-09-300001921865us-gaap:GeneralAndAdministrativeExpense2025-01-012025-09-300001921865aspi:SoftwareMember2025-12-310001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMembersrt:MaximumMember2021-12-200001921865aspi:SoftwareMember2026-09-300001921865us-gaap:ProductMember2026-07-012026-09-300001921865aspi:IsoBioIncMember2026-01-012026-09-300001921865aspi:SpecialistIsotopesAndRelatedServicesMember2025-12-310001921865aspi:ConvertibleNotesMember2026-01-012026-09-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMember2026-09-300001921865aspi:SkylineBuildersGroupHoldingLtdMember2026-09-300001921865aspi:FacilityAgreementMember2026-09-300001921865aspi:ClassBUnitsMemberaspi:NobleMemberaspi:RenergenMember2026-06-252026-06-250001921865aspi:NuMedDiagnosticsLLCMember2026-09-300001921865aspi:NuMedDiagnosticsLLCMember2026-01-310001921865aspi:NuMedDiagnosticsLLCMember2026-01-012026-01-310001921865us-gaap:FairValueInputsLevel1Memberus-gaap:ConvertibleNotesPayableMember2025-12-310001921865us-gaap:SecuredDebtMemberaspi:SBSALoanMember2026-01-012026-09-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001921865us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:UnsecuredDebtMemberaspi:AIRSOLMember2024-03-182024-03-180001921865us-gaap:RetainedEarningsMemberaspi:RenergenLimitedMember2026-01-012026-03-310001921865us-gaap:VehiclesMember2026-09-300001921865aspi:PlantAndOfficeBuildingsMember2026-01-012026-09-300001921865us-gaap:SalesRevenueNetMemberaspi:CustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-300001921865aspi:UnprovedReservesMember2026-09-300001921865us-gaap:IPOMemberus-gaap:NoncontrollingInterestMember2025-04-012025-06-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001921865aspi:SpecialistIsotopesAndRelatedServicesMember2026-07-012026-09-300001921865aspi:EastCoastNuclearPharmacyLLCMember2025-10-310001921865us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-3000019218652026-04-012026-06-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2026-09-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:CommonClassBMember2026-03-290001921865aspi:NuMedDiagnosticsLLCMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001921865us-gaap:NonoperatingIncomeExpenseaspi:ENDRALifeSciencesIncMember2026-07-012026-09-300001921865us-gaap:RestrictedStockUnitsRSUMemberaspi:AmericanVenturesLLCMember2025-10-012025-10-310001921865aspi:ClassBUnitsMemberaspi:NobleMemberaspi:MergerAgreementMember2026-06-252026-06-250001921865srt:MaximumMember2026-01-012026-09-300001921865us-gaap:IPOMemberus-gaap:TreasuryStockCommonMember2025-07-012025-09-300001921865us-gaap:FairValueInputsLevel3Member2026-09-300001921865aspi:OctoberTwoThousandTwentyFiveMember2025-10-310001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMember2024-12-310001921865us-gaap:ConstructionInProgressMember2025-12-310001921865us-gaap:ConvertibleNotesPayableMember2025-12-310001921865us-gaap:RetainedEarningsMember2025-06-300001921865aspi:OperatingLeasesMember2026-09-300001921865aspi:TerraPowerLoanAgreementMember2026-09-300001921865us-gaap:LandMember2025-12-310001921865aspi:RenergenLimitedMemberus-gaap:TreasuryStockCommonMember2026-07-012026-09-300001921865us-gaap:CommonStockMemberaspi:RenergenLimitedMember2026-04-012026-06-300001921865aspi:StockAwardsMember2025-01-012025-09-300001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMember2021-12-2000019218652026-04-012026-09-300001921865us-gaap:ResearchAndDevelopmentExpense2026-01-012026-09-3000019218652026-06-300001921865us-gaap:NonoperatingIncomeExpenseaspi:ENDRALifeSciencesIncMember2026-01-012026-09-300001921865aspi:CommonStockWarrantsMember2025-12-310001921865us-gaap:RetainedEarningsMember2026-03-310001921865us-gaap:IPOMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001921865aspi:MotorVehicleAndEquipmentLoansMembersrt:MaximumMember2026-01-012026-09-300001921865aspi:PromissoryNotesMember2025-12-310001921865us-gaap:RetainedEarningsMemberaspi:RenergenLimitedMember2026-04-012026-06-3000019218652025-01-012025-03-310001921865us-gaap:LandMember2026-09-300001921865aspi:ConvertibleNotesMember2026-07-150001921865us-gaap:ComputerEquipmentMember2025-12-310001921865aspi:MotorVehicleAndEquipmentLoansMember2026-09-300001921865aspi:RenergenLimitedMember2026-07-012026-09-300001921865aspi:HeliumAndLNGMember2025-12-310001921865us-gaap:StockOptionMember2025-07-012025-09-300001921865us-gaap:UnsecuredDebtMember2026-01-012026-09-300001921865aspi:TerraPowerLoanAgreementMember2025-05-310001921865aspi:ThirdPartyInvestorsMemberaspi:ConvertibleNotesMember2026-07-160001921865us-gaap:CommonStockMember2026-04-012026-06-300001921865srt:MinimumMemberaspi:SoftwareMember2026-01-012026-09-300001921865aspi:PETLabsMember2025-01-012025-01-310001921865aspi:RehabilitationAssetMember2025-12-310001921865us-gaap:FairValueInputsLevel2Memberus-gaap:OtherLongTermInvestments2025-12-310001921865us-gaap:FairValueInputsLevel1Memberus-gaap:OtherLongTermInvestments2025-12-310001921865us-gaap:RetainedEarningsMember2026-06-3000019218652026-01-012026-03-310001921865us-gaap:SecuredDebtMemberaspi:SecondAmendmentMember2026-09-300001921865us-gaap:ConstructionInProgressMember2026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2026-06-300001921865us-gaap:RetainedEarningsMember2025-01-012025-03-310001921865us-gaap:ConstructionInProgressMember2026-09-300001921865aspi:StockAwardsMember2026-09-300001921865us-gaap:NoncontrollingInterestMember2025-06-300001921865aspi:PlantAndOfficeBuildingsMember2025-12-310001921865aspi:FacilityAgreementMember2026-07-012026-09-300001921865us-gaap:RetainedEarningsMember2026-09-300001921865aspi:TwoThousandAndTwentyOneStockIncentivePlanMember2021-10-012021-10-310001921865aspi:TotalSegmentMember2026-07-012026-09-300001921865us-gaap:NoncontrollingInterestMember2025-09-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMember2026-09-300001921865aspi:RenergenMember2026-01-062026-01-0600019218652025-10-012025-10-310001921865aspi:FacilityAgreementMember2026-01-012026-09-3000019218652023-10-012023-10-310001921865us-gaap:SubsequentEventMemberaspi:RenergenMember2026-10-010001921865aspi:CollaborationRevenueMemberaspi:SpecialistIsotopesAndRelatedServicesMember2026-01-012026-09-3000019218652026-03-310001921865aspi:HeatherKiesslingMember2026-09-300001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001921865us-gaap:FairValueInputsLevel2Memberus-gaap:OtherLongTermInvestments2026-09-300001921865aspi:MolopoLoanActionMember2024-11-300001921865aspi:ENDRALifeSciencesIncMemberus-gaap:CommonStockMember2026-05-270001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMemberaspi:NuMedDiagnosticsLLCMember2026-01-012026-09-300001921865aspi:SkylineBuildersGroupHoldingLtdMember2025-07-012025-09-300001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMember2026-01-012026-09-300001921865aspi:NuMedDiagnosticsLLCMember2026-01-012026-09-300001921865us-gaap:TreasuryStockCommonMember2026-06-300001921865us-gaap:SalesRevenueNetMemberaspi:CustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001921865aspi:NuclearFuelsMember2025-12-310001921865us-gaap:ResearchAndDevelopmentExpense2026-07-012026-09-300001921865aspi:RenergenLimitedMemberaspi:RenergenFirmIntentionLetterAndLoanAgreementMember2025-05-190001921865us-gaap:CommonClassAMemberaspi:SecuritiesPurchaseAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2025-08-290001921865us-gaap:WarrantMemberaspi:StockPurchaseAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2025-08-290001921865aspi:StockAwardsMember2026-01-012026-09-300001921865us-gaap:LeaseholdImprovementsMember2025-12-310001921865aspi:NuMedDiagnosticsLLCMember2026-01-220001921865aspi:InterestRateAfterMarchSevenTwoThousandTwentyFiveMember2026-01-012026-09-3000019218652026-01-012026-01-310001921865us-gaap:RetainedEarningsMember2025-09-300001921865us-gaap:NoncontrollingInterestMember2025-04-012025-06-300001921865aspi:PETLabsMember2026-01-012026-09-300001921865us-gaap:ComputerEquipmentMember2026-01-012026-09-3000019218652025-01-012025-12-310001921865us-gaap:NoncontrollingInterestMember2025-07-012025-09-300001921865aspi:NuclearFuelsMember2026-07-012026-09-300001921865us-gaap:ComputerEquipmentMember2026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2025-09-300001921865aspi:EquityIncentivePlanMember2026-09-300001921865us-gaap:UnsecuredDebtMember2014-04-110001921865us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2026-09-300001921865aspi:PromissoryNotesTwoMember2026-09-300001921865us-gaap:CommonStockMember2026-06-300001921865aspi:DevelopedAssetsMember2025-12-3100019218652022-11-300001921865aspi:MotorVehicleAndEquipmentLoansMember2025-12-310001921865us-gaap:IPOMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-12-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001921865us-gaap:IPOMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-3000019218652025-08-012026-03-310001921865us-gaap:RetainedEarningsMember2025-04-012025-06-300001921865us-gaap:FairValueInputsLevel1Memberus-gaap:OtherLongTermInvestments2026-09-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:CommonClassBMember2026-01-012026-09-300001921865us-gaap:RetainedEarningsMember2025-03-310001921865aspi:EastCoastNuclearPharmacyLLCMember2025-10-012025-10-310001921865us-gaap:CommonStockMemberaspi:One30SevenIncMember2025-10-012025-10-310001921865us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2025-12-310001921865aspi:SharePurchaseAgreementRelatingToPetLabsMember2025-01-012025-01-310001921865aspi:RenergenMember2026-01-060001921865us-gaap:UnsecuredDebtMemberaspi:AIRSOLMember2023-08-302023-08-300001921865aspi:PETLabsMember2026-09-300001921865us-gaap:CommonStockMember2025-04-012025-06-300001921865us-gaap:GasGatheringAndProcessingEquipmentMember2026-09-300001921865us-gaap:LeaseholdImprovementsMember2026-09-300001921865srt:MinimumMemberaspi:MotorVehicleAndEquipmentLoansMember2026-01-012026-09-300001921865aspi:RenergenLimitedMemberus-gaap:NoncontrollingInterestMember2026-07-012026-09-300001921865us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:EquityMethodInvestmentsMember2026-09-300001921865aspi:One30SevenIncMemberaspi:MidiAndMaxiMembersrt:MaximumMember2025-10-012025-10-310001921865us-gaap:SecuredDebtMemberaspi:IDCLoanMember2026-07-012026-09-300001921865aspi:TerraPowerLoanAgreementMembersrt:MaximumMember2026-09-300001921865us-gaap:CommonClassAMemberaspi:SkylineBuildersGroupHoldingLtdMemberaspi:WarrantAMemberaspi:SecuritiesPurchaseAgreementMember2025-08-290001921865aspi:RenergenLimitedMemberus-gaap:TreasuryStockCommonMember2026-01-012026-03-310001921865aspi:RenergenLimitedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001921865us-gaap:SecuredDebtMemberaspi:SecondAmendmentMember2026-01-012026-09-300001921865aspi:RenergenLimitedMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-300001921865us-gaap:AdditionalPaidInCapitalMember2024-12-310001921865us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-3000019218652025-09-3000019218652024-04-040001921865aspi:NuclearFuelsMember2025-01-012025-09-300001921865us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMember2025-12-310001921865aspi:NuclearFuelsMemberus-gaap:ProductMember2025-07-012025-09-300001921865aspi:SkylineBuildersGroupHoldingLtdMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-300001921865aspi:IsoBioIncMember2025-10-012025-10-310001921865aspi:CustomerMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-300001921865aspi:NuclearFuelsMemberus-gaap:ProductMember2026-07-012026-09-300001921865us-gaap:RetainedEarningsMember2026-04-012026-06-300001921865aspi:ConstructionServicesSpecialistIsotopesAndRelatedServicesMemberaspi:EastCoastNuclearPharmacyLLCMember2025-01-012025-12-310001921865aspi:CollaborationRevenueMember2025-01-012025-09-300001921865us-gaap:FairValueInputsLevel2Memberus-gaap:EquityMethodInvestmentsMember2026-09-300001921865us-gaap:RestrictedStockUnitsRSUMember2025-09-012025-09-300001921865us-gaap:AdditionalPaidInCapitalMember2025-12-310001921865us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001921865aspi:JulyTwoThousandTwentyFiveMember2025-07-012025-07-310001921865aspi:QLE2024EquityIncentivePlanMember2026-01-012026-09-300001921865us-gaap:VehiclesMember2025-12-310001921865aspi:RenergenLimitedMember2026-01-012026-03-310001921865us-gaap:ProductMember2025-01-012025-09-300001921865us-gaap:RetainedEarningsMemberaspi:RenergenLimitedMember2026-07-012026-09-3000019218652025-07-012025-09-300001921865srt:MaximumMemberaspi:IsoBioAndSkylinesJointVenturesWithKC-GloryJVKC-GeotechJVAndKC-CRFGJVMember2026-09-300001921865aspi:SkylineExchangeAgreementMemberaspi:SkylineBuildersGroupHoldingLtdMember2026-07-012026-09-300001921865us-gaap:SegmentDiscontinuedOperationsMember2026-07-012026-09-300001921865aspi:MotorVehicleAndEquipmentLoansMember2025-01-012025-09-300001921865aspi:QLE2024EquityIncentivePlanMember2024-03-310001921865aspi:SpecialistIsotopesAndRelatedServicesMember2026-09-300001921865us-gaap:ProductMember2026-01-012026-09-300001921865aspi:NuclearFuelsMemberus-gaap:ProductMember2025-01-012025-09-300001921865us-gaap:CommonStockMemberaspi:SkylineBuildersGroupHoldingLtdMember2025-07-012025-09-300001921865us-gaap:FairValueInputsLevel2Member2025-12-310001921865aspi:SkylineBuildersGroupHoldingLtdMember2026-01-012026-09-300001921865aspi:SixthAddendumToASPITermLoanFacilityMemberaspi:RenergenMember2026-09-300001921865us-gaap:UnsecuredDebtMemberaspi:AIRSOLMember2026-09-300001921865us-gaap:FairValueInputsLevel1Memberus-gaap:ConvertibleNotesPayableMember2026-09-30xbrli:purexbrli:sharesaspi:Segmentiso4217:ZARiso4217:USDxbrli:sharesaspi:Customeraspi:Voteiso4217:USD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 10-Q

 

 

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File Number: 001-41555

 

ASP Isotopes Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

87-2618235

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

2200 Ross Avenue

Suite 4575E

Dallas, TX

75201

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (214) 432-8219

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

ASPI

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 16, 2026, the registrant had 155,834,430 shares of common stock, $0.01 par value per share, outstanding.

 

 

 


 

Table of Contents

 

 

Page

PART I.

FINANCIAL INFORMATION

 

5

Item 1.

Financial Statements (Unaudited)

 

5

Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025

 

5

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Month Periods ended September 30, 2026 and 2025

 

6

Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Month Periods ended September 30, 2026 and 2025

 

7

Condensed Consolidated Statements of Cash Flows for the Nine Month Periods ended September 30, 2026 and 2025

 

9

Notes to Unaudited Condensed Consolidated Financial Statements

 

11

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

39

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

53

Item 4.

Controls and Procedures

 

53

 

 

PART II.

OTHER INFORMATION

 

54

Item 1.

Legal Proceedings

 

54

Item 1A.

Risk Factors

 

54

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

54

Item 3.

Defaults Upon Senior Securities

 

54

Item 4.

Mine Safety Disclosures

 

54

Item 5.

Other Information

 

54

Item 6.

Exhibits

 

56

Signatures

 

57

 

2


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “would,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:

•
our ability to achieve or sustain positive cash flows from operations or profitability;
•
our ability to complete the construction of, commission and successfully operate isotope enrichment plants and Phase 2 of the Virginia Gas Project in a cost-effective manner;
•
our ability to meet, and to continue to meet, applicable regulatory requirements for the use of the isotopes we may produce using the ASP technology or the QE technology;
•
our ability to obtain regulatory approvals for the enrichment of uranium and the production and distribution of other isotopes;
•
our ability to comply on an ongoing basis with the numerous regulatory requirements applicable to the ASP technology, the QE technology and our enrichment facilities in South Africa;
•
our ability to execute on various projects and strategic initiatives with potential customers and partners, including our initiative to commence enrichment of uranium in South Africa and to complete development of Phase 2 of the Virginia Gas Project;
•
the success or profitability of our future offtake arrangements with respect to various isotopes that we may produce using ASP technology or the QE technology or with respect to helium or liquified natural gas (“LNG”) we may produce at the Virginia Gas Project;
•
a failure of demand for various isotopes that we may produce using ASP technology or the QE technology or for helium or LNG we produce at the Virginia Gas Project;
•
our future capital requirements and sources and uses of cash, including, without limitation, our outstanding debt obligations;
•
our ability to obtain funding for our operations and future growth;
•
the extensive costs, time and uncertainty associated with new technology development;
•
our ability to implement and maintain effective internal controls;
•
developments and projections relating to our competitors and industry;
•
the ability to recognize the anticipated benefits of acquisitions and investments, including our acquisition of Renergen;
•
our ability to complete the Merger (as defined below) within the anticipated timeframe or at all due to the conditions to the closing of the Merger not being satisfied, including the failure to obtain approval of the Merger from ENDRA Life Sciences Inc.’s stockholders;
•
our ability to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results;
•
problems with the performance of the ASP technology or the QE technology in the enrichment of isotopes;
•
our dependence on a limited number of third-party suppliers for certain components and our inability to obtain third-party providers or contractors to conduct our operations, including with respect to the development of Phase 2 of the Virginia Gas Project;
•
our inability to adapt to changing technology and diagnostic landscapes, such as the emergence of new diagnostic scanners or tracers;
•
our expected dependence on a limited number of key customers for isotopes that we may produce using ASP technology or the QE technology;
•
our inability to protect our intellectual property and the risk of claims asserting that we have infringed on the intellectual property of others;
•
our inability to compete effectively;
•
risks associated with the current economic environment, including any future economic downturn, the impact of inflation or tariffs, disruptions in financial credit and other disruptions resulting from geo-political events such as the Russian invasion of Ukraine, conflicts in the Middle East, including the United States-Israel-Iran war, and trade tensions between the U.S. and China;
•
fluctuations in the market price and demand for LNG, helium and other natural gases and the drivers of such fluctuations;
•
risks associated with our international operations;

3


 

•
our credit counterparty risks;
•
changes in applicable laws or regulations, including alteration, suspension or cancellation of our Exploration Rights and Production Right in South Africa;
•
our inability to manage commodity risks;
•
the highly speculative nature of Renergen’s exploration projects;
•
our inability to adequately protect our technology infrastructure;
•
our inability to hire or retain skilled employees and the loss of any of our key personnel;
•
operational risk;
•
costs and other risks associated with being a reporting company and being subject to the Sarbanes-Oxley Act;
•
our ability to complete the listing of Quantum Leap Energy as a standalone public company; and
•
other factors that are described in “Risk Factors,” on page 54.

These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item 1A - “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended), and other reports that we file with the SEC, including this Quarterly Report on Form 10-Q. Any forward-looking statement in this Quarterly Report on Form 10-Q reflects our current view with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

This Quarterly Report on Form 10-Q also contains estimates, projections, and other information concerning our industry, our business, and the potential markets for certain isotopes and for helium and LNG, including data regarding the estimated size of those respective markets, their respective projected growth rates, and, in the case of our isotope enrichment platform, the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived.

Note Regarding Company References

Unless the context otherwise requires, references to the “Company,” “our Company,” “ASPI,” “we,” “us” and “our” refer to ASP Isotopes Inc. and its direct and indirect subsidiaries; references to “ASP Isotopes” refer to ASP Isotopes Inc. and not to any of its subsidiaries; references to “QLE” refer to Quantum Leap Energy, LLC; references to “Renergen” refer to Renergen Limited, a public corporation incorporated in 2014 and existing under the South African Companies Act 71 of 2008, as amended, together with its subsidiaries unless the context dictates otherwise; references to “Tetra4” refer to Tetra4 Proprietary Limited; references to “Skyline” refer to Skyline Builders Group Holding Limited, together with its subsidiaries. The terms “dollar,” “USD” or “$” refer to U.S. dollars, and the terms “R,” “ZAR” or “rand” refer to the South African rand.

Trademarks

All trademarks, service marks, and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this report may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

4


 

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

ASP Isotopes Inc.

Condensed Consolidated Balance Sheets (unaudited)

(in thousands, except share and per share amounts)

 

 

September 30, 2026

 

 

December 31, 2025 *

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

201,663

 

 

$

279,572

 

Short-term investments

 

 

—

 

 

 

47,745

 

Restricted cash

 

 

19,121

 

 

 

—

 

Accounts receivable

 

 

3,273

 

 

 

1,078

 

Inventories

 

 

1,522

 

 

 

1,098

 

Note receivable

 

 

—

 

 

 

32,005

 

Deferred offering costs

 

 

135

 

 

 

1,782

 

Prepaid expenses and other current assets

 

 

10,814

 

 

 

4,949

 

Current assets of discontinued operations

 

 

—

 

 

 

31,690

 

Total current assets

 

 

236,528

 

 

 

399,919

 

Property and equipment, net

 

 

41,726

 

 

 

33,291

 

Natural gas properties, net

 

 

196,126

 

 

 

—

 

Operating lease right-of-use assets, net

 

 

5,417

 

 

 

1,464

 

Intangible assets

 

 

594

 

 

 

409

 

Goodwill

 

 

6,461

 

 

 

5,177

 

Lease receivable - noncurrent

 

 

3,997

 

 

 

426

 

Restricted cash - noncurrent

 

 

1,761

 

 

 

—

 

Equity method investments

 

 

23,005

 

 

 

—

 

Other investments

 

 

20,241

 

 

 

5,580

 

Other noncurrent assets

 

 

2,273

 

 

 

866

 

Noncurrent assets of discontinued operations

 

 

—

 

 

 

50,888

 

Total assets

 

$

538,129

 

 

$

498,020

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

9,570

 

 

$

3,814

 

Accrued expenses

 

 

8,950

 

 

 

4,414

 

Debt - current

 

 

47,690

 

 

 

584

 

Finance lease liabilities – current

 

 

157

 

 

 

167

 

Operating lease liabilities – current

 

 

928

 

 

 

544

 

Deferred revenue

 

 

882

 

 

 

882

 

Other current liabilities

 

 

496

 

 

 

501

 

Current liabilities of discontinued operations

 

 

—

 

 

 

21,790

 

Total current liabilities

 

 

68,673

 

 

 

32,696

 

Deferred tax liabilities

 

 

8,923

 

 

 

—

 

Convertible notes payable, at fair value

 

 

85,860

 

 

 

199,323

 

Debt - noncurrent

 

 

5,268

 

 

 

1,471

 

Finance lease liabilities – noncurrent

 

 

335

 

 

 

471

 

Operating lease liabilities – noncurrent

 

 

4,763

 

 

 

1,059

 

Deferred revenue - noncurrent

 

 

818

 

 

 

—

 

Other noncurrent liabilities

 

 

4,200

 

 

 

—

 

Noncurrent liabilities of discontinued operations

 

 

—

 

 

 

102

 

Total liabilities

 

 

178,840

 

 

 

235,122

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued
   and outstanding as of September 30, 2026 and December 31, 2025

 

 

—

 

 

 

—

 

Common stock, $0.01 par value; 500,000,000 shares authorized, 156,002,704 shares issued and 155,834,430 shares outstanding as of September 30, 2026 and 111,677,771 shares issued and outstanding as of December 31, 2025

 

 

1,558

 

 

 

1,117

 

Treasury stock at cost

 

 

2

 

 

 

—

 

Additional paid-in capital

 

 

649,007

 

 

 

431,757

 

Accumulated deficit

 

 

(303,629

)

 

 

(231,265

)

Accumulated other comprehensive income

 

 

2,365

 

 

 

2,542

 

Total stockholders’ equity attributed to ASP Isotopes Inc. stockholders

 

 

349,303

 

 

 

204,151

 

Noncontrolling interests in consolidated subsidiaries

 

 

9,986

 

 

 

58,747

 

Total stockholders’ equity

 

 

359,289

 

 

 

262,898

 

Total liabilities and stockholders’ equity

 

$

538,129

 

 

$

498,020

 

* Reclassified to reflect discontinued operations presentation.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5


 

ASP Isotopes Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(in thousands, except share and per share amounts)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025*

 

 

2026

 

 

2025*

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue

 

$

5,124

 

 

$

1,271

 

 

$

13,627

 

 

$

3,571

 

Collaboration revenue

 

 

—

 

 

 

—

 

 

 

800

 

 

 

—

 

Total revenue

 

 

5,124

 

 

 

1,271

 

 

 

14,427

 

 

 

3,571

 

Cost of revenue

 

 

4,331

 

 

 

1,029

 

 

 

10,487

 

 

 

2,430

 

Gross profit

 

 

793

 

 

 

242

 

 

 

3,940

 

 

 

1,141

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

7,236

 

 

 

3,098

 

 

 

19,324

 

 

 

5,508

 

Selling, general and administrative

 

 

34,072

 

 

 

12,131

 

 

 

84,214

 

 

 

30,541

 

Total operating expenses

 

 

41,308

 

 

 

15,229

 

 

 

103,538

 

 

 

36,049

 

Loss from operations

 

 

(40,515

)

 

 

(14,987

)

 

 

(99,598

)

 

 

(34,908

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Foreign exchange transaction loss

 

 

(511

)

 

 

(15

)

 

 

(1,610

)

 

 

(113

)

Change in fair value of share liability

 

 

—

 

 

 

(71

)

 

 

—

 

 

 

(200

)

Change in fair value of convertible notes payable

 

 

164

 

 

 

173

 

 

 

(3,863

)

 

 

(64,542

)

Change in fair value of equity investments

 

 

(988

)

 

 

—

 

 

 

138

 

 

 

—

 

Gain on extinguishment of convertible notes

 

 

11,250

 

 

 

—

 

 

 

11,250

 

 

 

—

 

Interest income

 

 

4,333

 

 

 

1,844

 

 

 

10,091

 

 

 

3,283

 

Interest expense

 

 

(3,481

)

 

 

(76

)

 

 

(6,984

)

 

 

(245

)

Total other income (expense)

 

 

10,767

 

 

 

1,855

 

 

 

9,022

 

 

 

(61,817

)

Loss before income tax expense

 

 

(29,748

)

 

 

(13,132

)

 

 

(90,576

)

 

 

(96,725

)

Income tax expense

 

 

(1,120

)

 

 

(52

)

 

 

(991

)

 

 

(77

)

Net loss from continuing operations

 

 

(30,868

)

 

 

(13,184

)

 

 

(91,567

)

 

 

(96,802

)

Income from discontinued operations, net of taxes

 

 

—

 

 

 

290

 

 

 

19,585

 

 

 

290

 

Net loss

 

 

(30,868

)

 

 

(12,894

)

 

 

(71,982

)

 

 

(96,512

)

Less: Net loss attributable to noncontrolling interests

 

 

(497

)

 

 

(277

)

 

 

(1,149

)

 

 

(387

)

Net loss attributable to ASP Isotopes Inc. shareholders

 

$

(30,371

)

 

$

(12,617

)

 

$

(70,833

)

 

$

(96,125

)

Net (loss) income per share, basic and diluted

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.22

)

 

$

(0.15

)

 

$

(0.71

)

 

$

(1.27

)

Discontinued operations

 

$

—

 

 

$

—

 

 

$

0.15

 

 

$

—

 

Attributable to ASP Isotopes Inc. shareholders

 

$

(0.21

)

 

$

(0.14

)

 

$

(0.55

)

 

$

(1.27

)

Weighted average shares of common stock outstanding,
   basic and diluted

 

 

143,385,783

 

 

 

88,552,309

 

 

 

128,891,373

 

 

 

75,985,507

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before allocation to noncontrolling interests

 

$

(30,868

)

 

$

(12,894

)

 

$

(71,982

)

 

$

(96,512

)

Foreign currency translation

 

 

(301

)

 

 

916

 

 

 

(1,673

)

 

 

3,115

 

Less: reclassification to earnings

 

 

—

 

 

 

—

 

 

 

1,496

 

 

 

—

 

Total comprehensive loss before allocation to noncontrolling interests

 

 

(31,169

)

 

 

(11,978

)

 

 

(72,159

)

 

 

(93,397

)

Less: Comprehensive (loss) income attributable to noncontrolling interests

 

 

(213

)

 

 

(145

)

 

 

(827

)

 

 

151

 

Total comprehensive loss

 

$

(30,956

)

 

$

(11,833

)

 

$

(71,332

)

 

$

(93,548

)

* Reclassified to reflect discontinued operations presentation.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6


 

ASP Isotopes Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)

(in thousands, except share and per share amounts)

 

 

Common Stock

 

 

Treasury

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Noncontrolling

 

 

Total Stockholders'

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Stock

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Interests

 

 

Equity

 

Balance as of December 31, 2025

 

 

111,677,771

 

 

$

1,117

 

 

 

—

 

 

$

—

 

 

$

431,757

 

 

$

2,542

 

 

$

(231,265

)

 

$

58,747

 

 

$

262,898

 

Issuance of common stock to acquire Renergen

 

 

14,270,000

 

 

 

142

 

 

 

—

 

 

 

—

 

 

 

92,755

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

92,897

 

Forfeiture of restricted common stock

 

 

(44,324

)

 

 

—

 

 

 

44,324

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,412

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,412

 

Deconsolidation of subsidiary

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(9

)

 

 

—

 

 

 

(86,774

)

 

 

(86,783

)

Fair value of noncontrolling interest at acquisition of Numed

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

597

 

 

 

597

 

Fair value of noncontrolling interest at acquisition of Renergen

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

7,276

 

 

 

7,276

 

Distribution to noncontrolling interest of Renergen

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(380

)

 

 

—

 

 

 

(380

)

Contributions from noncontrolling interest

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26,960

 

 

 

26,960

 

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(257

)

 

 

(257

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(6,688

)

 

 

—

 

 

 

429

 

 

 

(6,259

)

Reclassification to earnings

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,496

 

 

 

(1,496

)

 

 

—

 

 

 

—

 

Net loss - continuing operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(26,463

)

 

 

(243

)

 

 

(26,706

)

Gain on deconsolidation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

20,832

 

 

 

—

 

 

 

20,832

 

Net income - discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

249

 

 

 

3,281

 

 

 

3,530

 

Balance as of March 31, 2026

 

 

125,903,447

 

 

$

1,259

 

 

 

44,324

 

 

$

—

 

 

$

528,924

 

 

$

(2,659

)

 

$

(238,523

)

 

$

10,016

 

 

$

299,017

 

Issuance of common stock from exercise of options

 

 

62,766

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

139

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

139

 

Issuance of restricted common stock

 

 

4,273,555

 

 

 

43

 

 

 

—

 

 

 

—

 

 

 

(43

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Forfeiture/cancellation of restricted common stock

 

 

(91,070

)

 

 

(1

)

 

 

87,500

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Distribution to noncontrolling interest of Renergen

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(729

)

 

 

—

 

 

 

(729

)

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,542

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,542

 

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(215

)

 

 

(215

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

5,325

 

 

 

—

 

 

 

704

 

 

 

6,029

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(33,585

)

 

 

(408

)

 

 

(33,993

)

Balance as of June 30, 2026

 

 

130,148,698

 

 

$

1,301

 

 

 

131,824

 

 

$

1

 

 

$

533,562

 

 

$

2,666

 

 

$

(272,837

)

 

$

10,097

 

 

$

274,790

 

Issuance of restricted common stock

 

 

2,550,000

 

 

 

26

 

 

 

—

 

 

 

—

 

 

 

(26

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock for convertible notes

 

 

23,160,682

 

 

 

232

 

 

 

—

 

 

 

—

 

 

 

105,845

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

106,077

 

Forfeiture/cancellation of restricted common stock

 

 

(36,450

)

 

 

(1

)

 

 

36,450

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock from cashless exercise of options

 

 

11,500

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

23

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

23

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

9,603

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

9,603

 

Distribution to noncontrolling interest of Renergen

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(421

)

 

 

—

 

 

 

(421

)

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(70

)

 

 

(70

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(301

)

 

 

—

 

 

 

456

 

 

 

155

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(30,371

)

 

 

(497

)

 

 

(30,868

)

Balance as of September 30, 2026

 

 

155,834,430

 

 

$

1,558

 

 

 

168,274

 

 

$

2

 

 

$

649,007

 

 

$

2,365

 

 

$

(303,629

)

 

$

9,986

 

 

$

359,289

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7


 

ASP Isotopes Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited)

(in thousands, except share and per share amounts)

 

 

Common Stock

 

 

 

 

 

Treasury

 

 

Additional
Paid-in

 

 

Accumulated
Other
Comprehensive

 

 

Accumulated

 

 

Noncontrolling

 

 

Total Stockholders'

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Stock

 

 

Capital

 

 

(Loss) Income

 

 

Deficit

 

 

Interests

 

 

Equity

 

Balance as of December 31, 2024

 

 

72,068,059

 

 

$

721

 

 

 

—

 

 

$

—

 

 

$

105,515

 

 

$

(2,164

)

 

$

(56,173

)

 

$

3,268

 

 

 

51,167

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,890

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,890

 

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(38

)

 

 

(38

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,171

 

 

 

—

 

 

 

—

 

 

 

1,171

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(8,446

)

 

 

(16

)

 

 

(8,462

)

Balance as of March 31, 2025

 

 

72,068,059

 

 

$

721

 

 

 

—

 

 

$

—

 

 

$

107,405

 

 

$

(993

)

 

$

(64,619

)

 

$

3,214

 

 

$

45,728

 

Issuance of common stock from public offering, net of issuance costs of $3,238,630

 

 

7,518,797

 

 

 

75

 

 

 

—

 

 

 

—

 

 

 

46,686

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

46,761

 

Issuance of common stock from exercise of warrants

 

 

1,294,778

 

 

 

13

 

 

 

—

 

 

 

—

 

 

 

4,902

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,915

 

Issuance of restricted common stock

 

 

2,923,783

 

 

 

29

 

 

 

—

 

 

 

—

 

 

 

(29

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Settlement of liabilities with consultant

 

 

100,000

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

652

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

653

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,429

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,429

 

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(41

)

 

 

(41

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,023

 

 

 

—

 

 

 

—

 

 

 

1,023

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(75,063

)

 

 

(94

)

 

 

(75,157

)

Balance as of June 30, 2025

 

 

83,905,417

 

 

$

839

 

 

 

—

 

 

$

—

 

 

$

164,045

 

 

$

30

 

 

$

(139,682

)

 

$

3,079

 

 

$

28,311

 

Issuance of common stock from public offering, net of issuance costs of $3,693,950

 

 

7,500,000

 

 

 

75

 

 

 

—

 

 

 

—

 

 

 

56,231

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

56,306

 

Issuance of common stock from cashless exercise of warrants

 

 

123,497

 

 

 

1

 

 

 

—

 

 

 

—

 

 

 

(1

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock from cashless exercise of options

 

 

1,337,245

 

 

 

13

 

 

 

—

 

 

 

—

 

 

 

(13

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of restricted common stock

 

 

510,470

 

 

 

5

 

 

 

—

 

 

 

—

 

 

 

(5

)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Stock-based compensation expense

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,484

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,484

 

Fair value of noncontrolling interest at acquisition of Skyline

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

19,762

 

 

 

19,762

 

Distribution to noncontrolling interest of VIE

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(324

)

 

 

(324

)

Foreign currency translation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

921

 

 

 

—

 

 

 

38

 

 

 

959

 

Net loss - continuing operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(12,907

)

 

 

(277

)

 

 

(13,184

)

Net income - discontinued operations

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

33

 

 

 

257

 

 

 

290

 

Balance as of September 30, 2025*

 

 

93,376,629

 

 

$

933

 

 

 

—

 

 

$

—

 

 

$

224,741

 

 

$

951

 

 

$

(152,556

)

 

$

22,535

 

 

$

96,604

 

 

* Reclassified to reflect discontinued operations presentation.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

8


 

ASP Isotopes Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025*

 

Cash flows from Operating activities

 

 

 

 

 

 

Net loss

 

$

(71,982

)

 

$

(96,512

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

Income from discontinued operations

 

 

(249

)

 

 

(290

)

Foreign exchange transaction loss from intercompany

 

 

1,678

 

 

 

—

 

Depreciation, depletion and amortization

 

 

5,977

 

 

 

907

 

Gain on deconsolidation

 

 

(19,336

)

 

 

—

 

Gain on sale of property and equipment

 

 

(58

)

 

 

—

 

Noncash write-off of capitalized costs

 

 

569

 

 

 

—

 

Non cash interest income on note receivable

 

 

—

 

 

 

(1,189

)

Non cash interest expense on debt

 

 

4,116

 

 

 

—

 

Stock-based compensation

 

 

18,557

 

 

 

10,803

 

Shares issued for non-cash consultant expense

 

 

—

 

 

 

673

 

Change in fair value of share liability

 

 

—

 

 

 

200

 

Gain on extinguishment of convertible notes payable

 

 

(11,250

)

 

 

—

 

Change in fair value of convertible notes payable

 

 

3,863

 

 

 

64,542

 

Change in fair value of equity investments

 

 

(138

)

 

 

—

 

Change in right-of-use lease asset

 

 

768

 

 

 

427

 

Non-cash lease income

 

 

(337

)

 

 

(45

)

Change in deferred taxes

 

 

736

 

 

 

33

 

Changes in operating assets and liabilities, net of acquisition amounts:

 

 

 

 

 

 

Accounts receivable

 

 

(1,623

)

 

 

6

 

Receivable from noncontrolling interest

 

 

—

 

 

 

28

 

Inventories

 

 

(263

)

 

 

(697

)

Prepaid expenses and other current assets

 

 

(728

)

 

 

1,688

 

Other noncurrent assets

 

 

(1,407

)

 

 

1,187

 

Accounts payable

 

 

4,461

 

 

 

(30

)

Accrued expenses

 

 

1,172

 

 

 

339

 

Operating lease liabilities

 

 

(633

)

 

 

(435

)

Other current liabilities

 

 

216

 

 

 

(777

)

Other noncurrent liabilities

 

 

563

 

 

 

—

 

Net cash used in operating activities – continuing operations

 

 

(65,328

)

 

 

(19,142

)

Cash used in operating activities – discontinued operations

 

 

(1,121

)

 

 

(793

)

Net cash used in operating activities

 

 

(66,449

)

 

 

(19,935

)

Cash flows from investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

(13,573

)

 

 

(7,255

)

Purchases of short-term investments

 

 

(35,425

)

 

 

—

 

Proceeds from maturity of short-term investments

 

 

83,170

 

 

 

—

 

Principal collections from lease receivable

 

 

447

 

 

 

—

 

Proceeds from sale of property and equipment

 

 

123

 

 

 

—

 

Purchase of equity investments

 

 

(14,067

)

 

 

(5,000

)

Cash received (paid) for acquisition of business, net of cash paid

 

 

4,919

 

 

 

(2,500

)

Cash disposed of upon deconsolidation of subsidiary

 

 

(44,708

)

 

 

(8,943

)

Cash advance in exchanges for note receivable

 

 

—

 

 

 

(30,000

)

Net cash used in investing activities – continuing operations

 

 

(19,114

)

 

 

(53,698

)

Net cash provided by investing activities – discontinued operations

 

 

—

 

 

 

9,143

 

Net cash used in investing activities

 

 

(19,114

)

 

 

(44,555

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issuance of common stock

 

 

—

 

 

 

110,000

 

Payment of common stock issuance costs

 

 

(135

)

 

 

(6,933

)

Proceeds from exercise of warrants

 

 

—

 

 

 

4,915

 

Proceeds from exercise of options

 

 

162

 

 

 

—

 

Distribution to noncontrolling interest in VIE

 

 

(542

)

 

 

(404

)

Distribution to noncontrolling interest of Renergen

 

 

(1,530

)

 

 

—

 

Proceeds from issuance of debt

 

 

54

 

 

 

307

 

Payment of principal portion of debt

 

 

(9,653

)

 

 

(883

)

Payment of principal portion of finance leases

 

 

(177

)

 

 

(95

)

Net cash (used in) provided by financing activities – continuing operations

 

 

(11,821

)

 

 

106,907

 

Cash provided by financing activities – discontinued operations

 

 

45,886

 

 

 

578

 

Net cash provided by financing activities

 

 

34,065

 

 

 

107,485

 

Net change in cash, cash equivalents and restricted cash

 

 

(51,498

)

 

 

42,995

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

(5,529

)

 

 

114

 

Cash, cash equivalents and restricted cash - beginning of period

 

 

279,572

 

 

 

61,890

 

Cash, cash equivalents and restricted cash - end of period

 

$

222,545

 

 

$

104,999

 

Components of cash, cash equivalents, and restricted cash

 

 

 

 

 

 

Cash and cash equivalents

 

$

201,663

 

 

$

104,999

 

Restricted cash

 

 

20,882

 

 

 

—

 

Total cash, cash equivalents, and restricted cash

 

$

222,545

 

 

$

104,999

 

* Reclassified to reflect discontinued operations presentation.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

9


 

ASP Isotopes Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(in thousands)

 

 

Supplemental cash flow information:

 

 

 

 

 

 

Cash paid for Interest

 

$

3,175

 

 

$

—

 

Supplemental disclosures of non-cash investing and financing activities:

 

 

 

 

 

 

Derecognition of asset as a result of sales-type lease

 

$

1,689

 

 

$

370

 

Lease receivable

 

$

1,689

 

 

$

393

 

Purchase of property and equipment included in accounts payable

 

$

207

 

 

$

219

 

Purchase of property and equipment with bank loans

 

$

54

 

 

$

—

 

Right-of-use asset obtained in exchange for operating lease liability

 

$

4,675

 

 

$

114

 

Right-of-use asset obtained in exchange for finance lease liability

 

$

114

 

 

$

48

 

Common stock issued in acquisition of Renergen

 

$

92,897

 

 

$

—

 

Consideration relating to obligated purchase for acquisition of Numed

 

$

358

 

 

$

—

 

Issuance of common stock for the purchase of QLE convertible notes

 

$

106,076

 

 

$

—

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

10


 

ASP Isotopes Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization

Description of Business

ASP Isotopes Inc. was incorporated in the state of Delaware on September 13, 2021 and has its headquarters in Dallas, Texas. ASP Isotopes Inc., its subsidiaries and ASP Rentals (Pty) Ltd ("ASP Rentals") are collectively referred to as “the Company” throughout these condensed consolidated financial statements.

The Company is an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”). The Company's commercial radiodiagnostic activities are currently focused on radiopharmaceutical products used in positron emission tomography ("PET") and single-photon emission computed tomography ("SPECT") imaging, as well as therapeutic radiopharmaceuticals used in the treatment of oncology indications.

Quantum Leap Energy LLC (“QLE”), the Company's subsidiary, is currently pursuing an initiative to apply its enrichment technologies to the enrichment of Uranium-235 (“U-235”) in South Africa. The Company believes that the U-235 QLE may produce has the potential to be commercialized as a nuclear fuel component for use in the new generation of high-assay low-enriched uranium (“HALEU”)-fueled small modular reactors that are now under development for commercial and government uses. In furtherance of the Company's uranium enrichment initiative, in October 2024, the Company entered into a term sheet with TerraPower, LLC (“TerraPower”) which contemplates the parties entering into definitive agreements pursuant to which TerraPower would provide funding for the construction of a HALEU production facility and agree to purchase all HALEU produced at the facility over a 10-year period after the planned completion of the facility. In addition, in November 2024, the Company entered into a memorandum of understanding with The South African Nuclear Energy Corporation (“Necsa”), a South African state-owned company responsible for undertaking and promoting research and development in the field of nuclear energy and radiation sciences, to collaborate on the research, development and ultimately the commercial production of advanced nuclear fuels. As part of the collaboration contemplated by the MOU with Necsa, QLE’s South African subsidiary has entered into a Pre-Implementation Services Contract Agreement (“Services Contract”) with Necsa, pursuant to which Necsa has agreed to provide to QLE’s South African subsidiary certain facilities, infrastructure, utilities and services related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba. See the section captioned “TerraPower” below (Note 13) for disclosures regarding certain definitive agreements entered into between TerraPower and us and/or the Company's subsidiaries, including a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa and supply agreements for the future supply of HALEU to TerraPower, as a customer.

QLE acquired a controlling interest in Skyline in August 2025. Skyline is a holding company, and its operations are conducted through its wholly owned operating subsidiaries, Kin Chiu Engineering Limited and Kin Chiu Development Company Limited. Operations primarily consist of construction activities which include public civil engineering works, such as road and drainage works, in Hong Kong. Skyline mostly undertakes civil engineering works in the role as a subcontractor but is fully qualified to undertake such works in the capacity of a main contractor. QLE intends to pursue opportunities to acquire assets in the critical materials supply chain.

QLE entered into the Securities Exchange Agreement (the "Exchange Agreement") with a third party, effective as of March 29, 2026, which resulted in the deconsolidation of Skyline (Note 21). QLE retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following deconsolidation.

The Company acquired Renergen in January 2026. Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the natural gas reserve base that underpins Renergen’s natural gas development project (the “Virginia Gas Project”). The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s natural gas processing plant in the Free State Province of South Africa. Renergen’s principal asset is its 94.5% equity ownership in Tetra4, which holds an onshore petroleum production right and is the entity developing and operating the Virginia Gas Project.

Liquidity

The Company has incurred net losses and negative cash flows from operating activities since its inception. The Company incurred net losses from continuing operations of $91.6 million and $96.8 million for the nine months ended September 30, 2026 and 2025, respectively, and negative cash flows from operations of $66.4 million and $19.9 million for the nine months ended September 30, 2026 and 2025. The Company currently expects that its cash and cash equivalents of $201.7 million as of September 30, 2026, will be sufficient to fund its operating expenses and capital requirements for more than 12 months from the date the financial statements are issued.

There can be no assurance that the Company will achieve or sustain positive cash flows from operations or profitability. The Company anticipates it will need to continue to raise capital through additional equity and/or debt financings and/or collaborative development agreements to fund its operations. However, such funding may not be available on a timely basis on terms acceptable to the Company, or at all. If the Company is unable to raise additional capital when required or on acceptable terms, the Company may be required to scale back or discontinue the advancement of product candidates, reduce headcount, reorganize, merge with another entity, or cease operations.

2. Basis of Presentation and Summary of Significant Accounting Policies

Unaudited Financial Information

The Company’s unaudited condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"), and pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In the Company’s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

11


 

The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes for the year ended December 31, 2025.

Basis of Presentation and Use of Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and disclosure in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation, fair value of convertible notes, equity and other investments, gas reserves, provisions for environmental rehabilitation, loss contingencies and the accounting for acquisitions, including goodwill. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.

The Company has reclassified certain prior-year amounts to conform to the current-year’s presentation. The accounting requirements for reporting the separation of Skyline as a discontinued operation were met when the deconsolidation was completed on March 29, 2026. Accordingly, the historical results of Skyline are presented as discontinued operations and, as such, have been excluded from continuing operations and segment results for all periods presented. Refer to Note 21, “Discontinued Operations,” for additional information.

Principles of consolidation

The Company’s condensed consolidated financial statements include the accounts of ASP Isotopes Inc., its wholly-owned subsidiaries, the 80% owned Enlightened Isotopes (PTY) Ltd (“Enlightened Isotopes”), the 60% owned Numed Diagnostics, LLC ("Numed"), the 51% owned PET Labs Pharmaceuticals Proprietary Limited (“PET Labs”), the 94.5% owned Tetra4, and the 42% owned VIE ASP Rentals Proprietary Limited (“ASP Rentals”). All intercompany balances and transactions have been eliminated in consolidation.

Currency and currency translation

The condensed consolidated financial statements are presented in U.S. dollars, the Company’s reporting currency. The functional currency of ASP Isotopes Inc. and ASP Guernsey is the U.S. dollar. The functional currency of the Company’s subsidiaries ASP South Africa, Quantum Leap Energy South Africa and Renergen is the South African Rand. The functional currency of the 80% owned Enlighted Isotopes, the 51% owned PET Labs and the 42% owned VIE ASP Rentals is the South African Rand. The functional currency of the previously consolidated Skyline Builders Group Holding Limited (“Skyline”) is the Hong Kong Dollar. Adjustments that arise from exchange rate changes on transactions of each group entity denominated in a currency other than the functional currency are included in other income and expense in the condensed consolidated statements of operations and comprehensive loss. Assets and liabilities of the entities with functional currency of South African Rand or Hong Kong Dollar are recorded in South African Rand or Hong Kong Dollar, respectively, and translated into the U.S. dollar reporting currency of the Company at the exchange rate on the balance sheet date. Revenue and expenses of the entities with functional currency of South African Rand or Hong Kong Dollar are recorded in South African Rand or Hong Kong Dollar, respectively, and translated into the U.S. dollar reporting currency of the Company at the average exchange rate prevailing during the reporting period. Resulting translation adjustments are recorded separately in stockholders’ equity as a component of accumulated other comprehensive (loss) income.

Concentration of Credit Risk and other Risks

Cash balances are maintained at U.S. financial institutions and may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000 per depositor, per insured bank for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the nine months ended September 30, 2026 and 2025.

The Company's foreign subsidiaries held cash of approximately $28.0 million and $3.6 million as of September 30, 2026 and December 31, 2025, respectively, which is included in cash and cash equivalents, restricted cash and restricted cash - noncurrent on the condensed consolidated balance sheets. The Company's strategic plan does not require the repatriation of foreign cash in order to fund its operations in the U.S., and it is the Company's current intention to indefinitely reinvest its foreign cash outside of the U.S. If the Company were to repatriate foreign cash to the U.S., the Company would be required to accrue and pay U.S. taxes in accordance with applicable U.S. tax rules and regulations as a result of the repatriation.

The Company is potentially subject to concentrations of credit risk in accounts receivable. There was one customer in the Helium and LNG segment representing $0.4 million or 11% of accounts receivable in the condensed consolidated balance sheets as of September 30, 2026. There were no customers representing more than 10% of accounts receivable in the condensed consolidated balance sheets as of December 31, 2025.

Although the Company is directly affected by the financial condition of its customers, management does not believe significant credit risks existed as of September 30, 2026. Generally, the Company does not require customers to post collateral or other securities to support our associated accounts receivable.

There was one customer in the Helium and LNG segment representing $2.1 million, or 16%, of the Company's condensed consolidated product revenues for the nine months ended September 30, 2026. There were no customers representing more than 10% of the Company's condensed consolidated revenues for the nine months ended September 30, 2025.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents are stated at fair value and may include money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company had cash equivalents totaling $187.5 million and $267.4 million as of September 30, 2026 and December 31, 2025, respectively.

12


 

Restricted Cash

Restricted cash represents cash balances that are legally or contractually restricted as to withdrawal or use. Restricted cash is classified as current or noncurrent on the condensed consolidated balance sheet based on the nature and expected timing of the underlying restriction. Amounts classified as restricted cash are excluded from cash and cash equivalents and are disclosed separately on the balance sheet. As of September 30, 2026, the Company had current restricted cash of $14.0 million related to reserving all payments to fulfill obligations under the SBSA Loan (defined below), $2.9 million related to reserving six months of payments to fulfill obligations under the DFC Credit Facility (defined below) and $1.3 million related to reserving six months of payments to fulfill obligations under the IDC Loan (defined below). Refer to note 9, “Debt,” for additional information. Additionally, the Company had current restricted cash of $0.9 million for a secured letter of credit in lieu of a lease deposit for premises QLE occupies in Austin, Texas. As of September 30, 2026, the Company had noncurrent restricted cash of $1.2 million related to Renergen's obligation to manage the negative environmental impact associated with its operational activities and $0.5 million related to electricity payments and early termination guaranties with a public utility company.

Fair Value of Financial Instruments

Accounting guidance defines fair value, establishes a consistent framework for measuring fair value, and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Observable inputs such as quoted prices in active markets;

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The Company’s convertible notes payable (Note 9) is measured as a Level 3 fair value on a recurring basis.

 

Equity Method and Other Investments

The Company accounts for investments in entities over which it has significant influence, but not control, using the equity method of accounting in accordance with ASC Topic 323, Investments - Equity Method and Joint Ventures ("ASC 323"). Significant influence is generally presumed when the Company owns 20% to 50% of the voting interests in the investee, unless other factors indicate otherwise.

Under the equity method, the Company has elected the fair value option, under which it initially recorded the investment at fair value and subsequently adjusts the carrying amount to reflect its share of the investee’s earnings or losses, which are recognized in the condensed consolidated statements of operations and comprehensive loss. Dividends received from equity method investees reduce the carrying amount of the investment. The Company evaluates its equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Alternatively, the Company may elect to utilize the fair value option. The Company's equity method investments include the Company's investment in Skyline utilizing the fair value option.

The Company also holds investments in equity securities without readily determinable fair values. These investments are accounted for under the measurement alternative in accordance with ASC Topic 321, Investments - Equity Securities ("ASC 321"), which allows the Company to record the investments at cost, less impairments, plus or minus observable price changes in orderly transactions for the identical or similar investment. The Company's investments recorded at cost include IsoBio, Inc. ("IsoBio") and Opeongo, Inc. ("Opeongo").

If the Company determines that an impairment is other-than-temporary, it recognizes a loss equal to the difference between the investment’s carrying amount and its fair value. Equity method investments and investments at cost are included in “Equity method investments” and "Other investments", respectively, on the condensed consolidated balance sheet.

Accounts Receivable

Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for expected credit losses is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management's evaluation of outstanding accounts receivable. The Company maintains an allowance for expected credit losses for accounts receivable, which is recorded as an offset to accounts receivable, and changes in such are classified as selling, general and administrative expense in the condensed consolidated statements of operations and comprehensive loss. The Company assesses collectability by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when the Company identifies specific customers with known disputes or collectability issues. In determining the amount of the allowance for expected credit losses, the Company considers historical collectability based on past due status and make judgments about the creditworthiness of customers based on ongoing credit evaluations. The Company also considers customer-specific information and current market conditions. Bad debts are written off against the allowance when identified. As of September 30, 2026 and December 31, 2025 there was no allowance for expected credit losses.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined using the first in, first out inventory method. Inventory cost includes materials, labor, and applicable overhead incurred in bringing the inventories to their present location and condition. Net realizable value represents the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventories are primarily located in facilities in South Africa and are not pledged as collateral for any debt arrangements

13


 

The components of inventories as of September 30, 2026 and December 31, 2025 were as follows (in thousands):

 

 

September 30,
2026

 

 

December 31,
2025

 

Raw material

 

$

677

 

 

$

484

 

Work in process

 

 

726

 

 

 

614

 

Finished goods

 

 

119

 

 

 

—

 

Total inventories

 

$

1,522

 

 

$

1,098

 

No significant write-downs to net realizable value or reversals of write-downs occurred in the three and nine months ended September 30, 2026 and 2025.

Property and Equipment

Property and equipment include costs of assets constructed, purchased or leased under a finance lease, related delivery and installation costs and interest incurred on significant capital projects during their construction periods. Expenditures for renewals and betterments also are capitalized, but expenditures for normal repairs and maintenance are expensed as incurred. Costs associated with yearly planned major maintenance are generally deferred and amortized over 12 months or until the same major maintenance activities must be repeated, whichever is shorter. The cost and accumulated depreciation applicable to assets retired or sold are removed from the respective accounts, and gains or losses thereon are included in the statement of operations and comprehensive loss.

The Company assigns the useful lives of its property and equipment based upon its internal engineering estimates, which are reviewed periodically. The estimated useful lives of the Company's property and equipment range from 3 to 10 years, or the shorter of the useful life or remaining life of the lease for leasehold improvements. Depreciation for all assets other than Renergen’s gas exploration and gas gathering assets is recorded using the straight-line method. Depreciation for Renergen’s gas exploration and gas gathering assets is recorded using the units of production method.

Construction in progress (Note 6) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account, including, but not limited to, leasehold improvements or other such accounts.

Business Combination and Asset Acquisitions

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations ("ASC 805"), which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.

The consideration for the Company’s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the condensed consolidated statements of operations and comprehensive loss.

If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets’ carrying amounts on the acquiring entity’s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values.

Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.

Goodwill and Identifiable Intangible Assets

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Identifiable intangible assets recognized in conjunction with acquisitions are recorded at fair value. Significant unobservable inputs are used to determine the fair value of the identifiable intangible assets based on the income approach valuation model, whereby the present worth and anticipated future benefits of the identifiable intangible assets are discounted back to their net present value.

Goodwill and identifiable intangible assets with indefinite lives are not amortized and are subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill or identifiable intangible assets are impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company performs its annual test for goodwill or identifiable intangible assets as of October 31.

14


 

Identifiable intangible assets with definite lives are amortized over their estimated useful lives, ranging from 4 to 5 years. The Company's intangible assets include trademarks and customer-related intangible assets related to the East Coast Nuclear Pharmacy ("ECNP") and Numed acquisitions. The Company uses the straight-line method of amortization for identifiable intangible assets with definite lives.

Natural Gas Producing Activities

Effective January 6, 2026, the Company consolidates Renergen Limited and its subsidiaries, including Tetra4 Proprietary Limited, which holds South Africa’s first onshore petroleum production right. The Company’s natural gas producing activities are located entirely in South Africa (Free State Province). The Company follows the successful efforts method of accounting for its natural gas producing activities. Under this method, property acquisition costs and development costs are capitalized when incurred and depleted on a units-of-production basis over the remaining life of proved reserves and proved developed reserves, respectively. Unproved reserve assets and the related costs are transferred to proved reserve assets when proved reserves are found, or otherwise attributed to, the property.

The Company initially capitalizes exploratory well costs pending a determination whether proved reserves have been found. If proved reserves are found, costs remain capitalized; if no proved reserves are found or a well is uneconomic, costs are charged to expense. Other exploration costs, including geological and geophysical costs, are expensed as incurred. Costs to operate and maintain wells and field equipment are expensed as incurred.

Proved reserve assets and proved developed assets are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in accordance with ASC 360, Property, Plant and Equipment. As of September 30, 2026, no impairment indicators were identified with respect to Renergen’s proved properties.

The Company performs periodic assessments of unproved properties for impairment and recognizes a loss at the time of impairment. In determining whether an unproved property is impaired, the Company considers numerous factors including, but not limited to, current development and exploration drilling plans, favorable or unfavorable exploration activity on adjacent lands, and in-house geologists’ evaluation of the reservoir. As of September 30, 2026, no impairment indicators were identified with respect to Renergen’s unproved properties.

Impairment of Long-lived Assets

Long-lived assets consist primarily of property and equipment. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate the carrying amount of an asset is not recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the assets. The Company did not recognize any impairment losses for the three and nine months ended September 30, 2026 or 2025.

Asset Retirement Obligations

The Company accounts for legal obligations associated with the retirement of its natural gas properties in accordance with ASC 410-20, Asset Retirement and Environmental Obligations. An asset retirement obligation ("ARO") is recognized at fair value in the period in which it is incurred and when a reasonable estimate of fair value can be made. Upon initial recognition, the fair value of the ARO is capitalized as part of the carrying amount of the related long-lived asset (the "rehabilitation asset") and included in property and equipment, net, in the condensed consolidated balance sheets.

The ARO is measured at the present value of estimated future cash flows required to satisfy the retirement obligation, discounted at a credit-adjusted risk-free rate that reflects current market assessments of the time value of money and the risks specific to the liability. In subsequent periods, the liability is increased for the passage of time through accretion expense, which is recognized within cost of revenue. Revisions to the timing or amount of estimated future cash flows result in an adjustment to both the carrying amount of the ARO liability and the related rehabilitation asset.

The Company has production and exploration rights on land in South Africa. A rehabilitation obligation of $3.8 million has been recognized in other noncurrent liabilities with respect to the retirement of the Virginia Gas Project assets as of September 30, 2026. This obligation encompasses costs estimated to be incurred to address the following: disturbed infrastructure areas; existing production wells and all exploration wells; general surface rehabilitation; monitoring; and latent/residual environmental risk related to resealing wells.

The ARO was recognized at fair value on the acquisition date discounted at a pre-tax rate of 9.51% per annum, reflecting South African market conditions as of January 6, 2026. The capitalized rehabilitation asset of $3.6 million (included in natural gas properties, net) is depreciated on a basis consistent with the unit-of-production depletion of the underlying proved properties.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standard Codification ("ASC") Topic 606, Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.

The Company evaluates a transaction’s performance obligations to determine if promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers whether the goods or services are integral or dependent to other goods or services in the contract. The Company determines the transaction price based on the agreed government rates for the promised goods in the contract. The consideration is recognized as revenue when control is transferred for the related goods.

15


 

The Company enters into revenue generating transactions with certain customers that include payment for delivery of nuclear medical doses from its radiopharmacies in South Africa and the U.S. for PET and SPECT scanning. Revenue from its radiopharmacies is recognized upon delivery.

The Company’s collaboration revenue relates to TerraPower LLC ("TerraPower") (Note 13). At contract execution, the Company analyzes its collaborative arrangements and license agreements to assess whether both parties are active participants in the activities and are exposed to significant risks and rewards and therefore are within the scope of ASC 808, Collaborative arrangements (“ASC 808”). ASC 808 does not address the recognition and measurement of payments from collaborative arrangements and instead refers companies to use other authoritative accounting literature. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and therefore are within the scope of ASC 606, Revenue from Contracts with Customers. When the Company determines elements of a collaboration agreement do not reflect a vendor-customer relationship, the Company consistently applies a reasonable and rational policy election made by analogizing to authoritative accounting literature. The Company evaluates the income statement classification for presentation of amounts due from or owed to other participants in a collaboration arrangement based on the nature of each separate activity. The Company recognizes collaboration revenue from TerraPower as contractual deliverables are provided and the related performance obligations are satisfied. Amounts received in advance of performance are recorded as deferred revenue and recognized as revenue when the associated services or deliverables are transferred to the collaborator.

In January 2026, the Company acquired Renergen (Note 14). Renergen explores, produces and sells LNG in South Africa. Revenue from the sale of LNG is recognized upon delivery to the specified destination agreed to in the contract.

When consideration is received from a customer prior to transferring goods or services to the customer under the terms of long-term contracts, a token liability is recorded. The Company classifies these token liabilities within “Deferred revenue - noncurrent” on the Company’s condensed consolidated balance sheets since they have no expiration date. Token contract liabilities are recognized as revenue after control of the goods and services is transferred to the customer and all revenue recognition criteria have been met. The token liability was $0.8 million as of September 30, 2026.

Recently Issued Accounting Pronouncements

The Company has reviewed recently issued accounting pronouncements and plans to adopt those that are applicable to it. The Company does not expect the adoption of any recently issued pronouncements to have a material impact on its results of operations or financial position.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”) and is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. ASU 2024-03 requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The Company is still assessing the impact of adopting this standard.

In August 2025, the FASB issued ASU 2025-08, Financial Instruments—Credit Losses (Topic 326): Purchased Loans (“ASU 2024-08”) and is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years with early adoption permitted. ASU 2025-08 clarifies the accounting for purchased loans under the current expected credit loss (CECL) model, including guidance on recognizing and measuring expected credit losses and presentation of related amounts. The Company is still assessing the impact of adopting this standard.

In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software ("ASU 2025-06") and is effective January 1, 2028 with early adoption permitted. ASU 2025-06 modernizes the accounting for internal use software costs and requires entities to start capitalizing eligible costs when (1) management has authorized and committed to funding the software project, and (2) it is probable that the project will be completed and the software will be used to perform the function intended. The guidance can be applied on a prospective basis, a modified basis for in-process projects, or a retrospective basis. The Company is still assessing the impact of adopting this standard.

3. Short-term Investments

The Company had no held-to-maturity investments as of September 30, 2026. A summary of the Company’s held-to-maturity investments as of December 31, 2025 consisted of the following (in thousands):

 

 

Year Ended December 31, 2025

 

 

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Fair Value

 

U.S. Treasury securities - mature April 2026

 

$

47,745

 

 

$

32

 

 

$

—

 

 

$

47,777

 

Total

 

$

47,745

 

 

$

32

 

 

$

—

 

 

$

47,777

 

There is no allowance for credit losses in short-term investments as of September 30, 2026 and December 31, 2025.

4. Fair Value Measurements

The Company classified its U.S. Treasury securities (Note 3) within Level 2 because their fair values are determined using alternative pricing sources or models that utilized market observable inputs. The Company’s convertible notes payable (Note 9) is measured as a Level 3 fair value on a recurring basis and was $85.9 million and $199.3 million as of September 30, 2026 and December 31, 2025, respectively.

The Company holds an equity investment in IsoBio. The Company originally measured the investment at cost. In October 2025, IsoBio completed a preferred stock financing with unrelated third‑party investors. The transaction represented an observable price change for an identical or other similar equity security held by the Company. Accordingly, the Company remeasured the investment to fair value and recorded an unrealized gain of $0.6 million within Other income (expense). No further observable price changes have been identified. The resulting carrying value of the IsoBio investment is $5.6 million as of September 30, 2026 and December 31, 2025. Because the valuation incorporates significant unobservable inputs, the investment is classified as a Level 3 fair value measurement.

The Company holds an equity investment in Opeongo. The Company measured the investment at cost and no observable price changes were identified. The carrying value of the Opeongo investment is $10.0 million as of September 30, 2026. Because the valuation incorporates significant unobservable inputs, the investment is classified as a Level 3 fair value measurement.

16


 

The Company holds an equity investment in ENDRA Life Sciences, Inc. ("ENDRA"), consisting of common stock, pre-funded common stock warrants and common stock warrants. The Company measured the investment at fair value. The original carrying amount recorded in May 2026 was $3.8 million. The carrying amount was adjusted by $0.9 million for the three and nine months ended September 30, 2026, resulting in a total carrying value of the ENDRA investment of $4.7 million as of September 30, 2026. Because the valuation of the common stock and prefunded warrants incorporates observable inputs, that portion of the investment is classified as a Level 1 fair value measurement. Because the valuation of the common warrants incorporates significant unobservable inputs, that portion of the investment is classified as a Level 3 fair value measurement.

The Company holds an equity investment in Skyline. The Company measured the investment under the equity method and recorded the investment at $23.8 million as a result of the deconsolidation of Skyline during the first quarter of 2026. The Company has elected to account for the retained interest in Skyline under the fair value option (“FVO”). The carrying amount of the Skyline investment was $23.0 million as of September 30, 2026. The Company recognized an expense related to the change in fair value of investment of $1.9 million and $0.7 million for the three and nine months ended September 30, 2026. Because the valuation incorporates observable inputs, the investment is classified as a Level 1 fair value measurement.

There were no transfers among Level 1, Level 2 or Level 3 categories in the three months ended September 30, 2026. The carrying amounts of accounts payable, accrued expenses and debt are considered to be representative of their respective fair values because of the short-term nature of those instruments.

A summary of the assets and liabilities that are measured at fair value as of September 30, 2026 and December 31, 2025 is as follows (in thousands):

 

 

 

September 30, 2026

 

 

 

Carrying Value

 

 

Quoted Price in Active Markets for Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Equity method investments

 

 

23,005

 

 

 

23,005

 

 

 

—

 

 

 

—

 

Other investments (ASC 321)

 

 

20,241

 

 

 

3,446

 

 

 

—

 

 

 

16,795

 

Total

 

$

43,246

 

 

$

26,451

 

 

$

—

 

 

$

16,795

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable

 

 

85,860

 

 

 

—

 

 

 

—

 

 

 

85,860

 

Total

 

$

85,860

 

 

$

—

 

 

$

—

 

 

$

85,860

 

 

 

 

December 31,
2025

 

 

 

Carrying Value

 

 

Quoted Price in Active Markets for Identical Assets (Level 1)

 

 

Significant Other Observable Inputs (Level 2)

 

 

Significant Unobservable Inputs (Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. Treasury securities

 

$

47,745

 

 

$

—

 

 

$

47,745

 

 

$

—

 

Other investments (ASC 321)

 

 

5,580

 

 

 

—

 

 

 

—

 

 

 

5,580

 

Total

 

$

53,325

 

 

$

—

 

 

$

47,745

 

 

$

5,580

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Convertible notes payable

 

 

199,323

 

 

 

—

 

 

 

—

 

 

 

199,323

 

Total

 

$

199,323

 

 

$

—

 

 

$

—

 

 

$

199,323

 

The following table provides a reconciliation of the Company’s liabilities measured as a Level 3 at fair value on a recurring basis using significant unobservable inputs (in thousands):

 

 

Convertible
Notes Payable

 

Balance as of December 31, 2024

 

$

33,433

 

Fair value at issuance

 

 

42,171

 

Fair value adjustment

 

 

123,719

 

Balance as of December 31, 2025

 

 

199,323

 

Issuance of common stock for convertible notes

 

 

(117,326

)

Fair value adjustment

 

 

3,863

 

Balance as of September 30, 2026

 

$

85,860

 

 

5. Revenue and Segment Information

In connection with the Company's acquisitions of 51% ownership of PET Labs in October 2023, 100% ownership of ECNP in October 2025 and 60% ownership of Numed in January 2026, the Company manufactures and sells nuclear medical doses for PET and SPECT scanning in South Africa and the U.S. Beginning in the first quarter of 2026, primarily as a result of the acquisition of Renergen and the deconsolidation of Skyline, the Company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) helium and LNG. The Company’s prior “construction services” segment is shown below as “discontinued operations.”

17


 

The following table presents revenue from continuing operations disaggregated by geography based on the Company’s locations (in thousands):

 

 

Revenues

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

Segment

 

2026

 

 

2025

 

 

2026

 

 

2025

 

South Africa

 

$

3,331

 

 

$

1,271

 

 

$

9,358

 

 

$

3,571

 

United States

 

 

1,793

 

 

—

 

 

 

5,069

 

 

—

 

Total Revenue

 

$

5,124

 

 

$

1,271

 

 

$

14,427

 

 

$

3,571

 

The following table presents changes in the Company’s accounts receivable for the nine months ended September 30, 2026 (in thousands):

 

 

Balance as of
December 31,
2025

 

 

Additions (a)

 

 

Deductions

 

 

Balance as of
September 30,
2026

 

Accounts receivable

 

$

1,078

 

 

$

17,002

 

 

$

(14,807

)

 

$

3,273

 

(a)
The Company assumed accounts receivable as part of the Numed and Renergen acquisitions totaling $0.2 million and $3.2 million, respectively (Note 14).

Segment Information

Beginning in 2024, primarily as a result of increased business activities of its subsidiary, Quantum Leap Energy LLC, the Company had two operating segments: (i) specialist isotopes, and related services and (ii) nuclear fuels. Beginning in August 2025, primarily as a result of the acquisition of Skyline, the Company had three operating segments: (i) specialist isotopes and related services, (ii) nuclear fuels, and (iii) construction services. In January 2026, the Company acquired Renergen, which is an integrated producer of both liquid helium and LNG, which comprises the helium and LNG segment. As mentioned above, in late March 2026, the Company entered into the Exchange Agreement and completed the deconsolidation of Skyline. The Company retained approximately 8.6% of the outstanding Class A ordinary and preferred shares of Skyline immediately following the separation. The accounting requirements for reporting the separation of Skyline as a discontinued operation were met when the separation was completed. Subsequent to the deconsolidation of Skyline in March 2026, the Company has three operating segments: (i) specialist isotopes and related services, (ii) nuclear fuels, and (iii) helium and LNG.

The specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Molybdenum-100 (“Mo-100"), Si-28 and Yb-176) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging and semiconductors, as well as services related to these isotopes, and this segment includes operations of PET Labs, Numed and ECNP.

The nuclear fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market, and this segment includes operations of QLE.

The Helium and LNG segment is currently focused on the exploration, production and sale of helium and LNG in South Africa, and this segment includes operations of Renergen.

The Company’s chief operating decision maker (“CODM”) is its chief executive officer. The CODM regularly reviews segment operating income (loss) as the primary segment profit measure to evaluate segment performance, identify trends affecting operating results, and assess the effectiveness of the Company's operating strategies. The CODM uses this measure when evaluating resource allocation decisions, including capital investments, personnel decisions, operating expenditures, and acquisition opportunities.

In addition, the CODM reviews segment revenue and segment gross profit (loss) to evaluate pricing, customer mix, and direct cost performance within each segment. The CODM also reviews net income (loss) before income taxes to assess the overall financial performance of each segment and to facilitate comparisons among segments. The CODM regularly reviews any asset information by operating segment as well and, accordingly, asset information is reported on a segment basis.

The following table shows total assets by segment and a reconciliation to the condensed consolidated financial statements as of September 30, 2026 and December 31, 2025 (in thousands):

 

 

 

September 30,
2026

 

 

December 31,
2025

 

Segment assets:

 

 

 

 

 

 

Specialist isotopes and related services

 

$

210,920

 

 

$

321,190

 

Nuclear fuels

 

 

96,707

 

 

 

94,252

 

Helium and LNG

 

 

230,502

 

 

 

—

 

Discontinued operations

 

 

—

 

 

 

82,578

 

Total assets

 

$

538,129

 

 

$

498,020

 

 

Select information from the condensed consolidated statements of operations and comprehensive loss as of the three months ended September 30, 2026 and 2025 is as follows (in thousands):

 

 

Revenues

 

 

Segment Operating Loss

 

 

 

Three Months Ended September 30,

 

 

Three Months Ended September 30,

 

Segment

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Specialist isotopes and related services

 

$

4,257

 

 

$

1,271

 

 

$

(18,630

)

 

$

(11,763

)

Nuclear fuels

 

 

—

 

 

 

—

 

 

 

(11,466

)

 

 

(3,224

)

Helium and LNG

 

 

867

 

 

 

—

 

 

 

(10,419

)

 

 

—

 

 

$

5,124

 

 

$

1,271

 

 

$

(40,515

)

 

$

(14,987

)

 

18


 

Select information from the condensed consolidated statements of operations and comprehensive loss as of the nine months ended September 30, 2026 and 2025 is as follows (in thousands):

 

 

Revenues

 

 

Segment Operating Loss

 

 

 

Nine Months Ended September 30,

 

 

Nine Months Ended September 30,

 

Segment

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Specialist isotopes and related services

 

$

11,512

 

 

$

3,571

 

 

$

(50,094

)

 

$

(27,218

)

Nuclear fuels

 

 

800

 

 

 

—

 

 

 

(29,288

)

 

 

(7,690

)

Helium and LNG

 

 

2,115

 

 

 

—

 

 

 

(20,216

)

 

 

—

 

 

$

14,427

 

 

$

3,571

 

 

$

(99,598

)

 

$

(34,908

)

A reconciliation of total segment revenue to total consolidated revenue and of total segment gross profit and segment operating income to total consolidated income before income taxes, for the three months ended September 30, 2026 and 2025, is as follows (in thousands):

 

 

 

Three Months Ended September 30, 2026

 

 

 

Specialist isotopes and related services

 

 

Nuclear fuels

 

 

Helium and LNG

 

 

Total

 

Product revenue

 

$

4,257

 

 

$

—

 

 

$

867

 

 

$

5,124

 

Less: cost of sales

 

 

(2,631

)

 

 

—

 

 

 

(1,700

)

 

 

(4,331

)

Segment gross profit (loss)

 

 

1,626

 

 

 

—

 

 

 

(833

)

 

 

793

 

Personnel expenses

 

 

9,700

 

 

 

5,098

 

 

 

4,300

 

 

 

19,098

 

Professional fees

 

 

4,167

 

 

 

5,229

 

 

 

1,419

 

 

 

10,815

 

Other segment expenses

 

 

6,389

 

 

 

1,139

 

 

 

3,867

 

 

 

11,395

 

Segment operating loss

 

 

(18,630

)

 

 

(11,466

)

 

 

(10,419

)

 

 

(40,515

)

Foreign exchange transaction loss

 

 

192

 

 

 

(97

)

 

 

(606

)

 

 

(511

)

Change in fair value of investments

 

 

862

 

 

 

(1,850

)

 

 

—

 

 

 

(988

)

Change in fair value of convertible notes payable

 

 

(284

)

 

 

448

 

 

 

—

 

 

 

164

 

Gain on extinguishment of convertible notes

 

 

11,250

 

 

 

—

 

 

 

—

 

 

 

11,250

 

Interest income (expense), net

 

 

5,687

 

 

 

677

 

 

 

(5,512

)

 

 

852

 

Loss before income tax expense

 

$

(923

)

 

$

(12,288

)

 

$

(16,537

)

 

$

(29,748

)

 

 

 

Three Months Ended September 30, 2025

 

 

 

Specialist isotopes and related services

 

 

Nuclear fuels

 

 

Total

 

Product revenue

 

$

1,271

 

 

$

—

 

 

$

1,271

 

Less: cost of sales

 

 

(1,029

)

 

 

—

 

 

 

(1,029

)

Segment gross profit

 

 

242

 

 

 

—

 

 

 

242

 

Personnel expenses

 

 

5,454

 

 

 

2,512

 

 

 

7,966

 

Professional fees

 

 

2,426

 

 

 

410

 

 

 

2,836

 

Other segment expenses

 

 

4,125

 

 

 

302

 

 

 

4,427

 

Segment operating loss

 

 

(11,763

)

 

 

(3,224

)

 

 

(14,987

)

Foreign exchange transaction loss

 

 

(15

)

 

 

—

 

 

 

(15

)

Change in fair value of share liability

 

 

(71

)

 

 

—

 

 

 

(71

)

Change in fair value of convertible notes payable

 

 

—

 

 

 

173

 

 

 

173

 

Interest income, net

 

 

1,568

 

 

 

200

 

 

 

1,768

 

Loss before income tax expense

 

$

(10,281

)

 

$

(2,851

)

 

$

(13,132

)

 

A reconciliation of total segment revenue to total consolidated revenue and of total segment gross profit and segment operating income to total consolidated income before income taxes, for the nine months ended September 30, 2026 and 2025, is as follows (in thousands):

 

 

 

Nine Months Ended September 30, 2026

 

 

 

Specialist isotopes and related services

 

 

Nuclear fuels

 

 

Helium and LNG

 

 

Total

 

Product revenue

 

$

11,512

 

 

$

—

 

 

$

2,115

 

 

$

13,627

 

Collaboration revenue

 

 

—

 

 

 

800

 

 

 

—

 

 

 

800

 

Less: cost of sales

 

 

(6,473

)

 

 

—

 

 

 

(4,014

)

 

 

(10,487

)

Segment gross profit (loss)

 

 

5,039

 

 

 

800

 

 

 

(1,899

)

 

 

3,940

 

Personnel expenses

 

 

26,195

 

 

 

12,838

 

 

 

6,516

 

 

 

45,549

 

Professional fees

 

 

11,252

 

 

 

14,059

 

 

 

2,642

 

 

 

27,953

 

Other segment expenses

 

 

17,686

 

 

 

3,191

 

 

 

9,159

 

 

 

30,036

 

Segment operating loss

 

 

(50,094

)

 

 

(29,288

)

 

 

(20,216

)

 

 

(99,598

)

Foreign exchange transaction loss

 

 

218

 

 

 

(158

)

 

 

(1,670

)

 

 

(1,610

)

Change in fair value of investments

 

 

862

 

 

 

(724

)

 

 

—

 

 

 

138

 

Change in fair value of convertible notes payable

 

 

353

 

 

 

(4,216

)

 

 

—

 

 

 

(3,863

)

Gain on extinguishment of convertible notes

 

 

11,250

 

 

 

—

 

 

 

—

 

 

 

11,250

 

Interest income (expense), net

 

 

9,507

 

 

 

2,137

 

 

 

(8,537

)

 

 

3,107

 

Loss before income tax expense

 

$

(27,904

)

 

$

(32,249

)

 

$

(30,423

)

 

$

(90,576

)

 

19


 

 

 

Nine Months Ended September 30, 2025

 

 

 

Specialist isotopes and related services

 

 

Nuclear fuels

 

 

Total

 

Product revenue

 

$

3,571

 

 

$

—

 

 

$

3,571

 

Less: cost of sales

 

 

(2,430

)

 

 

—

 

 

 

(2,430

)

Segment gross profit

 

 

1,141

 

 

 

—

 

 

 

1,141

 

Personnel expenses

 

 

13,368

 

 

 

5,557

 

 

 

18,925

 

Professional fees

 

 

6,657

 

 

 

1,063

 

 

 

7,720

 

Other segment expenses

 

 

8,334

 

 

 

1,070

 

 

 

9,404

 

Segment operating loss

 

 

(27,218

)

 

 

(7,690

)

 

 

(34,908

)

Foreign exchange transaction loss

 

 

(113

)

 

 

—

 

 

 

(113

)

Change in fair value of share liability

 

 

(200

)

 

 

—

 

 

 

(200

)

Change in fair value of convertible notes payable

 

 

—

 

 

 

(64,542

)

 

 

(64,542

)

Interest income, net

 

 

2,461

 

 

 

577

 

 

 

3,038

 

Loss before income tax expense

 

$

(25,070

)

 

$

(71,655

)

 

$

(96,725

)

 

Other segment expenses primarily consist of selling and marketing expenses, professional fees, occupancy costs, information technology expenses, insurance, depreciation and amortization, and other general and administrative expenses that are regularly provided to the CODM and included in the measure used to determine segment operating loss.

 

6. Property and Equipment

Property and equipment as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):

 

 

Useful Lives
(Years)

 

September 30,
2026

 

 

December 31,
2025

 

Construction in progress

 

—

 

$

3,768

 

 

$

4,950

 

Plant and office buildings

 

10

 

 

30,786

 

 

 

21,291

 

Land

 

—

 

 

213

 

 

 

—

 

Tools, machinery and equipment

 

3 - 10

 

 

10,060

 

 

 

7,869

 

Computer equipment

 

3

 

 

874

 

 

 

332

 

Vehicles

 

5

 

 

1,436

 

 

 

828

 

Software

 

3-5

 

 

782

 

 

 

613

 

Office furniture

 

5 - 10

 

 

527

 

 

 

248

 

Leasehold improvements

 

Lesser of estimated useful life or the remaining lease term

 

 

700

 

 

 

114

 

Property and equipment, at cost

 

 

 

 

49,146

 

 

 

36,245

 

Less accumulated depreciation

 

 

 

 

(7,420

)

 

 

(2,954

)

Property and equipment, net

 

 

 

$

41,726

 

 

$

33,291

 

The Company has three isotope enrichment plants in Pretoria, South Africa: a C-14 plant, a multi-isotope plant and a laser isotope separation plant using QE technology. As of September 30, 2026 costs incurred for the expansion of PET Labs South Africa were considered construction in progress because the work was not complete. As of December 31, 2025, costs incurred for the expansion of PET Labs South Africa and the improvements to the laser isotope separation plant were considered construction in progress because the work was not complete.

Depreciation expense was $1.6 million and $0.6 million for the three months ended September 30, 2026 and 2025, respectively. Depreciation expense was $4.4 million and $0.9 million for the nine months ended September 30, 2026 and 2025, respectively. Depreciation expense included as part of inventory costs was $0 and $44,000 for the three and nine months ended September 30, 2026, respectively.

Natural gas properties at cost as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):

 

 

September 30,
2026

 

 

December 31,
2025

 

Proved reserves

 

$

35,518

 

 

$

—

 

Unproved reserves

 

 

72,368

 

 

 

—

 

Wells in process

 

 

5,982

 

 

 

—

 

Developed Assets

 

 

24,005

 

 

 

—

 

Gas processing and liquefaction equipment (Virginia Gas Project)

 

 

19,417

 

 

 

—

 

Construction in progress

 

 

36,847

 

 

 

—

 

Rehabilitation Asset

 

 

3,602

 

 

 

—

 

Natural gas properties, at cost

 

 

197,739

 

 

 

—

 

Less accumulated depreciation, depletion and amortization

 

 

(1,613

)

 

 

—

 

Net capitalized costs

 

$

196,126

 

 

$

—

 

 

Natural gas properties are depleted using the unit-of-production method. Acquisition costs (proved reserves) are depleted over total proved reserves; development costs (developed assets) are depleted over proved developed reserves. Gas processing and liquefaction equipment, including the plant, is depreciated using the straight-line method based on a useful life of 20 years. Construction in progress is not depleted or depreciated until the related assets are placed in service. The useful life of the rehabilitation asset is consistent with the units-of-production depletion of the underlying developed assets. Depreciation and depletion expense attributable to natural gas properties was $1.6 million for the period from January 6, 2026 through September 30, 2026 and $0.5 million for the three months ended September 30, 2026 and is included within the cost of revenue line in the condensed consolidated statements of operations and comprehensive loss.

20


 

7. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):

 

 

September 30,
2026

 

 

December 31,
2025

 

Value-added tax refund receivable

 

$

2,060

 

 

$

763

 

Insurance

 

 

2,033

 

 

 

1,982

 

Vendor advances and deposits

 

 

4,330

 

 

 

1,305

 

Lease receivable

 

 

556

 

 

 

—

 

Other

 

 

1,835

 

 

 

899

 

Total prepaid expenses and other current assets

 

$

10,814

 

 

$

4,949

 

 

8. Accrued Expenses

Accrued expenses as of September 30, 2026 and December 31, 2025 consisted of the following (in thousands):

 

 

September 30,
2026

 

 

December 31,
2025

 

Salaries and other employee costs

 

$

5,772

 

 

$

2,965

 

Professional

 

 

2,544

 

 

 

1,262

 

Other

 

 

634

 

 

 

187

 

Total accrued expenses

 

$

8,950

 

 

$

4,414

 

 

9. Debt

Debt consisted of the following as of September 30, 2026 and December 31, 2025 (in thousands):

 

 

September 30,

 

 

December 31,

 

 

2026

 

 

2025

 

Promissory notes

 

$

332

 

 

$

106

 

Motor vehicle and equipment loans

 

 

1,946

 

 

 

1,949

 

Credit facility

 

 

21,736

 

 

 

—

 

Secured term loans

 

 

22,374

 

 

 

—

 

Unsecured term loans

 

 

6,570

 

 

 

—

 

Total debt

 

 

52,958

 

 

 

2,055

 

less current portion of debt

 

 

(47,690

)

 

 

(584

)

Long term portion of debt

 

$

5,268

 

 

$

1,471

 

 

Credit facility and term loans contain a repayment on demand clause. Management believes the carrying values of debt outstanding approximates fair value based on the interest rates and scheduled maturities applicable to the outstanding borrowings.

Promissory Note Payable

In August 2025, the Company executed a promissory note payable with a finance company to fund a general liability insurance policy for $0.2 million. This note bears interest at an annual rate of 10.0% with twelve monthly payments beginning in August 2025. As of September 30, 2026 and December 31, 2025, this promissory note payable balance was $0 and $0.1 million, respectively.

In August 2026, the Company executed a promissory note payable with a finance company to fund a general liability insurance policy for $0.2 million. This note bears interest at an annual rate of 10.9% with twelve monthly payments beginning in August 2026. As of September 30, 2026 this promissory note payable balance was $0.2 million.

The Company assumed a promissory note in connection with the acquisition of Renergen in January 2026 to fund a general liability insurance policy for approximately $1.1 million. This note bears interest at an annual rate of 9.6% with eleven monthly payments beginning in December 2025. As of September 30, 2026, this promissory note payable balance was $0.1 million.

Motor Vehicle and Equipment Loans

Periodically, the Company enters into loans to purchase motor vehicles and certain equipment. For the nine months ended September 30, 2026, the Company entered into new loans totaling $0.1 million. These loans are secured by the underlying assets included in property and equipment. The loans have variable interest rates ranging from 9.25% to 11.25% and mature from September 2028 to February 2031. Minimum monthly payments total $0.1 million. For each of the three months ended September 30, 2026 and 2025, interest expense under the outstanding loans was $0.1 million. For each of the nine months ended September 30, 2026 and 2025, interest expense under the outstanding loans was $0.2 million. As of September 30, 2026 and December 31, 2025, motor vehicle and equipment loans totaled $1.9 million and $1.9 million, respectively.

Credit Facilities

Renergen's subsidiary Tetra4 entered into a $40.0 million finance agreement with the U.S. International Development Finance Corporation ("DFC"), as successor and assignee of the Overseas Private Investment Corporation ("DFC Credit Facility") on August 20, 2019 (as amended, the “Facility Agreement”). Drawdowns occurred between September 2019 and September 2021. Tetra4 is obligated to repay the loan in equal quarterly installments of $1.1 million on each payment date which began on August 2022 and will end on August 15, 2031. The drawdowns bear interest at rates ranging from 1.24% to 2.11% per annum. The DFC Credit Facility is secured by a pledge of Tetra4’s assets, land and the restricted cash accounts disclosed in Note 2. At all times Tetra4 is required to ensure that its debt service reserve account is funded in an amount equal to the aggregate amount of the sum of all payments of principal, interest and fees made or required to be made by Tetra4 in respect of its indebtedness with respect to the DFC Credit Facility Agreement for the immediately succeeding six-month period. As of September 30, 2026, Tetra4 was in default under the DFC Credit Facility as a result of (a) its failure to timely register the Servitude Security and provide DFC with evidence of such registration with the appropriate Deeds

21


 

Office in the Project Country; (b) its failure to timely deliver its audited annual financial statements, the related auditor reports and the Sponsor’s audited annual financial statements to DFC following Tetra4’s transition from IFRS to US GAAP and the extended PCAOB‑compliant audit procedures required to align with ASPI’s SEC periodic reporting obligations; and (c) cross-default provision of the DFC Credit Facility, which was triggered by Tetra4’s breaches of the IDC Loan Agreement. Tetra4 is actively engaged in discussions with DFC regarding the aforementioned defaults, and, while there can be no assurance that DFC will agree to an amendment or waiver on acceptable terms (or at all), DFC has informally indicated its willingness (i) to extend the deadline for the registration of the Servitude Security to a date falling six months after the anticipated completion date for Phase 1 of the Virginia Gas Project and (ii) to consider extending such audited annual financial statements delivery deadline to no later than the fourth quarter 2026. Failure to obtain such amendments or waivers from DFC could result in DFC exercising remedies available to it under the DFC Credit Facility, including declaring any portion or all of the outstanding principal amount and accrued interest thereon immediately due and payable. As a result of these defaults, DFC may be entitled to accelerate the DFC Credit Facility, which in turn give rise to an event of default under the cross-default provisions of the SBSA Loan. For the period January 6, 2026 through September 30, 2026, interest expense under the DFC Credit Facility was $1.0 million. For the three months ended September 30, 2026, interest expense was $0.3 million. As of September 30, 2026, the outstanding principal amount of the DFC Credit Facility totaled $21.7 million and is classified as current. All capitalized terms used in this paragraph but not defined herein have the meaning ascribed to them in the DFC Credit Facility.

Secured Term Loans

Renergen's subsidiary Tetra4 entered into a ZAR 160.7 million loan agreement (the “IDC Loan Agreement”) with the Industrial Development Corporation of South Africa Limited (“IDC”), as lender, on December 20, 2021 ("IDC Loan"). A drawdown occurred in December 2021 and is repayable in 102 equal monthly payments which commenced in July 2023. The loan terms included a 12-month interest capitalization and an 18-month capital repayment moratorium. The loan accrues interest at the prime lending rate plus 3.5% and is secured by a pledge of Tetra4’s assets, land and the restricted cash disclosed in Note 2. The following financial covenants apply to the IDC Loan: Tetra4 is required to maintain (a) a ratio of all interest bearing Debt to EBITDA of not more than 3.0 to 1; (b) a ratio of Current Assets to Current Liabilities of not less than 1 to 1; (c) a ratio of Cash Flow for the most recently completed four (4) consecutive full fiscal quarters, taken as a single accounting period, to Debt Service for the most recently completed four (4) consecutive full fiscal quarters, taken as a single accounting period, of not less than 1.30 to 1; (d) a ratio of Cash Flow for the most recently completed four (4) fiscal quarters, taken as a single accounting period, to Debt Service for the next succeeding four (4) consecutive full fiscal quarters of not less than 1.3 to 1; and (e) at all times, a Reserve Tail Ratio of not less than 25%. These financial covenants will be measured by Tetra4 on each Calculation Date (defined at the end of each fiscal quarter (including the fourth fiscal quarter) of each financial year, a date falling not less than 45 (forty-five) days thereafter; and at the end of each Fiscal Year, a date falling not less than 90 days thereafter). Additionally, at all times, Tetra4 is required to ensure that the debt service reserve account is funded in an amount equal to, on any given date, a Rand amount equal to the aggregate amount of the sum of all payments of principal, interest and fees made or required to be made by Tetra4 under the IDC Loan Agreement for the immediately succeeding six-month period, to be used as a payment buffer for Tetra4’s repayment obligations under and in terms of the IDC Loan Agreement. The IDC Loan Agreement contains negative covenants, which include that Tetra4 shall not make any shareholder dividend distribution, repay any shareholders’ loans and/or pay any interest on shareholders’ loans or make any payments whatsoever to its shareholders without the IDC’s prior written consent if (i) Tetra4 is in breach of any term of the IDC Loan Agreement; or (ii) the making of such payment would result in a breach of any one or more of the financial ratios described above. As of September 30, 2026, Tetra4 was not in compliance with the financial covenants described in clauses (a)-(d) above, which have been measured with effect from February 15, 2026. Tetra4 was also in breach of its undertakings under the IDC Loan Agreement to (i) register special notarial bonds over assets with an aggregate value of ZAR 150.0 million within one month of commissioning the plant, of which special notarial bonds over assets with an aggregate value of ZAR 72.7 million have been registered and a further special notarial bond over assets with a value of ZAR 13.7 million is in the process of being registered, and (ii) deliver its audited annual financial statements for the fiscal year ended February 28, 2026 within 120 days after the fiscal year end. Tetra4 is actively engaged in discussions with IDC regarding a waiver of these breaches and to amend the IDC Loan Agreement to align the Calculation Date with the completion of Phase 1 of the Virginia Gas Project. Although no assurance can be provided that a waiver will be received (if at all), the Company expects to receive a waiver from IDC in connection with the renegotiation of the applicable Calculation Date. The IDC Loan outstanding on September 30, 2026 amounted to ZAR 135.5 million ($8.3 million) and interest expense for the period January 6, 2026 through September 30, 2026 amounted to ZAR 12.7 million ($0.8 million). Since Tetra4 was in default under the IDC Loan Agreement, the loan balance was classified as current as of September 30, 2026. Interest expense for the three months ended September 30, 2026 amounted to ZAR 5.0 million ($0.3 million). Qualifying interest attributable to assets under construction is capitalized. All capitalized terms used in this paragraph but not defined herein have the meaning ascribed to them in the IDC Loan Agreement.

Pursuant to a Secured Term Loan Facility Agreement, Renergen obtained a ZAR 155.0 million secured loan from Standard Bank of South Africa Limited ("SBSA") on August 30, 2024. Such Secured Term Loan Facility Agreement was subsequently amended and restated on December 12, 2025 ("First Amendment") and August 14, 2026 ("Second Amendment"). The Second Amendment amended and replaced the First Amendment (as amended, the “SBSA Loan”). The drawdowns occurred between August 2024 and October 2024. Under the First Amendment, the SBSA Loan was scheduled to mature on the repayment date of March 31, 2026. Drawdowns under the SBSA Loan prior to the Second Amendment accrued compounded interest at a rate linked to the three-month Johannesburg Interbank Average Rate plus a variable margin (21.725% as of August 13, 2026). Pursuant to the Second Amendment all accrued but unpaid interest up to (but excluding) August 14, 2026 was capitalized, increasing the principal amount of the SBSA Loan to ZAR 230.5 million ($14.2 million), and the maturity date was extended to August 14, 2027. From August 14, 2026, interest on the SBSA Loan accrues at a per annum rate equal to the Compounded Reference Rate (based on the South African Rand Overnight Index Average (ZARONIA)) plus a margin of 1.46% (resulting in an initial effective rate of 8.31%). Upon the occurrence and during the continuance of a default, interest on overdue amounts accrues at an additional 2% per annum above the otherwise applicable rate. The SBSA Loan is a first-ranking cession in security by Renergen of its collateral account held with SBSA and all amounts standing to its credit. In addition, NTIGT Investment Proprietary Limited (“NTIGT”), an affiliate of Mr. Nicholas Mitchell and Mr. Stefano Marani, entered into a limited guarantee, cession and pledge agreement with SBSA, pursuant to which NTIGT guaranteed Renergen’s obligations under the SBSA Loan on a limited basis and had pledged and ceded in security its shares in, and claims against, Renergen and ASP Isotopes, including 1,546,268 shares of ASP Isotopes common stock issued to NTIGT in exchange for shares of Renergen prior to the acquisition by ASP Isotopes. In connection with the Second Amendment, on August 14, 2026, the Company, SBSA, and Renergen, as confirming party, entered into a Put Option Agreement (the “Put Option Agreement”) with respect to the shares pledged by NTIGT under which, in the event of a default, SBSA may put the pledged shares to the Company at a price equal to the volume weighted average price per share of the Company’s common stock traded on the JSE during the five preceding trading days. Additionally, the Company has a current restricted cash account of $14.0 million with SBSA reserving all payments to fulfill obligations under the SBSA Loan. The Molopo litigation discussed below and the need to procure the requisite equity injection by January 24, 2025 previously resulted in events of default with respect to the SBSA Loan. SBSA provided a waiver for both default events. As of September 30, 2026, Renergen was in breach of its obligations under the SBSA Loan to deliver the audited annual financial statements of Tetra4 and its audited consolidated

22


 

financial statements for the fiscal year ended February 28, 2026 within the required periods, and the breaches by Tetra4 under the IDC Loan Agreement and the DFC facility, which entitle those lenders to accelerate the relevant loans, constituted an event of default under the cross-default provisions of the SBSA Loan. As at the date of this report, SBSA has not exercised any remedies in respect of these events of default; however, there can be no assurance that it will not do so. The SBSA Loan outstanding on September 30, 2026 amounted to ZAR 231.4 million ($14.1 million), which is classified as current, and interest expense for the period January 6, 2026 through September 30, 2026 amounted to ZAR 29.3 million ($1.8 million). Interest expense for the three months ended September 30, 2026 amounted to ZAR 7.7 million ($0.5 million).

Unsecured Term Loans

Renergen entered into a $7.0 million unsecured convertible debenture subscription agreement ("Subscription Agreement") with AIRSOL, an Italian wholly-owned subsidiary of SOL S.p.A., on August 30, 2023. The Subscription Agreement provided for two tranches of funding: $3.0 million (“Tranche 1”), received on August 30, 2023, and $4.0 million (“Tranche 2”), received on March 18, 2024. The debentures include a contractual maturity date, initially set at February 28, 2025 and amended by agreement to August 31, 2025, subject to the terms of the Subscription Agreement (as amended) and the related Helium Sale and Purchase Agreement. The debentures accrue interest at 13% per annum, calculated and compounded semi-annually, with interest payable on February 28 and August 31 each year. On August 4, 2026, the legal dispute regarding the payment terms with AIRSOL was resolved and Renergen has agreed to pay the sum of the principal, accrued interest and certain fees for a total of $8.5 million in three equal installments ending in November 2026. As of September 30, 2026, Renergen made two installment payments totaling $5.5 million. The carrying amount of the debentures outstanding as of September 30, 2026 was $2.7 million and is classified as current and due to be paid on November 30, 2026.

Renergen's subsidiary Tetra4 entered into a ZAR 50.0 million loan agreement with Molopo on April 11, 2014. The loan term was for a period of 10 years and six months commencing on July 1, 2014 (repayable on August 31, 2024). During this period the loan was unsecured and is interest free. The loan was discounted on initial recognition and the amortization of the discount applied on initial recognition was recognized in borrowing costs as imputed interest.

As the loan was not repaid on August 31, 2024 it now accrues interest at the prime lending rate plus 2% (12.75% on September 30, 2026). The loan can only be repaid when Tetra4 declares a dividend and utilizes a maximum of 36% of the distributable profits in order to pay the dividend. It is not expected that the loan or interest will be repaid in the next 12 months given the unavailability of distributable profits based on Tetra4’s most recent forecasts. As such, the loan is classified as noncurrent. Interest expense was ZAR 1.9 million ($0.1 million) for the three months ended September 30, 2026 and ZAR 5.3 million ($0.3 million) for the nine months ended September 30, 2026. The Molopo loan outstanding on September 30, 2026 amounted to ZAR 64.2 million ($3.9 million).

In November 2024, Molopo initiated legal proceedings against Tetra4 in the High Court of South Africa, Gauteng Local Division, Johannesburg, by issuing a summons alleging a breach of contract when Renergen sold the 5.5% stake in Tetra4 to Mahlako Gas Energy Proprietary Limited ("MGE"). The claim pertains to a written loan agreement entered into between Molopo, as the lender, and Tetra4, as the borrower, in April 2014 (as described above). As a consequence, Molopo has purported to cancel the loan agreement, which cancellation is disputed by Tetra4 on the basis that the investment by MGE did not constitute a payment by Tetra4 to its parent in the sale. Based on current court timelines (including information published in the Lead Times Bulletin for the High Court in Gauteng), we do not expect the matter to proceed to a hearing within the next two to three years, hence the loan continues to be classified as noncurrent.

Scheduled maturities of the Company’s debt as of September 30, 2026 are as follows (in thousands):

 

2026 (remaining three months)

 

$

47,202

 

2027

 

 

630

 

2028

 

 

649

 

2029

 

 

467

 

2030

 

 

59

 

Thereafter

 

 

3,951

 

Total notes payable

 

$

52,958

 

Less debt - current

 

 

(47,690

)

Debt -noncurrent

 

$

5,268

 

 

Convertible Notes Payable

In March 2024, QLE issued convertible notes payable (“March 2024 Convertible Notes”) totaling $21.1 million and received aggregate cash of $20.6 million. One of the notes totaling $0.5 million was issued to the placement agent in lieu of cash issuance costs.

In June 2024, QLE issued additional convertible notes payable (“June 2024 Convertible Notes”) totaling $5.5 million and received aggregate cash of $5.4 million. One of the notes totaling $0.1 million was issued to the placement agent in lieu of cash issuance costs Issuance costs paid in cash were negligible. The March 2024 Convertible Notes and the June 2024 Convertible Notes are collectively the “2024 Convertible Notes”.

The 2024 Convertible Notes were payable on demand in March 2029 and bear interest at an annual rate of 6% through March 7, 2025 and 8% thereafter. Upon a qualified financing event, the 2024 Convertible Notes convert into the shares issued in that qualified financing event at a price per share equal to 80% of the share price issued subject to a valuation cap. Upon a qualified transaction, the noteholders may elect to receive either 1.5x the principal and accrued interest balance in cash or convert into common shares.

The 2024 Convertible Notes were recorded on the condensed consolidated balance sheet at their fair values. The fair value of the March 2024 Convertible Notes on the date of issuance was $21.1 million. The fair value of the June 2024 Convertible Notes on the date of issuance was $5.5 million. The fair value of the 2024 Convertible Notes as of September 30, 2025 was determined to be $98.1 million and the resultant change in fair value of $0.2 million and $64.5 million was recorded in other income and expense in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2025, respectively. In connection with the issuance of the 2025 Convertible Notes (as described below), QLE’s outstanding 2024 Convertible Notes originally issued in March 2024 and June 2024 automatically converted into 2025 Convertible Notes with a new principal amount of $147.7 million which is equal to its fair value on the date of conversion.

In November 2025, QLE issued convertible notes payable (“2025 Convertible Notes”) totaling $72.2 million and received aggregate cash of $69.6 million, including $30.0 million in gross proceeds from ASP Isotopes, its parent. Together with the conversion of the 2024 Convertible Notes, the Company issued 2025 Convertible Notes totaling $189.9 million. The maturity date of the 2025 Convertible Notes is November 19, 2030. The 2025 Convertible Notes automatically convert into common shares upon QLE’s closing

23


 

of an IPO or other qualifying public transaction at 80% of the share price, taking into consideration a valuation cap. Issuance costs paid in cash totaling $2.6 million were expensed in selling, general and administrative costs in the condensed consolidated statement of operations and comprehensive loss for the year ended December 31, 2025.

On July 15, 2026, QLE and ASP entered into separate, individually negotiated private securities exchange agreements with certain holders of the 2025 Convertible Notes, pursuant to which such noteholders exchanged approximately $109.2 million in aggregate principal amount of the outstanding 2025 Convertible Notes, plus accrued and unpaid interest thereon, for an aggregate of approximately 23.2 million shares of ASP's common stock (the “Exchange Transactions”). The Exchange Transactions closed on July 16, 2026. Upon the closing of the Exchange Transactions, the outstanding principal amount of 2025 Convertible Notes held by third party investors was reduced to approximately $80.6 million, and ASP holds approximately $139.2 million aggregate principal amount of 2025 Convertible Notes.

The 2025 Convertible Notes are recorded on the condensed consolidated balance sheet at their fair values. The fair value of the 2025 Convertible Notes as of September 30, 2026 and December 31, 2025 has been determined to be $85.9 million and $199.3 million, respectively. The Company recorded a gain on extinguishment of convertible notes of $11.3 million as a result of entering into the Exchange Transactions for the three and nine months ended September 30, 2026. The resultant change in fair value of the 2025 Convertible Notes for the three and nine months ended September 30, 2026 was $0.2 million and $3.9 million, respectively. Both the gain on extinguishment of convertible notes and change in fair value of convertible notes has been recorded in other income and expense in the condensed consolidated statement of operations and comprehensive loss. As of September 30, 2026, the total principal and accrued interest of the 2025 Convertible Notes was $80.6 million and $5.6 million, respectively, on the Company’s condensed consolidated balance sheet.

TerraPower Loan Agreement

The Company announced QLE and certain of its subsidiaries have entered into a loan agreement with TerraPower (the “TerraPower Loan Agreement”), a US nuclear innovation company, for a multiple advance term loan of up to $22.0 million related to financing support for the construction of a new uranium enrichment facility capable of producing HALEU in South Africa. Per the terms of the TerraPower Loan Agreement and subject to the satisfaction of various conditions precedent to each disbursement (including receiving all required licenses and permits to perform uranium enrichment in South Africa), the borrower could receive aggregate loan disbursements of $20.0 million.

10. Deferred Revenues

In June 2023, the Company entered into a Supply Agreement with a customer for the delivery of Mo-100 and molybdenum-98 beginning in 2024. In conjunction with the Supply Agreement, the Company received $0.9 million in September 2023, as an advance towards future revenue. The Company has recorded $0.9 million as deferred revenue on the balance sheet as of September 30, 2026 and December 31, 2025.

The Company assumed a token liability in connection with the acquisition of Renergen in January 2026. Tokens to acquire helium at a fixed price with a value of $0.8 million were issued during 2023 and have no expiration date. When a token is redeemed, revenue relating to the transaction will be recognized at the original value at which the token was issued. The Company has recorded $0.8 million as deferred revenue - noncurrent on the balance sheet as of September 30, 2026.

11. Commitments and Contingencies

Commitments

Share Purchase Agreement relating to PET Labs

On October 31, 2023, the Company entered into a Share Purchase Agreement with Nucleonics Imaging Proprietary Limited, a company incorporated in the Republic of South Africa (the “Seller”), relating to the purchase and sale of ordinary shares in the issued share capital of PET Labs. PET Labs is a South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.

Under the Purchase Agreement, the Company agreed to purchase from the Seller 51 ordinary shares in the issued share capital of PET Labs (the “Initial Sale Shares”) (representing 51% of the issued share capital of PET Labs). In addition to the purchase consideration, the Company has an option to purchase from the Seller the remaining 49 ordinary shares in the issued share capital of PET Labs (the “Option Shares”) (representing the remaining 49% of the issued share capital of PET Labs) for an agreed consideration totaling $2.2 million. The Company agreed to pay to the Seller an aggregate of $2.0 million for the Initial Sale Shares, of which aggregate amount of $0.5 million was payable on the completion of the sale of the Initial Sale Shares and $1.5 million was payable on demand after one calendar year from the agreement date. In January 2024, the Company agreed to pay $0.3 million to the Seller. The Company paid an additional $0.7 million and $0.5 million in January 2025 and December 2025, respectively, resulting in the Initial Sale Shares being paid in full as of December 31, 2025. The option is exercisable from the agreement date until January 31, 2027. The option has not been exercised as of September 30, 2026 and no amount relating to the option has been recognized.

PET Labs Global

In August 2024, PET Labs Global entered into a three-year service agreement with Cayman Enterprise City and is licensed to operate from within the Cayman Islands’ Special Economic Zone (“SEZ”). The service fee includes among other things the right to use certain office space and associated facilities within the SEZ. The Company has applied the guidance in ASC 842 and determined that this agreement is not a leasing arrangement. Management has determined that based on the nature of the combined services the expense should be recognized as incurred.

Renergen Firm Intention Letter and Loan Agreement

On March 31, 2025, the Company entered into an Exclusivity Agreement with Renergen, an entity in South Africa listed on the Johannesburg Stock Exchange (“JSE”), the Australian Stock Exchange and the A2X. On May 18, 2025, the Exclusivity Agreement was amended. Per the terms of the amended Exclusivity Agreement, the Company received the rights to negotiate the terms of the acquisition of Renergen during an exclusive negotiation period that ended on May 31, 2025. In April 2025, the Company paid an exclusivity fee of $10.0 million to Renergen.

As contemplated in the Exclusivity Agreement signed on March 31, 2025 and amended on May 18, 2025, the Company entered into a Firm Intention Letter with Renergen on May 19, 2025. The Firm Intention Letter sets the acquisition terms for the Company to purchase 100% of the outstanding shares of Renergen in exchange for shares of the Company. The completion of the acquisition was subject to several closing conditions including Renergen shareholder approval, which was obtained on July 10, 2025. The acquisition

24


 

was consummated on January 6, 2026, and as a result, Renergen became a direct, wholly owned subsidiary of the Company, and the Renergen Ordinary Shares were delisted from the JSE, the Australian Securities Exchange and the A2X (Note 14).

In addition, the Company entered into a loan agreement with Renergen ("Renergen Loan") in which a total of $30.0 million was provided by the Company for the purpose of funding Renergen’s operations. In conjunction with the Renergen Loan, the full amount of the previously paid exclusivity fee of $10.0 million was applied to the Renergen Loan. The remaining $20.0 million available under the Renergen Loan was paid by the Company to Renergen in June 2025. The Renergen Loan matured and repayment was due on September 30, 2025. The Renergen Loan bears interest at the South African Prime Rate, which was approximately 10.75% as of September 30, 2026. The Renergen Loan was amended to extend the repayment date to January 20, 2026 and amended again to establish the repayment date as sixty days after written demand by the Company. Pursuant to additional amendments, the aggregate principal amount available under the Renergen Loan was increased to $120 million. The Renergen Loan, including all interest accrued, is eliminated in consolidation.

Certain Commitments to the South Africa Competition Commission

In connection with the Company's acquisition of Renergen, the Company made certain commitments to the South Africa Competition Commission designed to address public interest concerns and promote historically disadvantaged persons (“HDP”) and worker ownership. These commitments to the South Africa Competition Commission include: (1) a moratorium on retrenchments of workers at Renergen’s operations for a period of two years from the merger closing date; and (2) a commitment to implement, within 12 months of the merger closing date, a trust for the benefit of qualifying workers employed by Renergen and certain HDP communities and people located within the production rights area of the Virginia Gas Project (the “HDP and Worker Trust”). Upon the effective implementation date of the HDP and Worker Trust, the HDP and Worker Trust are expected to hold an aggregate 5% of the issued shares in Tetra4 and Renergen is expected to hold 89.5% of the issued shares in Tetra4, subject to change in accordance with any capital raising activities of the Company, Renergen and/or Tetra4 following the merger closing date. In conjunction with the establishment of the HDP and Workers Trust, Tetra4 will issue an offsetting vendor financed loan to the HDP and Worker Trust. The HDP and Worker Trust will continue for the duration of the Production Right held by Tetra4, which will expire during 2042, unless extended.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues liabilities for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

On December 4, 2024, a purported stockholder of the Company filed a putative securities class action on behalf of purchasers of the Company’s securities between October 30, 2024 through November 26, 2024 against ASP Isotopes Inc. and certain of its executive officers in the United States District Court for the Southern District of New York (Corredor v. ASP Isotopes Inc., et al., Case No. 1:24-cv-09253 (S.D.N.Y.)) (the “Securities Class Action”). The Securities Class Action alleges that the Company, its chief executive officer and chief financial officer (“Defendants”) made materially misleading or false statements or omissions regarding the Company’s business and asserts purported claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and SEC Rule 10b-5 promulgated thereunder. The complaint seeks unspecified compensatory damages, attorney’s fees and costs. On May 2, 2025, the Court appointed Mark Leone (“Leone”) as lead plaintiff and directed the Clerk of court to amend the caption to substitute Leone for Alexander Corredor as plaintiff. On May 2, 2025, the Court also appointed lead counsel and set deadlines for filing an amended consolidated class action complaint and briefing schedules for a motion to dismiss, if any, and class certification. On May 27, 2025, Leone and two additional named plaintiffs (“Plaintiffs”) filed the amended class action complaint (“Amended Complaint”), that asserts the same causes of action and seeks the same relief as the initial complaint and is based upon substantially similar factual allegations as the initial complaint. On June 27, 2025, Defendants filed a motion to dismiss the Amended Complaint. Also on June 27, 2025, Plaintiffs filed a motion for class certification. On December 4, 2025, the Court denied in part Defendants’ motion to dismiss and granted Plaintiffs’ motion for class certification. On April 3, 2026, following a mediation in which the parties reached an agreement-in-principle to resolve all claims in the Securities Class Action, subject to the Court’s approval, the parties filed a Joint Stipulation agreeing to stay the Securities Class Action (the “Stipulation”). On April 6, 2026, the Court approved the Stipulation. On July 7, 2026, Plaintiffs filed a motion for preliminary approval of the settlement. The motion for preliminary approval of the settlement also requested that the Court certify the settlement class and approve the proposed notice to stockholders. On July 9, 2026, the Court granted such motion, issued an order preliminarily approving the settlement, and scheduled a settlement hearing for December 15, 2026. Under the proposed settlement, the Plaintiffs are expected to receive $9.35 million, which is expected to be substantially funded by insurance proceeds, and the defendants (including the Company) are expected to receive customary releases. The Company's remaining exposure likely consists primarily of applicable retentions and deductibles, which have been substantially paid or accrued as of September 30, 2026. The Company cannot be certain of the outcome of the Securities Class Action.

On January 30, 2026, a purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Northern District of Texas asserting claims for, among others, breach of fiduciary duty, violation of § 14(a) of the Exchange Act and a claim for contribution pursuant to § 21D thereof (Jenis v. Mann, et al., Case No. 3:26-cv-251 (N.D. Tex.)) (the “Jenis Action”). The Company is named as a Nominal Defendant. On March 2, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Southern District of New York asserting claims for, among others, breach of fiduciary duty, violations of §§ 14(a) and 20(a) of the Exchange Act, and a claim for contribution pursuant to § 21D thereof (Stewart v. Mann, et al., Case No. 1:26-cv-1712 (S.D.N.Y.)) (the “Stewart Action”)). The Company is named as a Nominal Defendant. On June 10, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Northern District of Texas asserting claims for, among others, breach of fiduciary duty, violations of §§ 10(b) and 14(a) of the Exchange Act, and a claim for contribution pursuant to § 21D thereof (Albers v. Mann, et al., Case No. 3:26-cv-1923 (N.D. Tex.)) (the “Albers Action”). The Company is named as a Nominal Defendant. On July 1, 2026, a different purported stockholder of the Company filed a derivative action against certain members of the Company’s board of directors in the United States District Court for the Southern District of New York asserting claims for, among others, breach of fiduciary duty and violation of § 14(a) of the Exchange Act (Manrique v. Mann, et al., Case No. 1:26-cv-5580 (S.D.N.Y.)) (the “Manrique Action”) (together with the Jenis Action, the Stewart Action, and the Albers Action, the “Derivative Actions”). The Company is named as a Nominal Defendant. The Derivative Actions arise out of similar allegations as those made in the Securities Class Action. The plaintiffs in the Derivative Actions seek unspecified damages, disgorgement of compensation, corporate governance reforms, fees, interests, and costs. On July 2, 2026 and July 7, 2026, the Courts in the Stewart Action and Jenis Action, respectively, upon joint motions by the parties, issued orders staying the action in light of the parties’ settlement discussions. The Company cannot be certain of the outcome of the Derivative Actions and, if decided adversely to us, our business and financial condition may be adversely affected.

25


 

In November 2024, Molopo Energy Limited ("Molopo") initiated legal proceedings against Tetra4 in the High Court of South Africa, Gauteng Local Division, Johannesburg, by issuing a summons alleging breach of a written loan agreement concluded between Molopo, as lender, and Tetra4, as borrower, in April 2014 (the "Molopo Loan Action"). The Molopo Loan Action alleges that Renergen, Tetra4's parent company, breached a condition of the loan agreement when it sold a 5.5% stake in Tetra4 to Mahlako Gas Energy Proprietary Limited ("MGE"), and that such breach entitled Molopo to cancel the loan agreement. Tetra4 disputes the purported cancellation on the basis that the investment by MGE did not constitute a payment by Tetra4 to its parent within the meaning of the loan agreement and is vigorously defending the Molopo Loan Action. Based on current court timelines (including information published in the Lead Times Bulletin for the High Court in Gauteng), we do not expect the matter to proceed to a hearing within the next two to three years. The Company cannot be certain of the outcome of the Molopo Loan Action and, if decided adversely to us, our business and financial condition may be adversely affected.

In addition to the matters described above, from time to time, the Company may become subject to arbitration, litigation or claims arising in the ordinary course of business. The results of any current or future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, reputational harm and other factors.

12. Leases

Operating leases

The Company is party to several facility leases in South Africa and the U.S. for office, manufacturing and laboratory space. Dr. Gerdus Kemp, an officer of PET Labs and an employee of ASP UK, is the sole owner of a leased office and production facility in Pretoria, South Africa. During 2026, the Company has expanded its facility leases in South Africa and entered into a lease for office space in Dallas, Texas, which serves as its corporate headquarters, and Austin, Texas, which serves as QLE's corporate headquarters. In conjunction with the acquisition of Renergen in January 2026, the Company recognized additional operating leases for its office space in South Africa. The Company also leases office and production space in Pretoria, South Africa and Cayman Islands that are accounted for as short-term leases.

Quantitative information regarding the Company’s operating lease liabilities is as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating Lease Cost

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease cost

 

$

393

 

 

$

209

 

 

$

1,052

 

 

$

552

 

Other Information

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows paid for amounts included in the
   measurement of lease liabilities

 

$

384

 

 

$

202

 

 

$

1,042

 

 

$

534

 

Operating lease liabilities arising from obtaining right-of-
   use assets

 

$

52

 

 

$

15

 

 

$

4,675

 

 

$

114

 

Weighted average remaining lease term (years)

 

 

17.18

 

 

 

3.45

 

 

 

17.18

 

 

 

3.45

 

Weighted average discount rate

 

 

11.34

%

 

 

8.80

%

 

 

11.34

%

 

 

8.80

%

Future lease payments under noncancelable operating lease liabilities as of September 30, 2026 are as follows (in thousands):

 

 

Operating
Leases

 

Future Lease Payments

 

 

 

2026 (remaining three months)

 

$

385

 

2027

 

 

1,578

 

2028

 

 

1,283

 

2029

 

 

922

 

2030

 

 

806

 

Thereafter

 

 

9,335

 

Total lease payments

 

$

14,309

 

Less: imputed interest

 

 

(8,618

)

Total operating lease liabilities

 

$

5,691

 

Less current portion

 

$

(928

)

Operating lease liability - noncurrent

 

$

4,763

 

The Company records the expense from short-term leases as incurred. Lease expense from short-term leases was $79,000 and $32,000 for the three months ended September 30, 2026 and 2025, respectively. Lease expense from short-term leases was $0.2 million and $96,000 for the nine months ended September 30, 2026 and 2025, respectively.

Financing leases

The Company is party to several ongoing finance leases in South Africa for vehicles and equipment. Some of these finance leases include arrangements with variable interest rates indexed to the prime interest rate in South Africa. There was no variable interest expense for the three months ended September 30, 2026 and 2025. The Company elects to include finance lease right-of-use assets in property and equipment, net.

26


 

Quantitative information regarding the Company’s finance lease liabilities is as follows (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Finance Lease Cost

 

 

 

 

 

 

 

 

 

 

 

 

Interest on lease liabilities

 

$

18

 

 

$

23

 

 

$

60

 

 

$

45

 

Other Information

 

 

 

 

 

 

 

 

 

 

 

 

Operating cash flows paid for amounts included in the
   measurement of finance lease liabilities

 

$

71

 

 

$

32

 

 

$

177

 

 

$

62

 

Amortization of right-of-use assets

 

$

28

 

 

$

13

 

 

$

86

 

 

$

53

 

Weighted average remaining lease term (years)

 

 

3.1

 

 

 

4.0

 

 

 

3.1

 

 

 

4.0

 

Weighted average discount rate

 

 

13.5

%

 

 

13.1

%

 

 

13.5

%

 

 

13.1

%

Future lease payments under noncancelable finance lease liabilities are as follows as of September 30, 2026 (in thousands):

 

 

Finance
Leases

 

Future Lease Payments

 

 

 

2026 (remaining three months)

 

$

53

 

2027

 

 

217

 

2028

 

 

196

 

2029

 

 

76

 

2030

 

 

75

 

Thereafter

 

 

—

 

Total lease payments

 

$

617

 

Less: imputed interest

 

 

(125

)

Total lease liabilities

 

$

492

 

Less current portion

 

$

(157

)

Finance lease liability - noncurrent

 

$

335

 

Lease receivable

The Company leases certain equipment to customers under sales-type leases and records the leases within lease receivables on the Company’s condensed consolidated balance sheets and records interest income in the Company’s condensed consolidated statements of operations and comprehensive loss. The Company does not have significant variable lease payments or residual value guarantees associated with these leases. Credit risk is monitored regularly, and no allowance for credit losses was recorded as of the reporting date.

The Company’s net investment in sales-type leases were comprised of the following (in thousands):

 

 

 

September 30, 2026

 

Total undiscounted cash flows

 

$

8,876

 

Present value discount

 

 

(4,323

)

Net investment in sales-type leases

 

$

4,553

 

Less current portion

 

$

(556

)

Net investment in sales-type leases - noncurrent

 

$

3,997

 

The current portion of sales-type leases is included in prepaid and other current assets on the balance sheet.

Future minimum lease payments to be collected under sales-type leases, excluding lease payments that are not fixed and determinable, as of September 30, 2026 are as follows (in thousands):

 

 

Sales-type
Leases

 

Future Lease Payments To Be Collected

 

 

 

2026 (remaining three months)

 

$

451

 

2027

 

 

1,275

 

2028

 

 

1,275

 

2029

 

 

1,275

 

2030

 

 

1,167

 

Thereafter

 

 

3,433

 

Total undiscounted cash flows

 

$

8,876

 

Interest income recognized from sales-type leases during the three and nine months ended September 30, 2026 was $0.2 million and $0.5 million respectively. Interest income recognized from sales-type leases during the three and nine months ended September 30, 2025 was $45,000.

13. License and Collaboration Agreements

TerraPower, LLC

TerraPower Agreement

On April 4, 2024, the Company entered into an agreement with TerraPower LLC (“TerraPower”) to develop a conceptual design, refined cost/schedule/financing, risk register, and term sheet for a HALEU facility (the “TerraPower R&D Agreement”). The TerraPower R&D Agreement may be terminated for (a) breach or default, (b) the Company’s convenience or (c) TerraPower’s convenience. TerraPower is obligated to make all payments for tasks completed by the Company per the statement of work in the TerraPower R&D Agreement totaling $2.0 million and these payments are nonrefundable. Neither party has any additional rights or obligations outside what is in the statement of work in the TerraPower R&D Agreement.

27


 

On October 18, 2024, the Company and TerraPower signed a term sheet (the “TerraPower Term Sheet”) that provides for the execution of two definitive agreements: (1) an agreement pursuant to which TerraPower will provide funding for the Company’s construction of a uranium enrichment facility capable of producing HALEU using the Company’s proprietary aerodynamic separation process technology to be located in the Republic of South Africa and (2) an agreement pursuant to which the Company will deliver to TerraPower the full capacity of the enrichment facility.

The Company accounts for the TerraPower R&D Agreement as a collaboration arrangement in accordance with ASC 808. The Company has concluded that other authoritative accounting literature does not apply directly to these payments from TerraPower, either directly or by analogy, including ASC 606 because TerraPower is not a customer. The Company has concluded that TerraPower is not a customer because TerraPower has not contracted with the Company to obtain goods or services that are an output of the Company’s ordinary activities in exchange for consideration. The Company also has concluded that there is no other authoritative accounting literature that is appropriate to apply by analogy, and, accordingly, its accounting policy is to evaluate the income statement classification for presentation of amounts associated with each separate activity. As a result, the Company concludes that all portions of the net receivable from TerraPower are directly related to the conceptual design of the HALEU facility. Furthermore, the Company and TerraPower will jointly develop criteria for optimization of the HALEU facility’s operations. TerraPower shares the risks and rewards of designing the HALEU facility since its successful completion will enable TerraPower to purchase output from the HALEU facility in the future.

For the nine months ended September 30, 2026, $0.8 million of collaboration revenue was recognized in the condensed consolidated statements of operations and comprehensive loss. No collaboration revenue was recognized for the three months ended September 30, 2026.

TerraPower Loan Agreement and HALEU Supply Agreements

In May 2025, the Company entered into the TerraPower Loan Agreement, which provides conditional commitments from TerraPower to the Company through one of its wholly-owned U.S.-based subsidiaries (“Borrower”) for a multiple advance term loan totaling $22.0 million for the purpose of partially funding the construction of a proposed new uranium enrichment facility in South Africa. The total loan amount is inclusive of a 10% original issue discount on each disbursement and carries a fixed interest rate of 10% per annum. Per the terms of the TerraPower Loan Agreement and subject to the satisfaction of various conditions precedent to disbursements (including receiving all required licenses and permits to perform uranium enrichment in South Africa), the Company will receive aggregate loan disbursements of $20.0 million. Such loan matures on May 16, 2032. Interest will begin accruing upon each milestone disbursement received by the Company and will be added to the principal balance until November 2027. Principal and interest payments will be made in equal installments beginning in November 2027. No drawdowns have been requested as of September 30, 2026.

In addition to the Terra Power Loan Agreement, the Company and TerraPower have entered into two supply agreements for the HALEU expected to be produced at the Company’s uranium enrichment facility. The initial core supply agreement is intended to support the supply of the required first fuel cores for the initial loading of TerraPower’s Natrium project in Wyoming. The long-term supply agreement is a 10-year supply agreement of up to a total of 150 metric tons of HALEU, commencing in 2028 through end of 2037.

American Ventures Advisory Agreement

On October 28, 2025, QLE entered into an Advisory Agreement (“Advisory Agreement”) with American Ventures LLC, a Delaware limited liability company (“American Ventures”). Under the Advisory Agreement, American Ventures will provide various services to the Company related to QLE and its present and future subsidiaries’ business and operations.

In October 2025, pursuant to the Advisory Agreement, QLE issued RSUs representing a right to receive a number of units or shares of common equity of QLE equal to 4.0% of the common equity of QLE deemed outstanding as of the date of grant, treating as outstanding only (i) ASP Isotopes’ membership interest in the Company and (ii) the shares or units of common equity issuable upon conversion of the 2024 Convertible Notes (or any securities issued upon conversion or exchange thereof). The total number of such RSUs cannot yet be calculated because the precise number of these units is based on a percentage of common equity deemed outstanding, which is contingent, in part, on the amount of securities issuable upon the conversion of certain of QLE’s 2025 Convertible Notes that were issued upon conversion of certain 2024 Convertible Notes. Such RSUs will vest as follows: (x) 50% upon the completion of the listing event, provided that such listing event occurs within 24 months of October 28, 2025, and (y) 50% on the six-month anniversary of such listing event.

 

14. Acquisitions and Merger Agreement

The Company accounts for business combinations in accordance with Business Combinations (Topic 805), which requires an acquirer to retrospectively adjust provisional amounts recognized in a business combination during the measurement period (which represents a period not to exceed one year from the date of the acquisition), in the reporting period in which the adjustment is determined, as well as present separately on the face of the income statement or as a disclosure in the notes to the condensed consolidated financial statements, the portion of the amount recorded in current period earnings that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date.

 

PET Labs Acquisition

In October 2023, the Company completed the acquisition of PET Labs. The acquisition is intended to accelerate the distribution of the Company’s nuclear medicine pipeline.

Pursuant to the terms of the agreement, the Company acquired 51% of the common shares issued and outstanding for total purchase consideration of $2.0 million in cash of which $0.5 million was paid up front. In December 2025, January 2025 and January 2024, the Company made partial payments of $0.5 million, $0.7 million and $0.3 million, respectively, resulting in no balance remaining as of December 31, 2025.

In addition to the purchase consideration, the Company has an option to purchase the remaining 49% of the issued and outstanding shares for an agreed consideration totaling $2.2 million. No consideration or value relating to this option was recognized as it was not considered probable at the time of acquisition and as of September 30, 2026.

Dr. Gerdus Kemp is an officer of PET Labs and, effective November 1, 2023, an employee of ASP Guernsey. In addition, Dr. Kemp controls the remaining 49% ownership of PET Labs.

28


 

East Coast Nuclear Pharmacy Acquisition

In October 2025, the Company completed the acquisition of ECNP. The acquisition is intended to supplement the distribution of the Company’s nuclear medicine pipeline. The acquisition of ECNP has been accounted for as a business combination in accordance with ASC 805.

Pursuant to the terms of the agreement, the Company acquired 100% of the issued and outstanding membership interests for total purchase consideration of $2.5 million of which $2.0 million was paid up front in cash and the remaining $0.5 million was deferred through the issuance of notes payable that were repaid in June 2026. The balance of the notes payable as of September 30, 2026 and December 31, 2025 was $0 and $0.5 million respectively.

The following table summarizes the allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):

 

Fair value of business combination

 

 

 

Cash consideration

 

$

2,000

 

Notes payable to Sellers

 

 

500

 

Identifiable assets acquired and liabilities assumed

 

 

 

Cash and cash equivalents

 

 

40

 

Accounts receivable

 

 

550

 

Inventory

 

 

92

 

Prepaid expenses and other current assets

 

 

6

 

Identifiable intangible assets

 

 

430

 

Accounts payable

 

 

(113

)

Other current liabilities

 

 

(79

)

Total identifiable assets acquired and liabilities assumed

 

 

926

 

Goodwill

 

 

1,574

 

Total purchase consideration

 

$

2,500

 

Goodwill arising from the acquisition as of October 1, 2025 of $1.6 million was attributable mainly to buyer specific synergies expected to arise from the acquisition. No goodwill from this acquisition is deductible for income tax purposes. The Company considered the contractual value of accounts receivable to be the same as the fair value and the full amount was collected. The results of ECNP have been included in the condensed consolidated financial statements from the date of the acquisition.

One 30 Seven Inc. ("One 30 Seven") Acquisition

In October 2025, QLE acquired substantially all of the assets, including an international patent application and its related rights, from One 30 Seven, a Canadian company engaged in the business of researching and developing decontamination solutions for nuclear waste, particularly radioactive waste from radioactive materials from nuclear power plants, radiopharmaceuticals, and military sources. QLE made an initial cash payment of $150,000 and issued 266,113 shares of the Company’s common stock and accounted for the transaction as a purchase of assets. The Company may be required to make additional payments, in cash or shares of the Company’s common stock, totaling $17.0 million upon completion of certain milestones. This contingent payment was not considered probable at the acquisition date and September 30, 2026 and therefore no contingent consideration was recorded for the year ended December 31, 2025 or the nine months ended September 30, 2026.

In connection with the acquisition of assets from One 30 Seven, QLE entered into a consulting agreement with B-Con Engineering Inc., led by inventor Brian Creber, to develop and validate the functional operation of a Creber Mini Unit designed to accelerate the beta decay of high-level waste and rapidly convert these long half-life isotopes into stable isotopes at an estimated cost of $4.5 million over 18 months, followed by either a Midi or Maxi Unit at approximately $12.5 million to $13.0 million over another 18 months. QLE has agreed to fund the project through quarterly advances, with acceptance testing and monthly reporting to ensure milestones are met. In addition, QLE entered into a royalty agreement with One 30 Seven pursuant to which QLE agreed to pay a 6.0% royalty on net revenues from product sales or licensing for 15 years per product, starting from the first commercial sale. The royalty agreement will terminate if the commercialization of a Creber Unit is not achieved by the fourth anniversary of closing of the acquisition of assets from One 30 Seven.

The Company determined that the cost to acquire the One 30 Seven assets was $2.7 million, based on the cash paid of $150,000, fair value of the equity consideration issued of $2.6 million and direct costs of the acquisition of $7,000. The One 30 Seven acquisition was accounted for as an asset acquisition as One 30 Seven was not considered to be a business under ASC 805 or SEC Rule 11-01(d) as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset. In the estimation of fair value of the asset purchase consideration, the Company used fair value attributable to the acquired IPR&D. Since One 30 Seven was in the development stage and no commercial production had commenced at the time of the acquisition, the cost attributable to the IPR&D was expensed in the Company’s condensed consolidated statements of operations and comprehensive loss for the year ended December 31, 2025, as the acquired IPR&D had no alternative future use.

Numed Diagnostics, LLC Acquisition

In January 2026, the Company completed the acquisition of Numed Diagnostics, LLC ("Numed"). The acquisition is intended to supplement the distribution of the Company’s pipeline. The acquisition of Numed has been accounted for as a business combination in accordance with ASC 805.

Pursuant to the terms of the agreement, the Company acquired 60% of the issued and outstanding membership interests for total purchase consideration of $0.8 million. In addition to the purchase consideration, the Company is obligated to purchase an additional 36% of Numed's membership interests for $0.5 million within two years and has an option to purchase the remaining 4% of the issued and outstanding membership interests for $50,000. Consideration relating to this obligated purchase of $0.4 million was recognized at acquisition and as of September 30, 2026.

29


 

The following table summarizes the preliminary allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):

 

Fair value of business combination

 

 

 

Cash consideration

 

$

721

 

Obligated Consideration

 

 

358

 

Identifiable assets acquired and liabilities assumed

 

 

 

Cash and cash equivalents

 

 

80

 

Accounts receivable

 

 

170

 

Inventory

 

 

66

 

Property and equipment, net

 

 

107

 

Other noncurrent assets

 

 

4

 

Identifiable intangible assets

 

 

300

 

Accounts payable

 

 

(208

)

Deferred tax liabilities

 

 

(80

)

Other current liabilities

 

 

(2

)

Total identifiable assets acquired and liabilities assumed

 

 

437

 

Goodwill

 

 

1,239

 

Noncontrolling interest

 

 

(597

)

Total purchase consideration

 

$

1,079

 

Goodwill arising from the acquisition as of January 22, 2026 of $1.2 million was attributable mainly to buyer specific synergies expected to arise from the acquisition. No goodwill from this acquisition is deductible for income tax purposes. The Company considered the contractual value of accounts receivable to be the same as the fair value and the full amount was collected. The results of Numed have been included in the condensed consolidated financial statements from the date of the acquisition.

The initial allocation of the purchase price was based upon a preliminary valuation, and accordingly, our estimates and assumptions are subject to change as we obtain additional information during the measurement period.

Renergen Acquisition

On January 6, 2026, the Company completed the acquisition of Renergen and acquired all of the issued Renergen ordinary shares from Renergen shareholders in exchange for shares of the Company's common stock at an exchange ratio of 0.09196 shares of Company common stock for each Renergen ordinary share (the “Consideration Shares”) through the implementation of the Scheme, resulting in the issuance of an aggregate of 14,270,000 Consideration Shares. As a result of the transaction, Renergen became a direct, wholly owned subsidiary of ASP Isotopes. In connection with the transaction, Renergen ordinary shares were delisted from the JSE and the Australian Securities Exchange (the "A2X").

The following table summarizes the preliminary allocation of the purchase consideration to the fair value of the assets acquired and liabilities assumed (in thousands):

 

Fair value of business combination

 

 

 

Equity consideration

 

$

92,897

 

Cash consideration

 

 

5

 

Note receivable

 

 

32,119

 

Identifiable assets acquired and liabilities assumed

 

 

 

Cash and cash equivalents

 

 

1,218

 

Restricted cash - short term

 

 

2,789

 

Accounts receivable

 

 

3,205

 

Lessor Receivable

 

 

2,434

 

Restricted cash - long term

 

 

1,650

 

Inventory

 

 

40

 

Property and equipment, net

 

 

8,621

 

Natural gas properties

 

 

188,311

 

Operating lease right-of-use asset, net

 

 

811

 

Accounts payable

 

 

(4,820

)

Finance lease liabilities – current

 

 

(55

)

Operating lease liabilities – current

 

 

(195

)

Borrowings

 

 

(58,664

)

Deferred revenue

 

 

(819

)

Finance lease liabilities – noncurrent

 

 

(204

)

Operating lease liabilities – noncurrent

 

 

(616

)

Other liabilities - long term

 

 

(3,287

)

Deferred tax liabilities

 

 

(8,122

)

Total identifiable assets acquired and liabilities assumed

 

 

132,297

 

Noncontrolling interest

 

 

(7,276

)

Total purchase consideration

 

$

125,021

 

 

Prior to closing the acquisition of Renergen, the Company advanced $30.0 million under the Renergen Loan. The financing was provided in advance of the acquisition and was contemplated by the parties as part of the overall transaction structure. Pursuant to the terms of the acquisition, the Renergen Loan was effectively settled upon consummation of the acquisition and was included as a component of the consideration transferred for the acquired business.

In accordance with ASC 805, the Company measured the consideration transferred at fair value as of the acquisition date. The fair value of the note receivable was determined to be approximately $32.1 million, which represented the outstanding balance immediately prior to closing. The Company concluded that the carrying amount approximated fair value because the note was effectively settled at

30


 

closing, the contractual terms were consistent with market participant assumptions, and there were no significant changes in credit risk or other factors that would have resulted in a material difference between carrying value and fair value.

Natural gas properties represent the estimated fair value assigned to Renergen’s interests associated with the Virginia Gas Project in South Africa. As of the Acquisition Date, natural gas properties consisted primarily of proved reserves, developed assets, wells in process, construction-in-progress related to natural gas properties and capitalized asset retirement costs.

Proved reserves represent acquisition-date amounts attributed to proved reserve interests and are depleted using the unit-of-production method based on estimated total proved reserves. Developed assets primarily represent developed production, gathering, processing and liquefaction infrastructure and are depleted using the unit-of-production method based on estimated proved developed reserves. Wells in process and construction-in-progress related to natural gas properties represent development projects that had not yet been placed into service as of the Acquisition Date and therefore were not subject to depletion. Capitalized asset retirement costs represent the asset retirement cost associated with environmental restoration and abandonment obligations and are depleted consistent with the related developed assets.

The Company engaged an independent third party valuation specialist to estimate the fair value of the acquired property and equipment. The valuation relied primarily on a third party petroleum engineer’s reserve report for reserve quantities and future production forecasts and associated cash flows.

The initial allocation of the purchase price was based upon a preliminary valuation, and accordingly, our estimates and assumptions are subject to change as we obtain additional information during the measurement period.

Renergen's principal asset is its 94.5% equity ownership in Tetra4, which owns an onshore petroleum production right and is engaged in the exploration and production of natural gas and the processing of natural gas into liquid natural gas and liquid helium in Free State Province, South Africa. Mahlako Gas Energy Limited (“MGE”) has a 5.5% equity ownership in Tetra4. MGE, Renergen and Tetra are parties to a Sale, Subscription and Shareholders’ Agreement, dated December 22, 2023 (the “SSSA”), pursuant to which MGE acquired its equity in Tetra4 for ZAR 550 million. Under the SSSA, Renergen granted to MGE a put option related to MGE's equity (the “Put Option”) exercisable upon the occurrence of a Put Option Event (as defined in the SSSA). The price payable for MGE’s equity under the Put Option is calculated pursuant to a formula set forth in the SSSA, but will be not less than the aggregate of (i) the purchase price of MGE's equity paid by MGE (ZAR 550 million) plus the face value of any claims, (ii) 3.5% of such purchase price, and (iii) MGE's documented due diligence costs.

ENDRA Merger Agreement

On June 25, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Company (“Noble”), Renergen and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA.

Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements (“Subscription Agreements”) with the Company and certain investors pursuant to which Noble agreed to sell approximately (i) 4,594,218 Class A Units of Noble (“Class A Units”) and/or pre-funded warrants to purchase Class A Units of Noble (the “Pre-Funded Warrants”) to certain institutional investors and other persons and (ii) 3,054,185 Class B Units of Noble (“Class B Units” and, together with the Class A Units, the “Units”) to the Company, at a price per unit of $6.57 (or $6.57 less the Pre-Funded Warrant exercise price of $0.0001 for the Pre-Funded Warrants), for aggregate gross proceeds to Noble of approximately $50 million (the “Noble Investment”). Pursuant to the Subscription Agreements, the Noble Investment shall close immediately prior to the Merger.

Additionally, prior to the effective time of the Merger (the “Effective Time”), the Company will contribute all of its equity interest in Renergen to Noble in exchange for 55,500,000 of Noble’s Class B Units (the “Contribution”). The shares of Class B Common Stock (as defined below) received by the Company upon conversion of the Class B Units in connection with the Merger will entitle the Company to 10 votes per share on all matters submitted to a vote of the stockholders of ENDRA.

Consummation of the Merger is subject to certain closing conditions, including, the approval by the shareholders of ENDRA, the receipt by Noble of the proceeds of the Noble Investment, Noble’s receipt of a written consent of the U.S. Internal Development Finance Corporation (formerly known as the Overseas Private Investment Corporation) (“OPIC”) as required under that certain Finance Agreement by and between OPIC and a subsidiary of Renergen and ENDRA’s having an amount of cash equal to or greater than $3.8 million.

The Merger Agreement may be terminated at any time prior to Closing by mutual written agreement between ENDRA and Noble or by either party if merger closing has not occurred by December 24, 2026. Either ENDRA or Noble may also terminate the Merger Agreement if the representations or warranties of the other party were inaccurate as of the date of the Merger Agreement or become inaccurate thereafter due to a breach of a covenant or agreement of that party prior to merger closing, or if the ENDRA Stockholder Matters are not approved by the ENDRA stockholders at the Special Meeting.

At or prior to the closing of the merger, the Company, ASPI South Africa Proprietary Limited, a wholly owned subsidiary of the Company (“ASPI SA”), and Renergen, shall enter into the sixth addendum to that certain ASPI Term Loan Facility, dated May 19, 2025, by and between the Company, ASPI SA and Renergen, pursuant to which the Company may provide loans to Renergen up to $200 million.

In connection with the Noble Investment, Noble entered into Subscription Agreements with certain of the Company’s directors and officers, pursuant to which Noble agreed to sell to those directors and officers Class A Units of Noble.

Goodwill

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. Goodwill is tested for impairment at least annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting segment exceeds its fair value. No goodwill impairments were recognized for the years presented.

The carrying amount of goodwill by reporting segment as of September 30, 2026 and December 31, 2025 is as follows (in thousands):

 

31


 

 

September 30, 2026

 

 

December 31,
2025

 

Specialist isotopes and related services

 

$

6,461

 

 

$

5,177

 

Total goodwill

 

$

6,461

 

 

$

5,177

 

The changes to the carrying value of goodwill, which is included in the isotopes and related services segment, is as follows:

 

Description

 

Amount

 

Balance as of December 31, 2025

 

$

5,177

 

Acquisition of Numed

 

 

1,239

 

Translation adjustment

 

 

45

 

Balance as of September 30, 2026

 

$

6,461

 

 

Intangible Assets

Amortization expense was $40,000 and $115,000 for the three and nine months ended September 30, 2026. There was no amortization expense related to identifiable intangible assets recorded for the three and nine months ended September 30, 2025.

The changes to the carrying value of intangible assets, which is included in the specialist isotopes and related services segments, is as follows (in thousands):

 

Description

 

Amount

 

Balance as of December 31, 2024

 

$

—

 

Trademarks from ECNP acquisition

 

 

430

 

Amortization

 

 

(21

)

Balance as of December 31, 2025

 

$

409

 

Trademarks from Numed acquisition

 

 

300

 

Amortization

 

 

(115

)

Balance as of September 30, 2026

 

$

594

 

 

The following table outlines the estimated future amortization expense related to intangible assets held as of September 30, 2026 (in thousands):

 

 

Amortization Expense

 

Year Ended December 31,

 

 

 

2026

 

$

40

 

2027

 

 

161

 

2028

 

 

161

 

2029

 

 

161

 

2030

 

 

71

 

Thereafter

 

 

—

 

   Total

 

$

594

 

 

15. Equity Method and Other Investments

Investment in IsoBio, Inc.

On July 28, 2025, the Company purchased 2,000,000 shares of IsoBio, Inc. (“IsoBio”) Series Seed-1 Preferred Stock at $2.50 per share for a total aggregate purchase price of $5.0 million. IsoBio is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics targeting both derisked and novel tumor antigens for patients in need of new cancer therapies.

As the owner of the Series Seed-1 Preferred Stock, the Company has the right to designate one board member. An officer and director of the Company was designated to fill that board seat. In addition, another board member of the Company is a board member, executive officer and shareholder of IsoBio.

The investment in IsoBio does not have a readily determinable fair value and is therefore measured at cost, adjusted for observable price changes and impairments, in accordance with ASC 321. As of September 30, 2026 and December 31, 2025, the carrying value of the investment was $5.6 million. This investment is included in “Other investments” on the condensed consolidated balance sheet.

The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. Therefore, the Company has included this investment in the fair value hierarchy disclosure (Note 4). During the three and nine months ended September 30, 2026, the Company did not identify any observable price changes or impairment indicators related to this investment.

Skyline Investment

In August 2025, QLE entered into a Stock Purchase Agreement to purchase all 1,995,000 of Skyline's Class B Ordinary Shares for the aggregate purchase price of $1.0 million ("Skyline Stock Agreement"). Additionally, QLE entered into a Securities Purchase Agreement to purchase (i) 454,794 Class A Ordinary Shares, (ii) a Prefunded Warrant to purchase 1,600,000 Class A Ordinary Shares at an exercise price of $0.0001 per share, (iii) a Class A Ordinary Share Purchase Warrant A to purchase up to 2,054,794 Class A Ordinary Shares at an exercise price of $0.60 per share, and (iv) a Class A Ordinary Share Purchase Warrant B to purchase 2,054,794 Class A Ordinary Shares at an exercise price of $0.65 per share, for the aggregate purchase price of $1.5 million ("Skyline Purchase Agreement"). Each Class B Ordinary Share entitled the holder thereof to twenty (20) votes on all matters subject to vote at general meetings of Skyline, which resulted in the Company having voting control of Skyline and resulted in its consolidation.

Effective as of March 29, 2026, QLE, entered into the Exchange Agreement with a third party investor in which the parties agreed to exchange 1,995,000 Class B common shares owned by QLE for 1,995,000 Class A shares owned by the third party investor, on a

32


 

one-for-one basis. This resulted in QLE's voting rights in Skyline decreasing to under 10% and the Company now accounts for the investment as an equity method investment in accordance with ASC 323. As a result of entering into the Exchange Agreement, the Company deconsolidated the results of Skyline and recorded a gain on deconsolidation of $19.3 million. The Company's total investment in Skyline was $23.8 million on the date of the Exchange Agreement. The Company has elected to account for the retained interest in Skyline under the fair value option (“FVO”). The carrying amount of the Skyline investment was $23.0 million as of September 30, 2026. The Company recognized a loss from the change in fair value of investment of $1.9 and $0.7 million for the three and nine months ended September 30, 2026, which is recorded in other income (expense) in the condensed consolidated statements of operations and comprehensive loss.

Investment in Opeongo, Inc.

On January 26, 2026, the Company purchased 4,356,918 shares of Opeongo, Inc. (“Opeongo”) Series Seed-1 Preferred Stock at $2.2952 per share for a total aggregate purchase price of $10.0 million. Opeongo is a U.S.-based biotechnology company developing novel therapeutics using extracellular matrix-modulating modulation to target fibrosis, inflammation and cancer.

As the owner of the Series Seed-1 Preferred Stock, the Company has the right to designate one board member. An officer and director of the Company was designated to fill that board seat. In addition, another board member of the Company is a board member and shareholder of Opeongo.

The investment in Opeongo does not have a readily determinable fair value and is therefore measured at cost, adjusted for observable price changes and impairments, in accordance with ASC 321. As of September 30, 2026, the carrying value of the investment was $10.0 million. This investment is included in “Other investments” on the condensed consolidated balance sheet.

The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. During the three and nine months ended September 30, 2026, the Company did not identify any observable price changes or impairment indicators related to this investment.

ENDRA Life Sciences, Inc.

On May 27, 2026, the Company purchased 66,846 shares of ENDRA Life Sciences, Inc. (“ENDRA”) common stock, 511,541 prefunded warrants to purchase shares of common stock and 1,156,774 common warrants to purchase shares of common stock for a total aggregate purchase price of $3.8 million. ENDRA is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ®), a technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care.

The investment in ENDRA is measured at fair value, adjusted for observable price changes and impairments, in accordance with ASC 321. As of September 30, 2026, the carrying value of the investment was $4.7 million. This investment is included in “Other investments” on the condensed consolidated balance sheet.

The Company monitors the investment for indicators of impairment and observable price changes on a quarterly basis. If indicators of impairment exist, the Company performs a qualitative assessment to determine whether the investment is impaired and adjusts the carrying value accordingly. The Company recognized a gain from the change in fair value of investment of $0.9 million for the three and nine months ended September 30, 2026, which is recorded in other income (expense) in the condensed consolidated statements of operations and comprehensive loss.

 

16. Stockholders’ Equity

Preferred stock

The Company has 10,000,000 shares of preferred stock authorized, of which no shares were issued and outstanding as of September 30, 2026 and December 31, 2025.

Common stock

The Company has 500,000,000 shares of common stock authorized, of which 155,834,430 and 111,677,771 shares were outstanding as of September 30, 2026 and December 31, 2025, respectively. Common stockholders are entitled to one vote for each share of outstanding common stock held at all meetings of stockholders and written actions in lieu of meetings. Common stockholders are entitled to receive dividends for each share of outstanding common stock, if and when declared by the Board. No dividends have been declared or paid by the Company through September 30, 2026.

In June 2025, the Company issued 7,518,797 shares of common stock at $6.65 per share resulting in net proceeds of approximately $46.8 million after deducting underwriting discounts, commissions and offering expenses.

In July 2025, the Company issued 7,500,000 shares of common stock at a public offering price of $8.00 per share resulting in net proceeds of approximately $56.3 million after deducting underwriting discounts, commissions and offering expenses.

In October 2025, the Company issued 17,167,380 shares of common stock at a public offering price of $12.25 per share resulting in net proceeds of approximately $199.3 million after deducting underwriting discounts, commissions and offering expenses.

In January 2026, the Company issued 14,270,000 shares of common stock in connection with the acquisition of Renergen.

In July 2026, the Company issued 23,160,682 shares of common stock with a fair value of $106.1 million in exchange for $109.2 million in aggregate principal amount of the outstanding 2025 Convertible Notes (See Note 9).

Treasury shares are recorded at cost and include forfeited shares from the Company's stock compensation plans. There were 168,274 shares forfeited and transferred to treasury stock through September 30, 2026.

Common Stock Warrants

In May 2025, a warrant to purchase 1,294,778 shares of common stock was exercised and the Company received gross proceeds of approximately $4.9 million. In July and September 2025, cashless exercises of warrants to purchase 151,741 shares of common stock were executed, resulting in the issuance of 123,497 shares of common stock. As of September 30, 2026 and December 31, 2025, there were warrants to purchase 69,778 shares of common stock outstanding.

33


 

17. Stock Compensation Plan

Equity Incentive Plans

In October 2021, the Company adopted the 2021 Stock Incentive Plan (“2021 Plan”) that provided for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2021 Plan provided for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2021 Plan is ten years. The maximum number of shares initially available for issuance under the 2021 Plan was 6,000,000. No further options are available to be issued under the 2021 Plan.

In November 2022, the Company adopted the 2022 Equity Incentive Plan (“2022 Plan”) that provides for the issuance of common stock to employees, nonemployee directors, and consultants. Recipients of incentive stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2022 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2022 Plan is ten years. The number of shares of the Company’s common stock initially reserved for issuance under the 2022 Plan is equal to 5,000,000, subject to an annual increase, to be added on the first day of each fiscal year, beginning with the fiscal year ending December 31, 2023 and continuing until, and including, the fiscal year ending December 31, 2033, equal to the lesser of 5% of the number of shares of the Company’s common stock outstanding on such date or an amount determined by the Company’s board of directors. On January 1, 2026, the Company added 5,583,889 shares to the 2022 Plan. As of September 30, 2026, 1,282,608 shares remain available for future grant under the 2022 Plan.

2024 Inducement Equity Incentive Plan

In June 2024, the Company adopted the 2024 Inducement Equity Incentive Plan (“2024 Plan”). The 2024 Plan will be used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4). Recipients of stock options are eligible to purchase shares of common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The 2024 Plan provides for the grant of non-statutory stock options, restricted stock, restricted stock units, stock awards and stock appreciation rights. The maximum contractual term of options granted under the 2024 Plan is ten years. The number of shares of the Company’s common stock initially reserved for issuance under the 2024 plan is equal to 2,500,000. As of September 30, 2026, 15,000 shares remain available for future grant under the 2024 Plan.

2025 Inducement Equity Incentive Plan

On July 16, 2025, upon recommendation of the Compensation Committee of the Company’s Board, the Board approved and adopted the Company’s 2025 Inducement Equity Incentive Plan (the “Inducement Equity Plan”), and subject to the adjustment provisions of the Inducement Equity Plan, reserved 2,000,000 shares of Common Stock for issuance of equity awards under the Inducement Equity Plan.

The Inducement Equity Plan was approved and adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Equity Plan provides for grants of stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards (consisting of performance shares or performance units) and other cash-based or stock-based awards (each, an “Inducement Award”). In addition, the Board also approved and adopted forms of Notice of Grant of Restricted Stock and Restricted Stock Agreement, and Notice of Grant of Stock Option and Stock Option Agreement for use with the Inducement Equity Plan. The terms and conditions of the Inducement Equity Plan are intended to comply with the Nasdaq inducement award rules.

In accordance with Nasdaq Listing Rule 5635(c)(4), the only persons eligible to receive grants of Inducement Awards are individuals who were not previously employees or directors of the Company (or following a bona fide period of non-employment), as an inducement material to the individuals’ entry into employment with the Company. As of September 30, 2026, 1,080,000 shares remain available for future grant under the Inducement Equity Plan.

QLE 2024 Equity Incentive Plan

In March 2024, the Company adopted the QLE 2024 Equity Incentive Plan (“QLE 2024 Plan”). The QLE 2024 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock awards, performance awards and stock appreciation rights to employees, nonemployee directors, and consultants. The maximum contractual term of options granted under the QLE 2024 Plan is ten years and incentive stock options granted under the QLE 2024 Plan shall not exceed 50% of the maximum number of shares or units of common equity that may be issued under the QLE 2024 Plan. The maximum number of shares or units of QLE’s common equity that may be issued under the QLE 2024 Plan is equal to 15% of the common equity deemed outstanding as of the effective date of the QLE 2024 Plan. As of September 30, 2026, no common equity deemed outstanding remain available for future grant under the QLE 2024 Plan.

In September 2025, QLE granted restricted stock units (“RSUs”) totaling 11% of the common equity deemed outstanding to certain officers, employees and directors of QLE and in October 2025, QLE granted RSU's totaling 4% to American Ventures (Note 13). The RSUs will vest subject to the occurrence of a Listing Event and, if applicable, an additional service-based vesting condition. A Listing Event shall mean the consummation of any of the following transactions by QLE, a corporate successor to QLE or a holding company established with respect to QLE’s equity securities in connection with any of the following transactions (a “Public Issuer”): (i) a listing of common equity of QLE (or the common equity of such Public Issuer) through acquisition by or merger of such Public Issuer with a special purpose acquisition company or another entity listed on the NYSE or NASDAQ, (ii) a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act and in connection with such offering the common equity of QLE is listed for trading on the Nasdaq, the NYSE or another exchange or marketplace approved by the Board, or (iii) a direct listing of common equity of QLE (or the common equity securities of the Public Issuer) on the NYSE or Nasdaq.

Since the vesting of the RSUs is based on a liquidity event, no compensation cost will be recognized until the Performance Goal (Listing Event) is consummated. However, the fair value of the awards is calculated at the date of grant, which results in a total fair value of approximately $37.4 million.

34


 

Stock Options

The following table sets forth the activity for the Company’s stock options during the periods presented:

 

 

Number of
Options

 

 

Weighted-
Average
Exercise
Price
per Share

 

 

Weighted
Average
Remaining
Contractual
Term
(in Years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding as of December 31, 2025

 

 

808,000

 

 

$

3.06

 

 

 

7.3

 

 

$

2,020,050

 

Granted

 

 

110,000

 

 

$

2.60

 

 

 

 

 

 

 

Exercised

 

 

(74,266

)

 

$

2.18

 

 

 

 

 

 

 

Forfeited

 

 

(15,394

)

 

$

6.16

 

 

 

 

 

 

 

Outstanding as of September 30, 2026

 

 

828,340

 

 

$

3.02

 

 

 

7.0

 

 

$

351,235

 

Exercisable as of September 30, 2026

 

 

605,487

 

 

$

2.40

 

 

 

6.1

 

 

$

346,646

 

Vested or expected to vest as of September 30, 2026

 

 

828,340

 

 

$

3.02

 

 

 

7.0

 

 

$

351,235

 

Options with a weighted average grant date fair value of $2.00 were granted for the nine months ended September 30, 2026. There were options to purchase 74,266 shares exercised for proceeds of $0.2 million for the nine months ended September 30, 2026.

The Company recorded stock-based compensation expense from options of $0.1 million and $(1,239) for the three months ended September 30, 2026 and 2025, respectively. The Company recorded stock-based compensation expense from options of $0.2 million and $0.3 million for the nine months ended September 30, 2026 and 2025 respectively. As of September 30, 2026, there was $0.7 million of unrecognized stock-based compensation expense related to non-vested stock options granted under the Plan.

Stock Awards

The Company recorded stock-based compensation expense from stock awards totaling $9.5 million and $4.5 million for the three months ended September 30, 2026 and 2025, respectively. The Company recorded stock-based compensation expense from stock awards totaling $18.4 million and $10.5 million for the nine months ended September 30, 2026 and 2025. As of September 30, 2026, there is $42.4 million of unrecognized stock-based compensation expense related to the non-vested portion of restricted stock awards that is expected to be recognized over 2.5 years.

The following table summarizes vesting of restricted common stock:

 

 

Number of
Shares

 

 

Weighted
Average Grant
Date Fair
Value
Per Share

 

Unvested as of December 31, 2025

 

 

4,169,955

 

 

$

5.68

 

Granted

 

 

6,823,555

 

 

$

5.96

 

Vested

 

 

(2,486,774

)

 

$

6.67

 

Forfeited

 

 

(171,844

)

 

$

7.06

 

Unvested as of September 30, 2026

 

 

8,334,892

 

 

$

5.58

 

Stock-based Compensation Expense

Stock-based compensation expense for all stock awards recognized in the accompanying condensed consolidated statements of operations and comprehensive loss is as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Selling, general and administrative

 

$

9,411

 

 

$

4,485

 

 

$

17,916

 

 

$

10,683

 

Research and development

 

 

192

 

 

 

(1

)

 

 

641

 

 

 

120

 

Total

 

$

9,603

 

 

$

4,484

 

 

$

18,557

 

 

$

10,803

 

 

18. Net Loss Per Share

The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stock after giving consideration to all potentially dilutive shares of common stock, including options to purchase common stock and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.

35


 

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2026 and 2025:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

$

(30,868

)

 

$

(13,184

)

 

$

(91,567

)

 

$

(96,802

)

Income from discontinued operations

 

 

—

 

 

 

290

 

 

 

19,585

 

 

 

290

 

Less: Net loss attributable to noncontrolling interests

 

 

(497

)

 

 

(277

)

 

 

(1,149

)

 

 

(387

)

Net loss attributable to ASP Isotopes Inc. shareholders

 

$

(30,371

)

 

$

(12,617

)

 

$

(70,833

)

 

$

(96,125

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common stock outstanding, basic and diluted

 

 

143,385,783

 

 

 

88,552,309

 

 

 

128,891,373

 

 

 

75,985,507

 

Net (loss) income per share, basic and diluted:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(0.22

)

 

$

(0.15

)

 

$

(0.71

)

 

$

(1.27

)

Discontinued operations

 

$

-

 

 

$

-

 

 

$

0.15

 

 

$

-

 

Attributable to ASP Isotopes Inc. shareholders

 

$

(0.21

)

 

$

(0.14

)

 

$

(0.55

)

 

$

(1.27

)

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:

 

 

As of September 30,

 

 

2026

 

 

2025

 

Options to purchase common stock

 

 

828,340

 

 

 

606,000

 

Restricted stock

 

 

8,334,892

 

 

 

4,684,286

 

Warrants to purchase common stock

 

 

69,778

 

 

 

69,778

 

Total shares of common stock equivalents

 

 

9,233,010

 

 

 

5,360,064

 

 

19. Income Taxes

The Company’s effective tax rate for the three months ended September 30, 2026 and 2025 was -3.8% and -0.4%. The Company’s effective tax rate for the nine months ended September 30, 2026 and 2025 was -1.1% and -0.1%. The effective tax rate for the three months ended September 30, 2026 and 2025 and the nine months ended September 30, 2026 and 2025 varied from the federal statutory rate primarily due to losses in jurisdictions for which a valuation allowance is recorded.

The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition threshold to be recognized. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the Company’s balance sheets and has not recognized interest and/or penalties in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026. Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustments may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue. As of September 30, 2026 and December 31, 2025, there were no uncertain tax positions.

As of September 30, 2026, the Company did not recognize any interest and penalties associated with unrecognized tax benefits. Due to net operating losses incurred, tax years from inception remain open to examination by the Federal and State taxing jurisdictions to which the Company is subject. The Company is not currently under Internal Revenue Services (IRS), state or local tax examination.

Ownership changes, as defined in the Internal Revenue Code (“IRC”), may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income pursuant to IRC Section 382 or similar provisions. Subsequent ownership changes could further affect the limitation in future years. The Company has not completed a study to assess whether a change of control has occurred or whether there have been multiple changes of control since the Company’s formation due to the significant complexity and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company’s ability to utilize net operating loss and research and development credit carryforwards in the future.

20. Related Party Transactions

PET Labs has an operating lease for office and production space in Pretoria, South Africa with monthly payment of about $30,000 per month and a term set to expire in March 2056. The sole owner of the facility under the lease agreement is Dr. Gerdus Kemp, an officer of PET Labs and an employee of ASP UK.

In connection with the Noble Investment, Noble entered into Subscription Agreements with certain of the Company’s directors and officers, pursuant to which Noble agreed to sell to those directors and officers Class A Units of Noble.

21. Discontinued Operations

Effective as of March 29, 2026, the Company entered into the Exchange Agreement and completed the deconsolidation of Skyline. The Company retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following the deconsolidation. The accounting requirements for reporting the separation of Skyline as a discontinued operation were met when the separation was completed. Accordingly, the historical results of Skyline have been presented as discontinued operations and, as such, have been excluded from continuing operations and segment results for all periods presented. Prior to the separation, Skyline was reported within the construction services segment.

36


 

The following table presents the major categories of income from discontinued operations for the nine months ended September 30, 2026 (in thousands):

 

 

Nine Months Ended

 

 

 

September 30, 2026

 

Gross profit

 

$

444

 

Selling, general and administrative expenses

 

 

(2,935

)

Change in fair value of investments

 

 

6,162

 

Other expenses, net

 

 

(124

)

Income from discontinued operations before income taxes

 

 

3,547

 

Income tax expense

 

 

(17

)

Net income before allocation to noncontrolling interests

 

 

3,530

 

Less: Net income attributable to noncontrolling interests

 

 

3,281

 

Income from discontinued operations

 

$

249

 

There was no income from discontinued operations for the three months ended September 30, 2026. As the controlling interest of Skyline was not acquired until August 2025, no income was recognized from Skyline for the three and nine months ended September 30, 2025.

The following table presents the major classes of assets and liabilities of discontinued operations as of December 31, 2025 (in thousands):

 

 

December 31,
2025

 

Cash and cash equivalents

 

$

5,991

 

Accounts receivable

 

 

16,804

 

Prepaid and other current assets

 

 

8,895

 

Total current assets of discontinued operations

 

$

31,690

 

Property, plant and equipment, net

 

 

161

 

Operating lease right-of-use lease assets

 

 

48

 

Intangibles

 

 

1,069

 

Goodwill

 

 

3,393

 

Equity investments

 

 

1,327

 

Other investments

 

 

40,399

 

Other noncurrent assets

 

 

4,491

 

Total non-current assets of discontinued operations

 

 

50,888

 

Total assets of discontinued operations

 

$

82,578

 

Accounts payable

 

 

1,941

 

Accrued expenses

 

 

1,809

 

Notes payable -current

 

 

12,301

 

Operating lease liabilities - current

 

 

40

 

Due to related parties

 

 

4,162

 

Other current liabilities

 

 

1,537

 

Total current liabilities of discontinued operations

 

 

21,790

 

Deferred Tax Liabilities

 

 

102

 

Total non-current liabilities of discontinued operations

 

 

102

 

Total liabilities of discontinued operations

 

$

21,892

 

The following table presents selected financial information related to cash flows from discontinued operations for the nine months ended September 30, 2026 (in thousands):

 

 

Nine Months Ended

 

 

 

September 30, 2026

 

Net cash used in operating activities

 

$

(1,121

)

Net cash provided by financing activities

 

$

45,886

 

The total net impact to stockholders' equity as a result of the separation was a reduction of $66.0 million, which has been reflected as a reduction of $86.8 million to noncontrolling interest and an increase to accumulated deficit and accumulated other comprehensive income/(loss) of $19.3 million and $1.5 million, respectively, in the condensed consolidated statement of equity as of September 30, 2026. The Company retained 8.6% of the outstanding Class A ordinary and preferred shares of Skyline, which had a net book value of $23.8 million as of March 28, 2026, the separation date.

22. Subsequent Events

The Company has evaluated subsequent events through November 16, 2026, the date on which the accompanying condensed consolidated financial statements were issued and concluded that no subsequent events have occurred that require disclosure except as described below.

First Amendment to Merger Agreement. As previously disclosed, on June 25, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA Life Sciences Inc., a Delaware corporation (“ENDRA”), Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of the Company (“Noble”), Renergen and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA.

On October 1, 2026, the Company, ENDRA, Noble, Renergen and Merger Sub entered into that certain First Amendment to the Merger Agreement (the “Amendment”) to, among other things, (i) amend ENDRA’s disclosure letter to permit ENDRA to amend the Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant”) and Common Stock Purchase Warrant (the “Common

37


 

Warrant” and, together with the Pre-Funded Warrant, the “Warrants”), each issued by ENDRA as of May 27, 2026 to LHE LNG Holdings LLC, a direct, wholly-owned subsidiary of the Company (the “ASPI ENDRA Purchaser”), (ii) remove the requirement that the board of directors immediately following the closing of the Merger be classified into three separate classes, (iii) revise the minimum cash closing condition to reflect a minimum cash requirement of $3,800,002.59, less certain agreed-upon expenses to permit ENDRA to engage in certain investor relations activities, (iv) replace the form of ENDRA’s Fifth Amended and Restated Certificate of Incorporation with an updated form that removes the classified board provisions and other provisions that would have required a supermajority vote of ENDRA’s stockholders to be approved, (v) amend Noble Africa’s disclosure letter to permit Renergen to enter into a fifth addendum to that certain Term Loan Facility Agreement, dated as of May 19, 2025, by and between Renergen, ASPI and ASPI South Africa Proprietary Limited, a wholly-owned subsidiary of ASPI (the “ASPI Term Loan Facility”), which would increase Renergen’s borrowing capacity from ASPI from $80 million to up to $120 million and (vi) contemplate a sixth addendum to the ASPI Term Loan Facility to be entered into at or prior to the closing of the Merger, which would further increase Renergen’s borrowing capacity from ASPI from $120 million to up to $200 million. Except as expressly modified by the Amendment, the terms of the Merger Agreement were ratified and remain in full force and effect.

38


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2026 and Amendment No. 1 to our Annual Report on Form 10-K/A filed with the SEC on April 30, 2026 (as amended, the “Annual Report”), along with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Annual Report. The Annual Report is accessible on the SEC’s website at www.sec.gov and on our website at www.aspisotopes.com. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled “Risk Factors” in the Annual Report and this Quarterly Report on Form 10-Q, and the section entitled “Special Note Regarding Forward-Looking Statements” above, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled “Risk Factors” in the Annual Report and this Quarterly Report on Form 10-Q, and the section entitled “Special Note Regarding Forward-Looking Statements” above to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.

Overview

We are an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and QE technology, are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”). Our commercial radiodiagnostic activities are currently focused on radiopharmaceutical products used in positron emission tomography ("PET") and single-photon emission computed tomography ("SPECT") imaging, as well as therapeutic radiopharmaceuticals used in the treatment of oncology indications.

We commenced commercial production of enriched isotopes at both of our ASP enrichment facilities located in Pretoria, South Africa during the first half of 2025. However, we have not generated any revenue from the sale of our enriched isotopes as of September 30, 2026. Our first ASP enrichment facility is designed to enrich light isotopes, such as C-14 and C-12. The second ASP enrichment facility, which is substantially larger than the first, should have the potential to enrich kilogram quantities of relatively heavier isotopes, including but not limited to Si-28. Depending on the timing and the quality of the feedstock received from our customer, our initial shipments of enriched C-14 may occur in 2027. We are targeting initial shipments of enriched Si-28 in the fourth quarter of 2026. We have also completed the commissioning phase of our third enrichment facility, a QE technology facility, which is our first laser-based enrichment plant. We are targeting initial shipments of Yb-176 in 2027.

In addition, we have started planning additional isotope enrichment plants both in South Africa and in other jurisdictions, including Iceland and the United States. We believe the C-14 we may produce using the ASP technology could be used in the development of new pharmaceuticals and agrochemicals. We believe the Si-28 we may produce using the ASP technology may be used to create advanced semiconductors and in quantum computing. We believe the Yb-176 we may produce using the QE technology may be used to create radiotherapeutics that treat various forms of oncology. We are considering the future development of the ASP technology for the separation of Zinc-68 and Xenon-129/136 for potential use in the healthcare end market, Germanium 70/72/74 for potential use in the semiconductor end market, and Chlorine -37 for potential use in the nuclear energy end market. We are also considering the future development of QE technology for the separation of Nickel-64, Gadolinium-160, Ytterbium-171, Lithium-6 and Lithium-7.

QLE, our subsidiary, is currently pursuing an initiative to apply our enrichment technologies to the enrichment of Uranium-235 (“U-235”) in South Africa. We believe that the U-235 QLE may produce has the potential to be commercialized as a nuclear fuel component for use in the new generation of high-assay low-enriched uranium (“HALEU”)-fueled small modular reactors that are now under development for commercial and government uses. In furtherance of our uranium enrichment initiative in South Africa, we have entered into certain definitive agreements with TerraPower, LLC (“TerraPower”), including a term loan subject to conditions to support construction of a new uranium enrichment facility at Pelindaba, South Africa and supply agreements for the future supply of HALEU to TerraPower, as a customer. In addition, QLE’s South African subsidiary has entered into a Pre-Implementation Services Contract Agreement (“Services Contract”) with The South African Nuclear Energy Corporation (“Necsa”), a South African state-owned company responsible for undertaking and promoting research and development in the field of nuclear energy and radiation sciences, pursuant to which Necsa has agreed to provide to QLE’s South African subsidiary certain facilities, infrastructure, utilities and services related to the siting, design, construction, commission and operation of an enrichment facility on the Necsa site in Pelindaba. In the period since our inception to date, we have not applied our enrichment technologies to the enrichment of U-235, nor received permission or regulatory approval to conduct testing of our enrichment technologies on U-235, except for the activities contemplated by the Services Contract with Necsa. Our expectation that QLE’s initiative to apply our enrichment technologies to the enrichment of U-235 could be successful is based upon research conducted by certain of our scientists prior to joining us, as well as the demonstrated effectiveness of QE technology on Yb-176.

We acquired Renergen in January 2026 and issued 14,270,000 Consideration Shares in connection with this acquisition. Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the natural gas reserve base that underpins Renergen’s Virginia Gas Project. The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s Virginia Gas Plant. Renergen’s principal asset is its 94.5% equity ownership in Tetra4, which holds an onshore petroleum production right and is the entity developing the Virginia Gas Project.

QLE entered into the Securities Exchange Agreement with a third party, effective as of March 29, 2026, which resulted in the deconsolidation of Skyline (Note 21). QLE retained approximately 8.6% percent of the outstanding Class A ordinary and preferred shares of Skyline immediately following deconsolidation.

39


 

Our Subsidiaries and Segments

We operate our proprietary enrichment activities principally through our subsidiaries. ASP Isotopes Guernsey Limited (the holding company for our subsidiaries in the Cayman Islands, South Africa, Iceland and the United Kingdom) is focused on the development and commercialization of high-value, low-volume isotopes for highly specialized end markets (such as C-14, Si-28, and Yb-176). ASP Isotopes UK Ltd is the owner of our technology.

QLE. In September 2023, we formed QLE, which also has subsidiaries in the United Kingdom (Quantum Leap Energy Limited) and South Africa (Quantum Leap Energy (Pty) Limited), to focus on the development and commercialization of advanced nuclear fuels, such as HALEU and Lithium-6. QLE’s direct wholly owned subsidiary QLE UK, has its operations in the United Kingdom. QLE UK’s direct wholly owned subsidiary, QLE South Africa, has its operations in South Africa. QLE also formed QLE SPE Borrower, as a wholly owned subsidiary to act as a special purpose borrower for a loan transaction with TerraPower, a US nuclear innovation company. The QLE SPE Borrower has formed a subsidiary in South Africa to act as the project company for a proposed new uranium enrichment facility at Pelindaba, South Africa.

QLE’s mission is to address perceived gaps in the nuclear fuel cycle, promote safe nuclear power, and enhance the sustainability of the nuclear fuel cycle for advanced nuclear reactors and fusion systems, as well as the existing nuclear fleet. We believe that many advanced nuclear reactors, including SMRs, will rely on fuels with higher uranium enrichment levels, specifically HALEU, which we intend to produce. QLE also intends to produce high-isotopic purity fuel feedstock, such as Lithium-6, for fusion reactors, and by extension, Lithium-7 for Light Water Reactor control. These fuels may enable greater efficiency, compact reactor footprints, and lengthened operational cycles between refueling. Given the flexible nature of our enrichment technology and integrated value chain approach, QLE also intends to make available LEU+ to the existing fleet of nuclear reactors currently running on LEU, thus enabling existing reactors to lengthen the time between refueling, cut costs and boost power output.

As previously announced, our board of directors intends to pursue the separation of our Nuclear Fuels business and Specialist Isotopes and Related Services business into two independent companies. The regulatory landscape and supply chain for nuclear fuel production differs significantly from that of medical isotopes, hence we and QLE have different business models and we believe that both companies would benefit if QLE is independently managed and financed. We plan to effect the separation through a listing of QLE in a transaction that results in QLE existing as a separate public company with shares listed on a U.S. national securities exchange and a portion of QLE’s common equity being distributed to our stockholders as of a to-be-determined future record date. While we currently believe that a listing of QLE as a separate public company is the most likely separation transaction, our board of directors remains committed to maximizing shareholder value creation, and will continue to evaluate other options for separation to maximize shareholder value.

We entered into a number of agreements with QLE, including a License Agreement, pursuant to which QLE has licensed from us the rights to technologies and methods used to separate U-235 and Lithium-6 (including but not limited to the QE and ASP technologies) in exchange for a perpetual royalty in the amount of 10% of all future QLE revenues, and an EPC Services Framework Agreement, pursuant to which we will provide services for the engineering, procurement and construction of one or more turnkey U-235 and Lithium-6 enrichment facilities in locations to be identified by QLE and owned or leased by QLE, and commissioning, start-up and test services for each such facility, subject to the receipt of all applicable regulatory approvals, permits, licenses, authorizations, registrations, certificates, consents, orders, variances and similar rights.

PET Labs. We have a 51% ownership stake in PET Labs, a South African radiopharmaceutical operations company focused on the production of fluorinated radioisotopes and active pharmaceutical ingredients, through which we entered the downstream medical isotope production and distribution market. Under the terms of the Share Purchase Agreement pursuant to which we acquired the shares in PET Labs, we agreed to pay a total of $2.0 million for the shares in two installments, which has been paid in full as of December 2025. In addition, we have an option to purchase the remaining 49% of the outstanding equity in PET Labs, exercisable until January 31, 2027, for $2.2 million.

East Coast Nuclear Pharmacy. In October 2025, we completed the acquisition of East Coast Nuclear Pharmacy ("ECNP"). Pursuant to the terms of the agreement, we acquired 100% of the issued and outstanding membership interests for total purchase consideration of $2.5 million of which $2.0 million was paid up front in cash and the remaining $0.5 million was deferred through the issuance of notes payable that were repaid in June 2026.

Numed Diagnostics, LLC ("Numed"). In January 2026, we acquired 60% of the issued and outstanding membership interests of Numed for $0.8 million. Numed is an independent radiopharmacy dedicated to nuclear medicine and the science of radiopharmaceutical production. In addition to the purchase consideration, we have an option to purchase the remaining 40% of the issued and outstanding membership interests within two years following the closing for an agreed consideration totaling $0.5 million.

Renergen Acquisition. On January 6, 2026, we acquired all of the issued and outstanding Renergen ordinary shares from Renergen shareholders in exchange for shares of our common stock through the implementation of the Scheme in accordance with Sections 114 and 115 of the South African Companies Act, No. 71 of 2008, resulting in the issuance of an aggregate of 14,270,000 shares of our common stock. As a result of the transactions contemplated by the Scheme, the Renergen ordinary shares, which were publicly traded on the Johannesburg Stock Exchange (JSE: REN) and the Australian Securities Exchange (ASX:RLT), were delisted and Renergen became a wholly owned subsidiary of ASP Isotopes.

Renergen is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG, both of which are produced from the large natural gas reserve base that underpins Renergen’s Virginia Gas Project. The Virginia Gas Project includes (i) the liquefaction of natural gas into LNG, (ii) the separation of helium from natural gas, and (iii) the further liquefaction of helium into 99.999% pure liquid helium. This liquefaction and separation takes place at Renergen’s Virginia Gas Plant in the Free State Province of South Africa. Based on the drilled and flow-tested wells, Renergen’s average helium concentration exceeds 3.0%, which is well above typical conventional natural gas reservoirs containing helium in small concentrations (less than 0.5%).

Renergen’s principal asset is its 94.5% equity ownership in Tetra4, which holds South Africa’s first and only onshore petroleum Production Right and is the entity developing the Virginia Gas Project. Phase 1 of the Virginia Gas Project has commenced commercial LNG operations. The Virginia Gas Project benefits from favorable supply and demand trends in both the LNG and liquid helium sectors. The LNG is and will continue to be sold domestically in South Africa into a market suffering energy and natural gas shortages, and we

40


 

plan to sell helium directly to global customers at a time when the world is suffering helium supply shortages, which have been further exacerbated by the ongoing United States-Israel-Iran conflict and associated disruptions to shipping through the Strait of Hormuz. The global helium supply chain has been materially disrupted by these geopolitical developments, with repairs to affected production infrastructure expected to take years rather than months. In addition, in April 2026, Russia introduced export controls on helium to maintain domestic supply, further constraining global availability. We believe that the U.S. International Development Finance Corporation (“DFC”) previously indicated its willingness to consider supporting the funding of Phase 2 of the Virginia Gas Project for up to $500 million as part of the U.S.’s initiative to ensure new helium supply comes online as aerospace and the semiconductor industry increase helium requirements in the face of diminished supply, while increasing South Africa’s domestic energy supply.

Helium is a vital and irreplaceable element in many modern industries because it is both chemically and electrically inert and, when in liquid form, is the coldest substance known to man at 4 degrees Kelvin (minus 454.3 degrees Fahrenheit). For these reasons, it can be used in the manufacture of semiconductors, to purge laboratory or manufacturing environments, act as a fuel propellant for other cryogenic fuels, and/or provide deep cryogenic cooling. It is commonly used in space exploration and rocketry, high-level physics experiments (e.g., particle accelerators, quantum mechanics), medical science within MRI devices, fiber optic cable production, commercial diving gas, specialized welding, coolant for nuclear power stations and lifting balloons.

We believe that Renergen’s LNG supply can play an important role in reducing South Africa's relatively high carbon emissions by being the first, and currently the only, LNG supplier in the country. According to Energy Institute (2024), coal has a 69% share of national primary energy consumption, with gas only around 3.5%. As such, according to the World Bank, South Africa ranks as the fifth-worst carbon emissions country per kilogram per purchasing power parity of gross domestic product (“GDP”). This ranking is largely due to South Africa’s high reliance on low-grade coal to provide electricity, supplemented by Sasol’s use of coal to liquids technology. Sasol Limited is one of the country’s largest energy suppliers and operator of the natural gas pipeline supplying gas from Mozambique into Johannesburg. LNG is a significantly lower carbon-emitting fuel than either of coal (by 50%) and diesel (25%), upon combustion. Therefore, the introduction of Renergen’s LNG into South Africa’s energy supply mix, including the possible direct substitution of Renergen’s LNG for first diesel, and then potentially coal, may help reduce South Africa’s overall carbon emissions intensity as the country moves towards its net zero carbon emissions targets by 2050.

Mahlako Gas Energy Limited (“MGE”) has a 5.5% equity ownership in Tetra4. MGE, Renergen and Tetra are parties to a Sale, Subscription and Shareholders’ Agreement, dated December 22, 2023 (the “SSSA”), pursuant to which MGE acquired its equity in Tetra4 for ZAR 550 million. Under the SSSA, Renergen granted to MGE a put option related to MGE's equity (the “Put Option”) exercisable upon the occurrence of a Put Option Event (as defined in the SSSA). The price payable for MGE’s equity under the Put Option is calculated pursuant to a formula set forth in the SSSA, but will be not less than the aggregate of (i) the purchase price of MGE's equity paid by MGE (ZAR 550 million) plus the face value of any claims, (ii) 3.5% of such purchase price, and (iii) MGE's documented due diligence costs.

Investments in Early Stage Drug Development Companies

IsoBio. On July 28, 2025, we purchased 2,000,000 shares of IsoBio Series Seed-1 Preferred Stock at $2.50 per share for a total aggregate purchase price of $5.0 million. IsoBio is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. As the owner of the Series Seed-1 Preferred Stock, we have the right to designate one board member. An officer and director of ours was designated to fill that board seat. In addition, another board member of ours is a board member and executive officer of IsoBio.

Opeongo. On January 26, 2026, we purchased 4,356,918 shares of Opeongo Series Seed-1 Preferred Stock at $2.2952 per share for a total aggregate purchase price of $10.0 million. Opeongo is a biotechnology company developing novel therapeutics using extracellular matrix modulation to target fibrosis, inflammation, and cancer. Opeongo was co-founded by David Baram, Ph.D. who serves as Opeongo’s Chief Executive Officer and director. As the owner of the Series Seed-1 Preferred Stock, we have the right to designate one board member. An officer and director of ours was designated to fill that board seat. In addition, another board member of ours is a board member and executive officer of Opeongo.

ENDRA. On May 27, 2026, we purchased 66,846 shares of ENDRA common stock, 511,541 prefunded warrants to purchase shares of common stock and 1,156,774 common warrants to purchase shares of common stock for a total aggregate purchase price of $3.8 million. ENDRA is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), a technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care.

Agreements with TerraPower LLC

On April 4, 2024, we entered into the TerraPower Agreement with TerraPower to develop a conceptual design, refined cost/schedule/financing, risk register, and term sheet for a HALEU facility. The TerraPower Agreement may be terminated for (a) breach or default, (b) our convenience or (c) TerraPower’s convenience. TerraPower is obligated to make all payments for milestones completed by us and these payments are nonrefundable.

On October 18, 2024, we signed the TerraPower Term Sheet that provides for the execution of two definitive agreements: (1) an agreement pursuant to which TerraPower will provide funding for our construction of a uranium enrichment facility capable of producing HALEU using our proprietary aerodynamic separation process technology to be located in the Republic of South Africa and (2) An agreement pursuant to which we will deliver to TerraPower the full capacity of the enrichment facility.

In May 2025, we entered into the TerraPower Loan Agreement, which provides conditional commitments from TerraPower to us through one of our wholly-owned U.S.-based subsidiaries for a multiple advance term loan totaling $22.0 million for the purpose of partially funding the construction of a proposed new uranium enrichment facility in South Africa. The total loan amount is inclusive of a 10% original issue discount on each disbursement and carries a fixed interest rate of 10% per annum. Per the terms of the TerraPower Loan Agreement and subject to the satisfaction of various conditions precedent to disbursements (including receiving all required licenses and permits to perform uranium enrichment in South Africa), we will receive aggregate loan disbursements of $20.0 million. Such loan matures on May 16, 2032. Interest will begin accruing upon each milestone disbursement we receive and will be added to the principal balance until November 2027. Principal and interest payments will be made in 60 equal installments beginning in November 2027.

41


 

In addition to the TerraPower Loan Agreement, in May 2025, we and TerraPower have entered into two supply agreements for the HALEU expected to be produced at our uranium enrichment facility. The initial core supply agreement is intended to support the supply of the required first fuel cores for the initial loading of TerraPower’s Natrium project in Wyoming. The long-term supply agreement is a 10-year supply agreement of up to a total of 150 metric tons of HALEU, commencing in 2028 through end of 2037.

Financings and Other Transactions

In June 2025, we issued 7,518,797 shares of common stock at $6.65 per share in a registered direct offering resulting in net proceeds of approximately $46.8 million after deducting underwriting discounts, commissions and offering expenses.

In July 2025, we issued 7,500,000 shares of common stock at $8.00 per share in a registered direct offering resulting in net proceeds of approximately $56.3 million after deducting underwriting discounts, commissions and offering expenses.

In October 2025, we issued 17,167,380 shares of common stock in a registered offering at the offering price of $12.25 per share, for net proceeds of approximately $199.3 million, after deducting underwriting discounts and commissions and estimated offering expenses.

On November 19, 2025, QLE received gross proceeds of $72.2 million through the issuance of convertible promissory notes with a stated interest rate of 8% (the “2025 Convertible Notes”), including $30.0 million in gross proceeds from ASP Isotopes, its parent. The maturity date of the 2025 Convertible Notes is November 19, 2030. The 2025 Convertible Notes automatically convert into common shares upon QLE’s closing of an IPO or other qualifying public transaction at 80% of the share price taking into consideration a valuation cap. In connection with the issuance of the 2025 Convertible Notes, QLE’s outstanding convertible promissory notes originally issued in March 2024 and June 2024 automatically converted into 2025 Convertible Notes with a value of $147.7 million.

On January 6, 2026, we issued 14,270,000 Consideration Shares in connection with the acquisition of Renergen.

On March 29, 2026, QLE, entered into an Exchange Agreement with a third party investor in which the parties agreed to exchange 1,995,000 Class B common shares owned by QLE for 1,995,000 Class A shares owned by the third party investor, on a one-for-one basis. This resulted in QLE's ownership in Skyline decreasing to under 10%.

On July 15, 2026, we and QLE entered into separate, individually negotiated private securities exchange agreements with certain holders of the 2025 Convertible Notes, pursuant to which such noteholders exchanged approximately $109.2 million in aggregate principal amount of the outstanding 2025 Convertible Notes, plus accrued and unpaid interest thereon, for an aggregate of 23,160,682 shares of our common stock (the “Exchange Transactions”). The Exchange Transactions closed on July 16, 2026. Upon the closing of the Exchange Transactions, the outstanding principal amount of 2025 Convertible Notes held by third party investors was reduced to approximately $80.6 million. ASP Isotopes holds approximately $139.2 million aggregate principal amount of 2025 Convertible Notes, which are eliminated in consolidation.

ENDRA Merger Agreement and Noble Private Placement

Merger Agreement. On June 25, 2026, we entered into an Agreement and Plan of Merger (the “Merger Agreement”), by and among ENDRA, Noble Africa LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of us (“Noble”), Renergen, ASP Isotopes, and Kruger Merger Sub LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of ENDRA (“Merger Sub”), pursuant to which Merger Sub will merge with and into Noble (the “Merger”), with Noble surviving the Merger as a direct wholly-owned subsidiary of ENDRA. Prior to the effective time of the Merger, we will contribute all of our equity interest in Renergen to Noble in exchange for 55,500,000 of Noble’s Class B Units. The shares of Class B common stock received by the Company upon conversion of the Class B Units in connection with the Merger will entitle the Company to 10 votes per share on all matters submitted to a vote of the stockholders of ENDRA. Following the Merger, ENDRA will be renamed “4K Resources, Inc.” and its Class A common stock is expected to be listed on Nasdaq.

Noble Private Placement. Concurrently with the entry into the Merger Agreement, Noble entered into subscription agreements with us and certain investors pursuant to which Noble agreed to sell approximately (i) 4,594,218 Class A Units of Noble and/or pre-funded warrants to purchase Class A Units of Noble to certain institutional investors and other persons and (ii) 3,054,185 Class B Units of Noble to us, at a price per unit of $6.57, for aggregate gross proceeds to Noble of approximately $50 million (the “Noble Investment”). The Noble Investment is expected to close immediately prior to the Merger.

Merger Agreement Amendment. On October 1, 2026, the Company, ENDRA, Noble, Renergen and Merger Sub entered into that certain First Amendment to the Merger Agreement (the “Amendment”) to, among other things, (i) amend ENDRA’s disclosure letter to permit ENDRA to amend the Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant”) and Common Stock Purchase Warrant (the “Common Warrant” and, together with the Pre-Funded Warrant, the “Warrants”), each issued by ENDRA as of May 27, 2026 to LHE LNG Holdings LLC, a direct, wholly-owned subsidiary of the Company (the “ASPI ENDRA Purchaser”), as further described below, (ii) remove the requirement that the board of directors immediately following the closing of the Merger be classified into three separate classes, (iii) revise the minimum cash closing condition to reflect a minimum cash requirement of $3,800,002.59, less certain agreed-upon expenses to permit ENDRA to engage in certain investor relations activities, (iv) replace the form of ENDRA’s Fifth Amended and Restated Certificate of Incorporation with an updated form that removes the classified board provisions and other provisions that would have required a supermajority vote of ENDRA’s stockholders to be approved, (v) amend Noble Africa’s disclosure letter to permit Renergen to enter into a fifth addendum to that certain Term Loan Facility Agreement, dated as of May 19, 2025, by and between Renergen, ASPI and ASPI South Africa Proprietary Limited, a wholly-owned subsidiary of ASPI (the “ASPI Term Loan Facility”), which would increase Renergen’s borrowing capacity from ASPI from $80 million to up to $120 million and (vi) contemplate a sixth addendum to the ASPI Term Loan Facility to be entered into at or prior to the closing of the Merger, which would further increase Renergen’s borrowing capacity from ASPI from $120 million to up to $200 million. Except as expressly modified by the Amendment, the terms of the Merger Agreement were ratified and remain in full force and effect.

ENDRA Investment. On May 27, 2026, ENDRA entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the ASPI ENDRA Purchaser pursuant to which ENDRA agreed to sell and issue to the ASPI ENDRA Purchaser in a private placement offering an aggregate of 66,846 shares of ENDRA common stock, par value $0.0001 per share (the “ENDRA Common Stock”), Pre-Funded Warrants to purchase an aggregate of up to 511,541 shares of ENDRA Common Stock (the “Pre-Funded Warrant Shares”) at a per share exercise price of $0.0001 and Common Warrants to purchase an aggregate of up to 1,156,774 shares of ENDRA Common Stock (the “Common Warrant Shares” and together with the Pre-Funded Warrant Shares, the “Warrant Shares”)) at a per share exercise price of $6.57. On October 1, 2026, ENDRA and the ASPI ENDRA Purchaser entered into (i) Amendment No. 1 to Common

42


 

Stock Purchase Warrant (the “Common Warrant Amendment”) and (ii) Amendment No. 1 to Pre-Funded Common Stock Purchase Warrant (the “Pre-Funded Warrant Amendment” and, together with the Common Warrant Amendment, the “Warrant Amendments”). The Warrant Amendments make changes to each Warrant to, among other things, remove the 4.99% beneficial ownership limitation on the ASPI ENDRA Purchaser’s ability to exercise each Warrant. Except as amended by the Warrant Amendments, the terms of each Warrant remain unaltered and in full force and effect. As previously disclosed, a portion of the Pre-Funded Warrants in respect of 324,372 Pre-Funded Warrant Shares and all of the Common Warrants will only become exercisable upon ENDRA obtaining stockholder approval of the issuance of such Pre-Funded Warrant Shares and Common Warrant Shares.

Closing of the Merger. In connection with the Merger, ENDRA filed a Registration Statement on Form S-4 (File No. 333-299256) (the "Registration Statement") with the SEC on October 2, 2026. We refer you to the disclosures in the proxy statement/prospectus (which is preliminary and subject to completion) that is included in the Registration Statement for additional information relating to the Merger and ENDRA. Consummation of the Merger is subject to certain closing conditions, including the approval by ENDRA’s stockholders, the effectiveness of the Registration Statement, the approval for listing of the Class A Common Stock on Nasdaq, ENDRA having an amount of cash equal to or greater than $3.8 million, the receipt by Noble of the proceeds of the Noble Investment, we having contributed our equity interests in Renergen to Noble, and Noble’s receipt of a written consent of the U.S. International Development Finance Corporation as required under the finance agreement with Tetra4. The Merger Agreement may be terminated by either party if the Merger has not been completed by December 24, 2026. The Merger is anticipated to close in the fourth quarter of 2026 or, subject to the parties’ agreement to extend the outside date for consummating the Merger, the first quarter of 2027.

 

Other Contractual Obligations

We enter into contracts in the normal course of business for testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice. For additional details regarding our contractual obligations, see Note 11 "Commitments and Contingencies" and Note 12 “Leases” to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

Components of Results of Operations

Revenue

We recognize product revenue from the sale of nuclear medical doses for PET scanning. Beginning in the fourth quarter of 2025, we started recognizing product revenue from the sale of nuclear medical doses for SPECT scanning. Effective with the acquisition of 100% of Renergen in the first quarter of 2026, we started recognizing product revenue from the sale of LNG. We also recognize collaboration revenue from our TerraPower R&D Agreement.

Cost of Revenue

Cost of revenue associated with the sale of nuclear medical doses for PET and SPECT scanning and the sale of LNG consist of labor, processing costs, delivery and materials. There is no cost of revenue associated with our collaboration revenue.

Operating Expenses

Our operating expenses consist of (i) research and development expenses and (ii) selling, general and administrative expenses.

Research and Development

Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the development activities for our future isotopes.

Direct costs include:

•
external research and development expenses; and
•
costs related to designing the development processes of isotope production.

Indirect costs include:

•
personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation expense, for personnel engaged in research and development functions; and
•
facilities and other various expenses.

Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.

We expect that our research and development expenses will increase substantially for the foreseeable future as we continue the development of our future isotopes. We cannot determine with certainty the timing of initiation, the duration or the completion costs of development activities. Actual development timelines, the probability of success and development costs can differ materially from expectations.

We will need to raise substantial additional capital in the future. In addition, we cannot forecast which future isotopes may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

Our research and development expenses may vary significantly based on a variety of factors, such as:

•
the scope, rate of progress, expense and results of our development activities;
•
the phase of development of our future isotopes;
•
the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and foreign regulatory authorities;
•
significant and changing government regulation and regulatory guidance;

43


 

•
the cost and timing of designing the development processes of isotope production;
•
the extent to which we establish additional strategic collaborations or other arrangements; and
•
the impact of any business interruptions to our operations or to those of the third parties with whom we work.

A change in the outcome of any of these variables with respect to the development of any of our future isotopes could significantly change the costs and timing associated with the development of that future isotope.

Selling, General and Administrative

Selling, general and administrative expenses consist primarily of personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation expense, for personnel in executive, sales, finance and other administrative functions. Other significant costs include legal fees relating to corporate matters, professional fees for accounting and consulting services and facility-related costs.

We expect that our ongoing selling, general and administrative expenses will increase substantially for the foreseeable future to support our increased research and development activities and increased costs of operating as a public company and in building our internal resources. These increased costs will include increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor and public relations costs associated with operating as a public company.

Segment Information

Beginning in 2024, primarily as a result of increased business activities of our subsidiary, QLE, we had two operating segments: (i) nuclear fuels, and (ii) specialist isotopes and related services. Beginning in August 2025, primarily as a result of the acquisition of Skyline, we had three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Beginning in the first quarter of 2026, primarily as a result of the acquisition of Renergen and the deconsolidation of Skyline, we have three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) Helium and LNG. Our prior “construction services” segment is shown below as “discontinued operations” due to the deconsolidation of Skyline.

The specialist isotopes and related services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Si-28 and Yb-176) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging and semiconductors, as well as services related to these isotopes, and this segment includes operations of PET Labs, Numed, and ECNP.

The nuclear fuels segment is focused on research and development of technologies and methods used to produce HALEU and Lithium-6 for the advanced nuclear fuels target end market, and this segment includes operations of QLE.

The Helium and LNG segment is focused on the exploration, production and sale of LNG in South Africa, and this segment includes operations of Renergen.

The financial information is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources. Our CODM is our chief executive officer. The CODM regularly reviews any asset information by operating segment and, accordingly, asset information is reported on a segment basis.

The following table shows total assets by segment and a reconciliation to the condensed consolidated financial statements as of September 30, 2026 and December 31, 2025 (in thousands):

 

 

 

September 30,
2026

 

 

December 31,
2025

 

Segment assets:

 

 

 

 

 

 

Specialist isotopes and related services

 

$

210,920

 

 

$

321,190

 

Nuclear fuels

 

 

96,707

 

 

 

94,252

 

Helium and LNG

 

 

230,502

 

 

 

—

 

Discontinued operations

 

 

—

 

 

 

82,578

 

Total assets

 

$

538,129

 

 

$

498,020

 

Select information from the condensed consolidated statements of operations and comprehensive loss as of the three months ended September 30, 2026 and 2025 is as follows:

 

Revenues

 

 

Segment Operating Loss

 

 

 

Three Months Ended September 30,

 

 

Three Months Ended September 30,

 

Segment

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Specialist isotopes and related services

 

$

4,257

 

 

$

1,271

 

 

$

(18,630

)

 

$

(11,763

)

Nuclear fuels

 

 

—

 

 

 

—

 

 

 

(11,466

)

 

 

(3,224

)

Helium and LNG

 

 

867

 

 

 

—

 

 

 

(10,419

)

 

 

—

 

 

$

5,124

 

 

$

1,271

 

 

$

(40,515

)

 

$

(14,987

)

Select information from the condensed consolidated statements of operations and comprehensive loss as of the nine months ended September 30, 2026 and 2025 is as follows:

 

Revenues

 

 

Segment Operating Loss

 

 

 

Nine Months Ended September 30,

 

 

Nine Months Ended September 30,

 

Segment

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Specialist isotopes and related services

 

$

11,512

 

 

$

3,571

 

 

$

(50,094

)

 

$

(27,218

)

Nuclear fuels

 

 

800

 

 

 

—

 

 

 

(29,288

)

 

 

(7,690

)

Helium and LNG

 

 

2,115

 

 

 

—

 

 

 

(20,216

)

 

 

—

 

 

$

14,427

 

 

$

3,571

 

 

$

(99,598

)

 

$

(34,908

)

 

44


 

Results of Operations

Comparison of the Three Months Ended September 30, 2026 and 2025

The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025:

 

Three Months Ended September 30,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Product revenue

 

$

5,124

 

 

$

1,271

 

 

$

3,853

 

Total revenue

 

 

5,124

 

 

 

1,271

 

 

 

3,853

 

Cost of revenue

 

 

4,331

 

 

 

1,029

 

 

 

3,302

 

Gross profit

 

 

793

 

 

 

242

 

 

 

551

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

7,236

 

 

 

3,098

 

 

 

4,138

 

Selling, general and administrative

 

 

34,072

 

 

 

12,131

 

 

 

21,941

 

Total operating expenses

 

 

41,308

 

 

 

15,229

 

 

 

26,079

 

Other (expense) income:

 

 

 

 

 

 

 

 

 

Foreign exchange transaction loss

 

 

(511

)

 

 

(15

)

 

 

(496

)

Change in fair value of share liability

 

 

—

 

 

 

(71

)

 

 

71

 

Change in fair value of convertible notes payable

 

 

164

 

 

 

173

 

 

 

(9

)

Change in fair value of investments

 

 

(988

)

 

 

—

 

 

 

(988

)

Gain on extinguishment of convertible notes

 

 

11,250

 

 

 

—

 

 

 

11,250

 

Interest income

 

 

4,333

 

 

 

1,844

 

 

 

2,489

 

Interest expense

 

 

(3,481

)

 

 

(76

)

 

 

(3,405

)

Total other income

 

 

10,767

 

 

 

1,855

 

 

 

8,912

 

Loss before income tax expense

 

$

(29,748

)

 

$

(13,132

)

 

$

(16,616

)

Revenue, Cost of Revenue and Gross Profit

Product revenue. Product revenue for the three months ended September 30, 2026 increased by $3.9 million to $5.1 million compared to $1.3 million for the three months ended September 30, 2025. We have recognized revenue of our radiopharmacies from the sale of nuclear medical doses for PET and SPECT scanning of $4.3 million and $1.3 million for the three months ended September 30, 2026 and 2025, respectively. The increase of $3.0 million was primarily attributable to (1) revenue of $0.8 million related to the acquisition of NuMed in January 2026, (2) revenue of $0.9 million related to the acquisition of ECNP in October 2025, and (3) an increase of $1.3 million related to the increase in sales of our nuclear medicine pipeline through PET Labs. With the acquisition of Renergen in January 2026, we recognized revenue from the sale of LNG of $0.9 million for the three months ended September 30, 2026.

Collaboration revenue. We did not recognize any collaboration revenue from the TerraPower R&D Agreement for the three months ended September 30, 2026 and 2025.

Cost of revenue. We have recognized the related cost of revenue of our radiopharmacies and Renergen for the same periods. The cost of revenue was $4.3 million and $1.0 million for the three months ended September 30, 2026 and 2025, respectively. The increase in cost of revenue of $3.3 million was primarily attributable to (1) the acquisitions of ECNP of $0.8 million, (2) the acquisitions of Numed of $0.5 million, (3) the acquisition of Renergen of $1.7 million and (4) an increase of $0.3 million related to the increase in sales of our nuclear medicine pipeline through PET Labs.

Gross profit. Gross profit for the three months ended September 30, 2026 increased by $0.6 million to $0.8 million compared to $0.2 million for the three months ended September 30, 2025. The gross profit from our radiopharmacies increased from $0.2 million to $1.6 million while gross margin increased from 19% to 38% over this period primarily attributable to the acquisitions of Numed and ECNP as well as higher sales volumes at PET Labs spreading fixed operating costs over a larger revenue base. These increases were partially offset by a Helium and LNG segment loss of $0.8 million related to the acquisition of Renergen in January 2026 which resulted in a negative gross margin of 96% for that segment. The negative gross margin was primarily attributable to fixed operating costs associated with operating and maintaining the production facility while production volumes remained below levels necessary to absorb such costs. Management expects margins in the Helium and LNG segment to improve in 2027 as production volumes increase and fixed operating costs are absorbed over a larger production base.

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended September 30, 2026 and 2025:

 

Three Months Ended September 30,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Personnel-related costs

 

$

2,138

 

 

$

1,114

 

 

$

1,024

 

Manufacturing engineering

 

 

793

 

 

 

1,121

 

 

 

(328

)

Contract services, consulting and professional

 

 

2,372

 

 

 

42

 

 

 

2,330

 

Facility and depreciation expenses

 

 

1,458

 

 

 

793

 

 

 

665

 

Exploratory costs

 

 

408

 

 

 

—

 

 

 

408

 

Other expenses

 

 

67

 

 

 

28

 

 

 

39

 

Total research and development expenses

 

$

7,236

 

 

$

3,098

 

 

$

4,138

 

45


 

Research and development expenses were $7.2 million for the three months ended September 30, 2026, compared to $3.1 million for the three months ended September 30, 2025. The overall increase of $4.1 million was primarily attributable to the following:

•
an increase in personnel-related costs of $1.0 million primarily attributable to an increase in headcount and salaries;
•
a decrease in manufacturing engineering expenses of $0.3 million primarily attributable to timing of pre-commercial operations;
•
an increase in contract services, consulting and professional expenses of $2.3 million in order to optimize commercial production;
•
an increase in facility and depreciation expenses of $0.7 million primarily attributable to an increase in space dedicated to development, noncapitalized expenses and repairs and maintenance; and
•
an increase in exploratory costs at Renergen of $0.4 million.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $34.1 million for the three months ended September 30, 2026, compared to $12.1 million for the three months ended September 30, 2025. The overall increase of $21.9 million was primarily attributable to the following:

•
an increase in personnel-related costs of $10.8 million primarily attributable to an increase in headcount, salaries and stock-based compensation and the acquisition of Renergen in January 2026 and ECNP in October 2025;
•
an increase in consulting and professional fees of $5.5 million primarily attributable to corporate development activity and the acquisition of Renergen and Numed in January 2026 and ECNP in October 2025;
•
an increase in facility and depreciation expenses of $2.7 million primarily attributable to an increase in space dedicated to development, noncapitalized expenses and repairs and maintenance and the acquisition of Renergen in January 2026;
•
an increase in insurance premiums of $0.8 million primarily attributable to overall increased coverage and the acquisition of Renergen and Numed in January 2026 and ECNP in October 2025;
•
an increase in employee travel and related expenses of $0.7 million primarily attributable to increased corporate activity; and
•
an increase in other general and administrative expenses of $1.6 million, which includes expense from the acquisition of Renergen and Numed in January 2026 and ECNP in October 2025.

Other Income (Expense)

Other income for the three months ended September 30, 2026 was $10.8 million, which includes interest income of $4.3 million, a gain on extinguishment of convertible notes payable of $11.3 million and $0.2 million from the change in fair value of the convertible notes payable, partially offset by a foreign exchange transaction loss of $0.5 million, an expense of $1.0 million due to change in fair value of our investments and interest expense of $3.5 million.

Other income for the three months ended September 30, 2025 was $1.9 million, which includes a $0.2 million gain from the change in fair value of the convertible notes payable and interest income of $1.8 million, partially offset by interest expense of $0.1 million.

Comparison of the Nine Months Ended September 30, 2026 and 2025

The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025:

 

Nine Months Ended September 30,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Product revenue

 

$

13,627

 

 

$

3,571

 

 

$

10,056

 

Collaboration revenue

 

 

800

 

 

 

—

 

 

 

800

 

Total revenue

 

 

14,427

 

 

 

3,571

 

 

 

10,856

 

Cost of revenue

 

 

10,487

 

 

 

2,430

 

 

 

8,057

 

Gross profit

 

 

3,940

 

 

 

1,141

 

 

 

2,799

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

 

19,324

 

 

 

5,508

 

 

 

13,816

 

Selling, general and administrative

 

 

84,214

 

 

 

30,541

 

 

 

53,673

 

Total operating expenses

 

 

103,538

 

 

 

36,049

 

 

 

67,489

 

Other (expense) income:

 

 

 

 

 

 

 

 

 

Foreign exchange transaction loss

 

 

(1,610

)

 

 

(113

)

 

 

(1,497

)

Change in fair value of share liability

 

 

—

 

 

 

(200

)

 

 

200

 

Change in fair value of convertible notes payable

 

 

(3,863

)

 

 

(64,542

)

 

 

60,679

 

Change in fair value of investments

 

 

138

 

 

 

—

 

 

 

138

 

Gain on extinguishment of convertible notes

 

 

11,250

 

 

 

—

 

 

 

11,250

 

Interest income

 

 

10,091

 

 

 

3,283

 

 

 

6,808

 

Interest expense

 

 

(6,984

)

 

 

(245

)

 

 

(6,739

)

Total other income (expense)

 

 

9,022

 

 

 

(61,817

)

 

 

70,839

 

Loss before income tax expense

 

$

(90,576

)

 

$

(96,725

)

 

$

6,149

 

Revenue, Cost of Revenue and Gross Profit

Product revenue. Product revenue for the nine months ended September 30, 2026 increased by $10.1 million to $13.6 million compared to $3.6 million for the nine months ended September 30, 2025. We have recognized revenue of our radiopharmacies from the sale of nuclear medical doses for PET and SPECT scanning of $11.5 million and $3.6 million for the nine months ended September 30, 2026 and 2025, respectively. The increase of $7.9 million was primarily attributable to (1) revenue of $2.2 million related to the acquisition of NuMed in January 2026, (2) revenue of $2.9 million related to the acquisition of ECNP in October 2025, and (3)

46


 

an increase of $2.8 million related to the increase in sales of our nuclear medicine pipeline through PET Labs. With the acquisition of Renergen in January 2026, we recognized revenue from the sale of LNG of $2.1 million for the nine months ended September 30, 2026.

Collaboration revenue. We recognized $0.8 million in collaboration revenue from the TerraPower R&D Agreement for the nine months ended September 30, 2026. No collaboration revenue was recognized for the nine months ended September 30, 2025.

Cost of revenue. We have recognized the related cost of revenue of our radiopharmacies and Renergen for the same periods. The cost of revenue was $10.5 million and $2.4 million for the nine months ended September 30, 2026 and 2025, respectively. The increase in cost of revenue of $8.1 million was primarily attributable to (1) cost of revenue of $1.7 million related to the acquisitions of ECNP in October 2025, (2) cost of revenue of $1.6 million related to the acquisitions of Numed in January 2026, (3) cost of revenue of $4.0 million related to the acquisition of Renergen in January 2026 and (4) an increase of $0.8 million related to the increase in sales of our nuclear medicine pipeline through PET Labs.

Gross profit. Gross profit for the nine months ended September 30, 2026 increased by $2.8 million to $3.9 million compared to $1.1 million for the nine months ended September 30, 2025. The gross profit from our radiopharmacies increased from $1.1 million to $5.0 million while gross margin increased from 32% to 44% over this period primarily attributable to the acquisitions of Numed and ECNP as well as higher sales volumes at PET Labs spreading fixed operating costs over a larger revenue base. We also received $0.8 million from our collaboration with TerraPower. These increases were partially offset by a Helium and LNG segment loss of $1.9 million related to the acquisition of Renergen in January 2026 which resulted in a negative gross margin of 90% for that segment. The negative gross margin was primarily attributable to fixed operating costs associated with operating and maintaining the production facility while production volumes remained below levels necessary to absorb such costs. Management expects margins in the Helium and LNG segment to improve in 2027 as production volumes increase and fixed operating costs are absorbed over a larger production base.

Research and Development Expenses

The following table summarizes our research and development expenses for the nine months ended September 30, 2026 and 2025:

 

Nine Months Ended September 30,

 

 

 

 

 

 

2026

 

 

2025

 

 

Change

 

Personnel-related costs

 

$

7,065

 

 

$

1,781

 

 

$

5,284

 

Manufacturing engineering

 

 

1,440

 

 

 

1,246

 

 

 

194

 

Contract services, consulting and professional

 

 

4,873

 

 

 

152

 

 

 

4,721

 

Facility and depreciation expenses

 

 

4,226

 

 

 

2,030

 

 

 

2,196

 

Exploratory costs

 

 

1,318

 

 

 

—

 

 

 

1,318

 

Other expenses

 

 

402

 

 

 

299

 

 

 

103

 

Total research and development expenses

 

$

19,324

 

 

$

5,508

 

 

$

13,816

 

Research and development expenses were $19.3 million for the nine months ended September 30, 2026, compared to $5.5 million for the nine months ended September 30, 2025. The overall increase of $13.8 million was primarily attributable to the following:

•
an increase in personnel-related costs of $5.3 million primarily attributable to an increase in headcount and salaries;
•
an increase in manufacturing engineering expenses of $0.2 million primarily attributable to pre-commercial operations;
•
an increase in contract services and consulting expenses of $4.7 million in order to optimize commercial production;
•
an increase in facility and depreciation expenses of $2.2 million primarily attributable to an increase in space dedicated to development, noncapitalized expenses and repairs and maintenance; and
•
an increase in exploratory costs at Renergen of $1.3 million.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $84.2 million for the nine months ended September 30, 2026, compared to $30.5 million for the nine months ended September 30, 2025. The overall increase of $53.7 million was primarily attributable to the following:

•
an increase in personnel-related costs of $21.9 million primarily attributable to an increase in headcount, salaries and stock-based compensation and the acquisition of Renergen in January 2026 and ECNP in October 2025;
•
an increase in consulting and professional fees of $15.0 million primarily attributable to corporate development activity and the acquisition of Renergen in January 2026 and ECNP in October 2025;
•
an increase in facility and depreciation expenses of $8.1 million primarily attributable to an increase in space dedicated to development, noncapitalized expenses and repairs and maintenance and the acquisition of Renergen in January 2026;
•
an increase in insurance premiums of $2.3 million primarily attributable to overall increased coverage and the acquisition of Renergen and Numed in January 2026 and ECNP in October 2025;
•
an increase in employee travel and related expenses of $1.8 million primarily attributable to increased corporate activity; and
•
an increase in other general and administrative expenses of $4.7 million, which includes expense from the acquisition of Renergen and Numed in January 2026 and ECNP in October 2025.

Other Income (Expense)

Other income for the nine months ended September 30, 2026 was $9.0 million, which includes a $11.3 million gain on extinguishment of convertible notes payable, interest income of $10.1 million and a gain from a change in the fair value of our investments of $0.1 million, partially offset by an expense of $3.9 million from the change in fair value of the convertible notes payable, interest expense of $7.0 million and a foreign exchange transaction loss of $1.6 million.

Other expense for the nine months ended September 30, 2025 was $61.8 million, which includes an expense of $64.5 million from the change in fair value of the convertible notes payable, an expense of $0.2 million from the change in fair value of share liability

47


 

related to the shares issuable to consultants, interest expense of $0.2 million and a foreign exchange transaction loss of $0.1 million, partially offset by interest income of $3.3 million.

Non-GAAP Financial Information

We use certain measures to assess the financial performance of our business, as well as to comply with the reporting requirements of the JSE. Certain of these measures are termed “non-GAAP measures” because they exclude amounts that are included in, or include amounts that are excluded from, the most directly comparable measure calculated and presented in accordance with GAAP, or are calculated using financial measures that are not calculated in accordance with GAAP. These non-GAAP measures include headline loss, and headline loss per common share.

An explanation of the relevance of the non-GAAP measure, a reconciliation of the non-GAAP measure to the most directly comparable measure calculated and presented in accordance with GAAP and a discussion of its limitations are set out below. We do not regard these non-GAAP measures as a substitute for, or superior to, the equivalent measure calculated and presented in accordance with GAAP or that calculated using financial measures that are calculated in accordance with GAAP and such measures may not be comparable to similarly titled measures used by other companies.

Headline Loss per Share

In connection with our secondary listing on the JSE, we are required to calculate and publicly disclose headline loss per share and diluted headline loss per share. Headline loss per share is calculated using net loss which has been determined in accordance with GAAP. Headline loss for the period represents the loss for the period attributable to our common stockholders adjusted for the remeasurements that are more closely aligned to the operating or trading results as set forth below, and headline loss per share represents headline loss divided by the weighted average number of shares of common stock outstanding.

The table below presents a reconciliation between net loss attributable to common stockholders to headline loss.

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net loss attributable to ASP Isotopes Inc. shareholders

 

$

(30,371

)

 

$

(12,617

)

 

$

(70,833

)

 

$

(96,125

)

Adjusted for:

 

 

 

 

 

 

 

 

 

 

 

 

Gain on extinguishment of convertible notes

 

 

(11,250

)

 

 

—

 

 

 

(11,250

)

 

 

—

 

Change in fair value of share liability

 

 

—

 

 

 

71

 

 

 

—

 

 

 

200

 

Change in fair value of convertible notes payable

 

 

(164

)

 

 

(173

)

 

 

3,863

 

 

 

64,542

 

Change in fair value of equity investments

 

 

988

 

 

 

—

 

 

 

(138

)

 

 

—

 

Headline loss

 

$

(40,797

)

 

$

(12,719

)

 

$

(78,358

)

 

$

(31,383

)

Weighted average common shares outstanding on which the net loss attributable to ASP Isotopes Inc. shareholders per share and headline loss per share has been calculated - basic and diluted

 

 

143,385,783

 

 

 

88,552,309

 

 

 

128,891,373

 

 

 

75,985,507

 

Net loss per share, attributable to ASP Isotopes Inc. shareholders, basic and diluted

 

$

(0.21

)

 

$

(0.14

)

 

$

(0.55

)

 

$

(1.27

)

Headline loss per share, attributable to ASP Isotopes Inc. shareholders, basic and diluted

 

$

(0.28

)

 

$

(0.14

)

 

$

(0.61

)

 

$

(0.41

)

The above disclosure was prepared for the purpose of complying with the reporting requirements of the JSE and includes certain non-GAAP measures, such as headline loss and headline loss per common share, and related reconciliations.

Liquidity and Capital Resources

Sources of Liquidity

We have incurred net losses and negative cash flows from operations since our inception, and we expect to continue to incur significant and increasing net losses for the foreseeable future. We have principally financed our operations to date through the issuance of our common stock, including our IPO, and the issuance of convertible notes payable.

As of September 30, 2026, we had cash and cash equivalents of $201.7 million. We have not generated any revenue from the sale of our enriched isotopes, and our ability to generate product revenue from the sale of enriched isotopes sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future enriched isotopes.

We recognize product revenue from the sale of nuclear medical doses for PET and SPECT scanning in South Africa and the U.S. Our ability to generate product revenue from the sale of nuclear medical doses for PET and SPECT scanning sufficient to achieve profitability will depend on the successful expansion of production capabilities and commercialization of the results of that expansion. Effective with the acquisition of Renergen in January 2026, we also recognize revenue from the sale of helium and LNG. Our ability to generate revenue from the sale of helium and LNG sufficient to achieve profitability will depend on the successful expansion of production capabilities and commercialization of the results of that expansion. Renergen’s outstanding debt funding may also materially affect our liquidity. We also recognize collaboration revenue from our TerraPower R&D Agreement.

Future Funding Requirements

Based on our current operating plan, we estimate that our existing cash and cash equivalents, proceeds from short-term investments, as well as cash flow from operations, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months from the date the financial statements are issued and beyond. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of developing isotopes is costly, and the timing of progress and expenses in these development activities is uncertain.

48


 

Our future capital requirements will depend on many factors, including:

•
the type, number, scope, progress, expansions, results, costs and timing of, our development activities for our future isotopes, helium and LNG;
•
the outcome, timing and costs of regulatory review of our future isotopes or for helium or LNG we produce during Phase 2 of the Virginia Gas Project;
•
our ability to negotiate and enter into binding definitive agreements with DFC or SBSA for senior debt funding for Phase 2 of the Virginia Gas Project;
•
our ability to restructure our outstanding debt and the adequacy of our available funds to pay our outstanding debt obligations as they come due;
•
the costs and timing of manufacturing for our future isotopes and of exploring for, developing or producing natural gas and helium;
•
our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;
•
the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;
•
the costs and timing of establishing or securing sales and marketing and distribution capabilities, whether alone or with third parties, to commercialize future isotopes or with respect to LNG and helium we produce at the Virginia Gas Plant for which we may obtain regulatory approval, if any;
•
the timing of construction of Phase 2, which based on our latest cost estimate is expected to be in excess of $1.0 billion (including borrowing costs and general corporate costs during construction);
•
the price at which we sell our LNG and liquid helium;
•
unforeseen plant disruptions, operational issues and the cost and availability of raw materials, including current supply chain issues, related to the Virginia Gas Project;
•
our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;
•
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
•
the costs of obtaining, expanding, maintaining and enforcing our patent and other intellectual property rights;
•
the costs to list QLE as a separate public company and costs associated with the ENDRA Merger; and
•
costs associated with any products or technologies that we may in-license or acquire.

Developing and commercializing isotopes is a time-consuming, expensive and uncertain process that takes years to complete, and we may never achieve the necessary results required or obtain applicable regulatory approval for any isotopes or generate revenue from the sale of any future isotopes (assuming applicable regulatory approval is received). In addition, our future isotopes (assuming applicable regulatory approval is received) may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of isotopes that we do not expect to be commercially available until the fourth quarter of 2026. If we receive permits and licenses to enrich U-235 (which in itself is highly uncertain), we do not expect U-235 to be commercially available for at least several years, if ever. As a result, we may need substantial additional financing to support our continuing operations and further the development of and commercialization of our future isotopes.

Expansion of the production and distribution of nuclear medical doses for PET scanning is a time-consuming, expensive and uncertain process that may take years to complete. As a result, we may need substantial additional financing to support our continuing operations and further the development of and commercialization of future nuclear medical doses for PET scanning.

Large amounts of capital are required to support the growth in our business and operations in South Africa, including to maintain and progress toward full commercial operation of Phase 1 of the Virginia Gas Project, and for the construction and development of Phase 2 of our Virginia Gas Project, and long-term production and processing requires both significant capital expenditure and ongoing maintenance expenditure. Our revenues related to the sale of helium and LNG may vary significantly from period to period as a result of changes in volumes of production sold and commodity prices. Natural gas prices have historically been volatile. Lower commodity prices may not only decrease our revenues, but also potentially the amount of natural gas that we can produce economically. We plan to add reserves through drilling. Our ability to add reserves through drilling projects is dependent on many factors, including our ability to borrow or raise capital and procure materials, services and personnel. Phase 2 of the Virginia Gas Project requires a significant amount of capital and is currently estimated to cost in excess of $1.0 billion (including borrowing costs and general corporate costs during construction) based on our latest cost estimate, which could change based on inaccurate assumptions and changing economic and operating conditions. We intend to continue to pursue senior debt funding for Phase 2 of the Virginia Gas Project from institutional lenders, including the U.S. International Development Finance Corporation ("DFC") and Standard Bank of South Africa ("SBSA"). Renergen received a letter of conditional approval from the DFC, pursuant to the DFC’s application review process, for up to $500 million in senior secured debt financing (the “Commitment Letter”). On September 30, 2026, the DFC agreed to extend its commitment to permit the finalization of the finance agreement under the Commitment Letter to July 1, 2029. The financing under the Commitment Letter is expected to be conditional upon, among other things, certain equity investments; the right to use a portion of the real property on which the Phase 2 facilities and wells are located, whether through ownership, leases, easements, rights-of-way or similar arrangements; Tetra4's entry into business, construction and operational arrangements satisfactory to the lenders for the delivery of the Phase 2 facilities; established marketing plans for helium and LNG sales, including timing, volumes and pricing to comply with the financial covenants under the proposed debt facilities; entry into definitive helium and LNG offtake agreements providing contracted revenues sufficient to cover a percentage of the projected debt service under the proposed debt facilities; certain debt-to-equity ratios; and the receipt of certain regulatory approvals. The Commitment Letter is non-binding and subject to a number of terms and conditions, contingencies and uncertainties. There can be no assurance that we will ultimately enter into a binding definitive agreement with the DFC or that the terms of such agreement will not differ, possibly materially, from those described herein.

In addition, SBSA has previously indicated its willingness to consider supporting Phase 2 of the Virginia Gas Project for up to $250 million of senior debt funding. No binding definitive agreements have been executed with respect to either facility. There can be no assurance we will be able to obtain financing from the DFC or the SBSA for Phase 2 of the Virginia Gas Project on terms that are

49


 

favorable to us or at all. As a result, we may need substantial additional or alternative financing to support our continuing operations, ramp up production of Phase 1, and further the development of Phase 2 and commercialization of the Virginia Gas Project.

Until such time as we can generate significant revenue from sales of our future isotopes, nuclear medical doses for PET and SPECT scanning and sales of helium and LNG, if ever, we expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting severely diminished liquidity and credit availability, increased interest rates, inflationary pressures, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our future isotopes, future helium and LNG production and sales, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our future isotopes and helium and LNG production even if we would otherwise prefer to develop and market such isotopes, helium and LNG ourselves.

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

Net cash provided by (used in):

 

 

 

 

 

 

Operating activities(1)

 

$

(66,449

)

 

$

(19,935

)

Investing activities

 

 

(19,114

)

 

 

(44,555

)

Financing activities(2)

 

 

34,065

 

 

 

107,485

 

Change in cash and cash equivalents

 

$

(51,498

)

 

$

42,995

 

(1) includes cash flows used in discontinued operations of $1.1 million and $0.8 million for the nine months ended September 30, 2026 and 2025, respectively.

(2) Includes cash flows provided by discontinued operations of $9.1 million for the nine months ended September 30, 2025.

(3) includes cash flows provided by discontinued operations of $45.9 million and $0.6 million for the nine months ended September 30, 2026 and 2025, respectively.

Operating Activities

Net cash used in operating activities was $66.4 million for the nine months ended September 30, 2026, including $1.1 million from discontinued operations, and was primarily attributable to our net loss from continuing operations of $91.6 million, adjusted for a gain on deconsolidation of $19.3 million, gain on extinguishment of convertible notes payable of $11.3 million, stock-based compensation expense of $18.6 million, amortization of right-of-use asset of $0.8 million, depreciation and amortization expense of $6.0 million, change in fair values of investments of $0.1 million, change in fair values for the convertible notes payable of $3.9 million, noncash interest on debt of $4.1 million, change in deferred taxes of $0.7 million and a $1.8 million change in our operating assets and liabilities.

Net cash used in operating activities was $19.9 million for the nine months ended September 30, 2025, and was primarily attributable to our net loss from continuing operations of $96.8 million, adjusted for stock-based compensation expense of $10.8 million, amortization of right-of-use asset of $0.4 million, depreciation expense of $0.9 million, issuance of common stock to a consultant with a fair value of $0.7 million, change in fair values for the convertible notes payable of $64.5 million and a $1.3 million change in our operating assets and liabilities.

Investing Activities

Net cash used in investing activities was $19.1 million for the nine months ended September 30, 2026 and was comprised of purchase of short-term investments of $35.4 million, purchase of Opeongo and ENDRA investment of $14.1 million, cash disposed of upon deconsolidation of Skyline of $44.7 million and the purchases of machinery and equipment, vehicles and construction in progress of $13.6 million, partially offset by maturity of short-term investments of $83.2 million and net cash provided by acquisitions of $4.9 million.

Net cash used in investing activities was $44.6 million for the nine months ended September 30, 2025, including $9.1 million from discontinued operations, and was comprised of the purchases of machinery and equipment, vehicles and construction in progress of $7.3 million, purchase of IsoBio investment of $5.0 million, investment in Skyline of $2.5 million, cash disposed of upon deconsolidation of Skyline of $8.9 million and the advancement of $30.0 million loan to Renergen prior to the close of the acquisition.

Financing Activities

Net cash provided by financing activities was $34.1 million for the nine months ended September 30, 2026, including $45.9 million from discontinued operations, and was comprised primarily of $0.2 million for the exercise of stock options, $0.1 million in proceeds from the issuance of notes payable, partially offset by principal payments on debt, finance leases and bank loans of $9.8 million, distribution to noncontrolling interest of Renergen of $1.5 million and distribution to noncontrolling interest in VIE of $0.5 million.

Net cash provided by financing activities was $107.5 million for the nine months ended September 30, 2025, including $0.6 million from discontinued operations. and was comprised primarily of $103.1 million in proceeds from the issuance of common stock net of issuance costs, $4.9 million in proceeds from the exercise of warrants and $1.0 million in principal payments on debt and finance leases.

50


 

Contractual Obligations and Commitments

Leases

We lease several facilities in the United States and South Africa for office, manufacturing and laboratory space under leases with current combined monthly rent payments of approximately $115,000 with terms expiring between October 31, 2026 and March 31, 2056. We also lease additional space on a short term basis in the United States, South Africa, United Kingdom, and Cayman Islands under leases with current combined monthly rent payments of approximately $32,000.

Promissory Note and Loans

In August 2025, we executed a promissory note payable with a finance company to fund a general liability insurance policy for $0.2 million. We assumed a promissory note in connection with the acquisition of Renergen in January 2026 to fund a general liability insurance policy for approximately $1.1 million. Periodically, we enter into loans to purchase motor vehicles and certain equipment. For the nine months ended September 30, 2026, we entered into new loans totaling $0.1 million. These loans are secured by the underlying assets included in property and equipment. Refer to Note 9 ("Debt") to our condensed consolidated financial statements in this Quarterly Report on Form 10-Q for information regarding interest rates and maturities.

QLE Convertible Notes

As previously discussed, QLE issued the 2025 Convertible Notes, which include certain contractual obligations and commitments. See Note 9 "Debt" for additional information.

Renergen Contractual Obligations and Commitments

As previously discussed, we acquired Renergen (and its indirect 94.5% equity ownership in Tetra4) in January 2026, which entities are subject to certain contractual obligations and commitments discussed further below. See also Note 9 "Debt" for additional information.

Certain Commitments to the South Africa Competition Commission

In connection with our acquisition of Renergen, we made certain commitments to the South Africa Competition Commission designed to address public interest concerns and promote historically disadvantaged persons (“HDP”) and worker ownership. These commitments to the South Africa Competition Commission include: (1) a moratorium on retrenchments of workers at Renergen’s operations for a period of two years from the merger closing date; and (2) a commitment to implement, within 12 months of the merger closing date, a trust for the benefit of qualifying workers employed by Renergen and certain HDP communities and people located within the production rights area of the Virginia Gas Project (the “HDP and Worker Trust”). Upon the effective implementation date of the HDP and Worker Trust, the HDP and Worker Trust are expected to hold an aggregate 5% of the issued shares in Tetra4 and Renergen is expected to hold 89.5% of the issued shares in Tetra4, subject to change in accordance with any capital raising activities of us, Renergen and/or Tetra4 following the merger closing date. In conjunction with the establishment of the HDP and Workers Trust, Tetra4 will issue an offsetting vendor financed loan to the HDP and Worker Trust. The HDP and Worker Trust will continue for the duration of the Production Right held by Tetra4, which will expire during 2042, unless extended.

Normal Course Operating Agreements

In addition, we entered into contracts in the normal course of business with vendors for services and products for operating purposes. These contracts do not contain any minimum purchase commitments and generally provide for termination after a notice period and, therefore, are not considered long-term contractual obligations. Payments due upon cancellation consist only of payments for services provided and expenses incurred up to the date of cancellation.

Off-balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Significant Judgments and Estimates

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. In preparing these financial statements, management is required to make estimates and assumptions that affect the reported amount of revenues, expenses, assets, liabilities and the disclosure of contingent liabilities. Actual results may differ from these estimates. Critical accounting estimates are those estimates that involve a significant level of estimation uncertainty and could have a material impact on our financial condition or results of operations.

The most significant estimates in our consolidated financial statements relate to stock-based compensation, fair value of convertible notes, equity and other investments, loss contingencies and the accounting for acquisitions, including goodwill. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may materially differ from these estimates and assumptions.

Stock-Based Compensation

Stock-based compensation represents a critical accounting estimate because determining the grant-date fair value of equity awards requires significant judgment and the use of assumptions that are inherently uncertain. For stock options and certain other equity awards, we estimate fair value using valuation models that require assumptions regarding expected stock price volatility, expected term, risk-free interest rates, forfeiture rates, and, where applicable, the fair value of our common stock. These assumptions are developed using a combination of historical information, market data, and management's expectations regarding future events.

Changes in these assumptions may materially affect the estimated fair value of awards granted and the amount of compensation expense recognized in future periods. For example, higher assumptions regarding expected volatility, longer expected terms, or increases in the estimated fair value of common stock would generally increase stock-based compensation expense. Such changes would primarily affect operating expenses, loss from operations, and net loss.

Fair Value Measurements of Convertible Notes

The valuation of convertible notes and related embedded features requires significant management judgment, particularly when observable market information is limited. The fair value estimates incorporate assumptions regarding expected volatility of our equity securities, market interest rates, credit risk, probability of conversion, expected term, and other market-based factors. Because certain

51


 

assumptions are not directly observable in the marketplace, changes in estimates could result in materially different fair value measurements.

Changes in these assumptions may result in increases or decreases to the carrying value of the convertible instruments and related liabilities, as well as non-cash gains or losses recognized in the statement of operations. As a result, changes in fair value assumptions could materially affect net loss and earnings per share in future reporting periods.

Equity and Other Investments

We hold investments in certain private and publicly traded companies. Determining the carrying value of these investments, particularly those that do not have readily determinable fair values, requires significant judgment. Our analysis considers available market transactions, financial performance of investee companies, financing activities, industry conditions, macroeconomic factors, and other indicators that may affect fair value or indicate impairment.

If actual operating performance of investee companies differs from our expectations, market conditions deteriorate, or other impairment indicators arise, we may be required to record impairment charges or valuation adjustments. Such adjustments could materially impact other income (expense), net income (loss), and the carrying amount of investments reported on our balance sheet.

Loss Contingencies

We are involved in various legal, regulatory, tax, and other matters arising in the normal course of business. The assessment of loss contingencies requires significant judgment regarding both the likelihood and magnitude of potential losses. When evaluating contingencies, management considers information obtained through investigations, communications with external legal counsel, settlement discussions, prior experience in similar matters, and the status of regulatory or judicial proceedings.

Because these matters are inherently uncertain, actual outcomes may differ significantly from current estimates. Future developments could require us to record additional accruals or reverse previously recorded amounts. Any such changes could materially affect operating expenses, accrued liabilities, net loss, and cash flows in the period in which new information becomes available.

Business Combinations, Intangible Assets and Goodwill

Accounting for acquisitions requires significant estimates and assumptions in determining the fair value of assets acquired and liabilities assumed. The most significant judgments typically relate to estimated future cash flows, customer retention rates, revenue growth assumptions, discount rates, royalty rates, useful lives of acquired intangible assets, and expected synergies. These estimates directly affect the amount assigned to identifiable intangible assets and goodwill.

Changes in assumptions used in purchase accounting could result in adjustments to the recorded values of acquired assets and liabilities during the measurement period. In addition, future changes in market conditions, operating results, or other factors may indicate that goodwill or intangible assets are impaired.

Goodwill impairment assessments are particularly sensitive to assumptions regarding revenue growth, operating margins, projected cash flows, and discount rates. A decline in expected future performance, increases in discount rates, adverse economic conditions, or changes in market multiples could result in impairment charges. Such charges could materially affect operating income, net income, total assets, and stockholders' equity.

See Note 2 to our condensed consolidated financial statements which discusses new accounting pronouncements.

52


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Item 10 of Regulation S-K and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in connection with our evaluation of our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K (as amended) for the year ended December 31, 2025, our disclosure controls and procedures were not effective as of September 30, 2026.

Management’s Plan for Remediation of the Material Weakness

As previously described in Part II, Item 9A of our Annual Report, we began implementing a remediation plan to address the material weaknesses mentioned in such Annual Report. In order to remediate the material weaknesses, we expect to enhance our formal documentation over internal control procedures and management controls infrastructure to allow for more consistent execution of control procedures and hire additional accounting, and finance and information technology resources or consultants with public company experience. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Although we intend to complete the remediation process as promptly as possible, we cannot at this time estimate how long it will take to remediate the material weaknesses described in the Annual Report. We may discover additional material weaknesses that require additional time and resources to remediate, and we may decide to take additional measures to address the material weaknesses or modify the remediation steps described above.

Changes in Internal Control

Except for the activities taken related to the remediation of the material weaknesses described in the Annual Report, there has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

53


 

PART II-OTHER INFORMATION

Item 1. Legal Proceedings.

Except as described in Note 11 ("Commitments and Contingencies") to our condensed consolidated financial statements in this Quarterly Report on Form 10-Q, we are not currently party to, and our property is not currently the subject of, any material pending legal matters or claims.

In addition, from time to time, we may become subject to arbitration, litigation or claims arising in the ordinary course of business. The results of any current or future claims or proceedings cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and litigation costs, diversion of management resources, reputational harm and other factors.

Item 1A. Risk Factors.

In addition to the information set forth in this Quarterly Report on Form 10-Q, including under the heading “Special Note Regarding Forward-Looking Statements,” the risks and uncertainties which could adversely affect our business, financial condition, results of operations and future growth prospects that we believe are most important for you to consider are discussed in “Part I, Item 1A—Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 10, 2026 and as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026 and other reports that we file with the SEC, including our Quarterly Reports on Form 10-Q. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended) and such other reports that we file with the SEC are not the only risks we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.

In connection with the Merger, ENDRA filed a Registration Statement on Form S-4 (File No. 333-299256) (the "Registration Statement") with the SEC on October 2, 2026. The section entitled "Risk Factors" of the proxy statement/prospectus (which is preliminary and subject to completion) that is included in the Registration Statement contains additional risk factors relating to the Merger and Renergen’s business, among other matters, and is incorporated by reference herein, and should be read together with the risk factors set forth in this Quarterly Report on Form 10-Q. ENDRA intends to file amendments and/or supplements to the Registration Statement, which will contain important information about the Merger and Renergen. You should read the Registration Statement, including any amendments and supplements to it, and the definitive proxy statement/prospectus, when available, for additional information about the Merger, Renergen and the risks relating to them. The information set forth under the heading “Risk Factors—Risks Related to Renergen” in the Registration Statement is attached hereto for convenience as Exhibit 99.1 and incorporated herein by reference.

Except as set forth in the paragraph above, there have been no material changes to our risk factors as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025 (as amended).

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

 

Director and Officer Trading Arrangements

A portion of the compensation of the Company’s directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers may engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in Company securities by directors and officers are required to be made in accordance with the Company’s insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in the Company’s securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

On July 10, 2026, Heather Kiessling, the Company’s Chief Financial Officer, terminated a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (the “Kiessling Trading Plan”). The Kiessling Trading Plan was originally adopted on December 19, 2025 for the purpose of selling shares of the Company’s common stock in connection with tax withholding obligations incident to the vesting of a restricted stock award, covered the potential sale of up to 92,496 shares of our common stock, and absent such termination, would have terminated on April 14, 2027. As of July 10, 2026, a total of 46,248 shares had been sold pursuant to the Kiessling Trading Plan. No further trades will be executed under the Kiessling Trading Plan.

The Company has implemented mandatory, non-discretionary, "sell-to-cover" arrangements for the purpose of satisfying tax withholding obligations incurred upon the vesting of equity awards in certain of its equity award agreements. This arrangement provides for the automatic sale of shares of the Company’s common stock that would otherwise be issuable on each vesting date of a covered restricted stock award (RSA) in an amount necessary to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation. The number of shares that will be sold under these arrangements is not currently determinable as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSAs subject to this arrangement.

Other than the trading arrangements described above, during the three months ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) of ours adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

54


 

 

55


 

Item 6. Exhibits.

 

Exhibit

Number

 

Description

2.1

 

Amendment No. 1 to Agreement and Plan of Merger, dated as of October 1, 2026, by and among ENDRA Life Sciences Inc., Kruger Merger Sub LLC, Renergen Limited, Noble Africa LLC and ASP Isotopes Inc. (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by ENDRA Life Sciences Inc. on October 1, 2026).

3.1

 

 

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Form S-1/A filed on November 9, 2022 (File No. 333-267392)).

3.2

 

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K for the year ended December 31, 2023, filed on April 10, 2024).

10.1

 

Second Amendment and Restatement Agreement, dated August 14, 2026, between Renergen Limited and The Standard Bank of South Africa Limited and countersigned by ASP Isotopes South Africa Proprietary Limited (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 20, 2026).

10.2

 

Put Option Agreement, dated August 14, 2026, among The Standard Bank of South Africa Limited, ASP Isotopes Inc. and Renergen Limited (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 20, 2026).

10.3*

 

Fourth Addendum to the Term Loan Facility Agreement, between ASP Isotopes Inc., Renergen Limited and ASP Isotopes South Africa Proprietary Limited, dated May 28, 2026.

10.4*

 

Fifth Addendum to the Term Loan Facility Agreement, between ASP Isotopes Inc., Renergen Limited and ASP Isotopes South Africa Proprietary Limited, dated September 29, 2026.

10.5

 

Non-Employee Director Compensation Policy effective July 1, 2026 (incorporated by reference to Exhibit 10.5 to the Company's Current Report on Form 10-Q filed on August 14, 2026).

10.6

 

Form of Securities Exchange Agreement by and among ASP Isotopes Inc., Quantum Leap Energy LLC and the person or entity identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 16, 2026).

10.7*

 

Sale, Subscription And Shareholders’ Agreement between Mahlako Gas Energy Proprietary Limited and Renergen Limited and Tetra4 Proprietary Limited.

31.1*

 

Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2*

 

Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1**

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

99.1*

 

Risks Related to Renergen

101.INS

 

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

 

Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Exhibits filed herewith.

** Exhibits furnished herewith.

+ Management contract or compensatory plan or arrangement.

# Certain schedules, annexes and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of any such schedules, annexes and exhibits to the SEC upon request.

56


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

ASP Isotopes Inc.

Date: November 16, 2026

By:

/s/ Paul E. Mann

Paul E. Mann

Chief Executive Officer, Executive Chairman and Director

(Principal Executive Officer)

Date: November 16, 2026

By:

/s/ Heather Kiessling

Heather Kiessling

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

57


Keep reading